<SEC-DOCUMENT>0001178913-20-002481.txt : 20200820
<SEC-HEADER>0001178913-20-002481.hdr.sgml : 20200820
<ACCEPTANCE-DATETIME>20200820163044
ACCESSION NUMBER:		0001178913-20-002481
CONFORMED SUBMISSION TYPE:	F-1
PUBLIC DOCUMENT COUNT:		5
FILED AS OF DATE:		20200820
DATE AS OF CHANGE:		20200820

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Check-Cap Ltd
		CENTRAL INDEX KEY:			0001610590
		STANDARD INDUSTRIAL CLASSIFICATION:	X-RAY APPARATUS & TUBES & RELATED IRRADIATION APPARATUS [3844]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3

	FILING VALUES:
		FORM TYPE:		F-1
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-248200
		FILM NUMBER:		201120366

	BUSINESS ADDRESS:	
		STREET 1:		ABBA HUSHI AVENUE
		STREET 2:		P.O. BOX 1271
		CITY:			ISFIYA
		STATE:			L3
		ZIP:			3009000
		BUSINESS PHONE:		972-4-8303400

	MAIL ADDRESS:	
		STREET 1:		ABBA HUSHI AVENUE
		STREET 2:		P.O. BOX 1271
		CITY:			ISFIYA
		STATE:			L3
		ZIP:			3009000
</SEC-HEADER>
<DOCUMENT>
<TYPE>F-1
<SEQUENCE>1
<FILENAME>zk2024844.htm
<DESCRIPTION>F-1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: ZKG
         Document created using EDGARfilings PROfile 7.0.1.0
         Copyright 1995 - 2020 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="line-height: 1.25;">
      <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">As filed with the Securities and Exchange Commission on August 20, 2020</div>
    <div style="text-align: right; line-height: 1.25; font-weight: bold;">Registration No. 333-</div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><font style="background-color: #FFFFFF;">UNITED STATES</font><br>
      <font style="background-color: rgb(255, 255, 255); font-size: 14pt; font-family: 'Times New Roman',Times,serif;">SECURITIES AND EXCHANGE COMMISSION</font><br>
      Washington, D.C. 20549</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><font style="background-color: rgb(255, 255, 255); font-size: 14pt; font-family: 'Times New Roman',Times,serif;">FORM F-1</font><br>
      &#160;<br>
      REGISTRATION STATEMENT<br>
      UNDER<br>
      THE SECURITIES ACT OF 1933</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><font style="background-color: rgb(255, 255, 255); font-size: 16pt; font-family: 'Times New Roman',Times,serif;">Check-Cap Ltd.</font><br>
      (Exact name of registrant as specified in its charter)</div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zd6c6a0f1dec44b839dbeff79526b8401">

        <tr>
          <td style="width: 32%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">State of Israel</div>
          </td>
          <td style="width: 2.01%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 32%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">3844</div>
          </td>
          <td style="width: 2.01%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 32%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Not applicable</div>
          </td>
        </tr>
        <tr>
          <td style="width: 32%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">(State or other jurisdiction of<br>
              incorporation or organization)</div>
          </td>
          <td style="width: 2.01%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 32%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">(Primary Standard Industrial<br>
              Classification Code Number)</div>
          </td>
          <td style="width: 2.01%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 32%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">(I.R.S. Employer<br>
              Identification No.)</div>
          </td>
        </tr>

    </table>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Check-Cap Building</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">29 Abba Hushi Avenue</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">P.O. Box 1271</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Isfiya, 3009000, Israel</div>
    <div style="text-align: center; line-height: 1.25;"><font style="font-weight: bold;">&#160;</font>(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Puglisi &amp; Associates</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">850 Library Avenue</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Newark, Delaware 19711</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">(302) 738-6680</div>
    <div style="text-align: center; line-height: 1.25;">(Name, address, including zip code, and telephone number, including area code, of agent for service)</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Copies to:</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z7e334f13ba684dc39bf409051804889c">

        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Mark Selinger, Esq.</div>
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Gary Emmanuel, Esq.</div>
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">McDermott Will &amp; Emery LLP</div>
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">340 Madison Avenue</div>
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">New York, NY 10173</div>
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">+1 212 547 5400</div>
          </td>
          <td style="width: 1%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 49%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Sharon Rosen, Adv.</div>
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Fischer Behar Chen Well</div>
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Orion &amp; Co.</div>
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">3 Daniel Frisch Street</div>
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Tel Aviv, 6473104, Israel</div>
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">+972 3 6944111</div>
          </td>
        </tr>

    </table>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-weight: bold;">Approximate date of commencement of proposed sale to the public:</font> As soon as practicable after this registration statement is declared
      effective.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following
      box. <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9746;</font></div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act
      registration statement number of the earlier effective registration statement for the same offering. <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number
      of the earlier effective registration statement for the same offering. <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number
      of the earlier effective registration statement for the same offering. <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Emerging growth company <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9746;</font></div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended
      transition period for complying with any new or revised financial accounting standards&#8224; provided pursuant to Section 7(a)(2)(B) of the Securities Act. <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9746;</font></div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold;">The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a
      further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective on
      such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <!--PROfilePageNumberReset%LCR%2%%%-->
    <div style="text-align: center; line-height: 1.25;">&#160; <br>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">CALCULATION OF REGISTRATION FEE</div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zc4903ae342544f1fa789ee94033ae1c1" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">

        <tr>
          <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25; font-weight: bold;">Title of Each Class of Securities to be Registered</div>
          </td>
          <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Amount<br>
              to be<br>
              Registered<br>
              (1)</div>
          </td>
          <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Proposed<br>
              Maximum<br>
              Offering<br>
              Price per<br>
              Security<br>
              (2)</div>
          </td>
          <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Proposed<br>
              Maximum<br>
              Aggregate<br>
              Offering Price<br>
              (2)</div>
          </td>
          <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Amount of<br>
              Registration<br>
              Fee</div>
          </td>
          <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF; width: 52%; padding-bottom: 2px;">
            <div style="line-height: 1.25;">Ordinary shares, par value NIS 2.40 per share, underlying Warrants to Purchase Ordinary Share(3)(4)</div>
          </td>
          <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td>
          <td valign="bottom" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;">
            <div style="line-height: 1.25;">20,388,864</div>
          </td>
          <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td valign="bottom" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;">
            <div style="line-height: 1.25;">0.471</div>
          </td>
          <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td valign="bottom" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;">
            <div style="line-height: 1.25;">9,603,154.9440</div>
          </td>
          <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td valign="bottom" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;">
            <div style="line-height: 1.25;">1,246.4895</div>
          </td>
          <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF; width: 52%;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
          <td valign="bottom" colspan="1" style="background-color: #FFFFFF; vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" colspan="1" style="background-color: #FFFFFF; vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: #FFFFFF; vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
          <td valign="bottom" colspan="1" style="background-color: #FFFFFF; vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" colspan="1" style="background-color: #FFFFFF; vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: #FFFFFF; vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
          <td valign="bottom" colspan="1" style="background-color: #FFFFFF; vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" colspan="1" style="background-color: #FFFFFF; vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: #FFFFFF; vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
          <td valign="bottom" colspan="1" style="background-color: #FFFFFF; vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" colspan="1" style="background-color: #FFFFFF; vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: #FFFFFF; vertical-align: bottom; width: 1%;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF; width: 52%; padding-bottom: 4px;">
            <div style="line-height: 1.25;">Total</div>
          </td>
          <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td>
          <td valign="bottom" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;">
            <div style="line-height: 1.25;">20,388,864</div>
          </td>
          <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>
          <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td valign="bottom" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;">
            <div style="line-height: 1.25;">0.471</div>
          </td>
          <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>
          <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td valign="bottom" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;">
            <div style="line-height: 1.25;">9,603,154.9440</div>
          </td>
          <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>
          <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td valign="bottom" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;">
            <div style="line-height: 1.25;">1,246.4895</div>
          </td>
          <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z20619e3305c6491b868b233ef70b028b">

        <tr>
          <td style="width: 0.1pt;"><br>
          </td>
          <td style="width: 27pt; vertical-align: top; align: right;">(1)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>This registration statement also includes an indeterminate number of shares that may become offered, issuable or sold to prevent dilution resulting from share splits, share dividends and similar transactions, which are included pursuant to
              Rule&#160;416 under the Securities Act of 1933, as amended.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb20ebd0746074a6393347af8b9e09729">

        <tr>
          <td style="width: 0.1pt;"><br>
          </td>
          <td style="width: 27pt; vertical-align: top; align: right;">(2)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(c) promulgated under the Securities Act of 1933, as amended, based on the average of the equivalent high and low sales prices of the ordinary shares
              on the Nasdaq Capital Market on August 18, 2020.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za5b658d856e546ea9a77c526f2fe649d">

        <tr>
          <td style="width: 0.1pt;"><br>
          </td>
          <td style="width: 27pt; vertical-align: top; align: right;">(3)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Consists of (i) 19,265,068 ordinary shares issuable upon the exercise of warrants originally issued in a private placement on July 27, 2020, or the July 2020 Private Placement, and (ii) 1,123,796 ordinary shares issuable upon the exercise
              of placement agent warrants issued in the July 2020 Private Placement.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z4972998c6fb748248f56a32f4fc8d5cc">

        <tr>
          <td style="width: 0.1pt;"><br>
          </td>
          <td style="width: 27pt; vertical-align: top; align: right;">(4)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Pursuant to Rule 429, this amount does not include an aggregate of 5,508,334 ordinary shares, consisting of (i) 4,166,667 ordinary shares issuable upon the exercise of warrants and (ii) 1,341,667 ordinary shares issuable upon the exercise
              of placement agent warrants, each previously registered in a Registration Statement on Form F-1 (File No. 333-238532).</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">ii</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: center; margin-right: 0.1pt; margin-left: 0.1pt; line-height: 1.25; font-weight: bold;">Explanatory Note</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; margin-right: 0.1pt; margin-left: 0.1pt; line-height: 1.25;">This registration statement, which is a new registration statement, relates first to the resale, by the selling shareholders identified in this prospectus, of
      an aggregate of up to 20,388,864 ordinary shares, consisting of (i) 19,265,068 ordinary shares issuable upon the exercise of warrants originally issued in a private placement on July 27, 2020, or the July 2020 Private Placement, and (ii) 1,123,796
      ordinary shares issuable upon the exercise of placement agent warrants issued in the July 2020 Private Placement.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; margin-right: 0.1pt; margin-left: 0.1pt; line-height: 1.25;">Second, this registration statement relates to, and shall act, upon effectiveness, as Post-Effective Amendment No. 1 on Form F-1 to the Registration Statement
      on Form F-1 (File No. 333-238532), or the June 2020 Registration Statement, containing an updated prospectus with respect to the resale by the selling shareholders named therein of up to an aggregate of 5,508,334 ordinary shares, consisting of (i)
      833,333 ordinary shares issuable upon the exercise of warrants originally issued in a private placement on April 22, 2020, or the April 2020 Private Placement, (ii) 466,667 ordinary shares issuable upon the exercise of placement agent warrants issued
      in the April 2020 Private Placement, (iii) 1,666,667 ordinary shares issuable upon the exercise of warrants originally issued in a private placement on May 4, 2020, or the First May 2020 Private Placement, (iv) 525,000 ordinary shares issuable upon
      the exercise of placement agent warrants issued in the First May 2020 Private Placement, (v) 1,666,667 ordinary shares issuable upon the exercise of warrants originally issued in a private placement on May 13, 2020, or the Second May 2020 Private
      Placement, and (vi) 350,000 ordinary shares issuable upon the exercise of placement agent warrants issued in the Second May 2020 Private Placement.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; margin-right: 0.1pt; margin-left: 0.1pt; line-height: 1.25;">This registration statement contains a combined prospectus relating to the securities described in the immediately preceding paragraph. Pursuant to Rule 429,
      this registration statement constitutes a post-effective amendment to the June 2020 Registration Statement, or the Prior Registration Statement, with respect to the unsold shares registered in the Prior Registration Statement, which is not currently
      being terminated by Check-Cap Ltd.. Such post-effective amendment will become effective concurrently with the effectiveness of this registration statement in accordance with Section 8(a) of the Securities Act.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; margin-right: 0.1pt; margin-left: 0.1pt; line-height: 1.25;">The information included in this filing updates the Prior Registration Statement and the prospectuses contained therein. No additional securities covered by
      the Prior Registration Statement are being registered in this registration statement. All filing fees payable in connection with the registration of the securities covered by the Prior Registration Statement were paid at the respective times of the
      original filings of the Prior Registration Statement.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="background-color: #FFFFFF; line-height: 1.25;">
      <div style="text-align: justify; line-height: 1.25;">The information in this prospectus is not complete and may be changed. The selling shareholders may not sell these securities until the registration statement filed with the Securities and Exchange
        Commission is effective. This preliminary prospectus is not an offer to sell these securities and we are not soliciting an offer to buy these securities in any state or jurisdiction where the offer or sale is not permitted.</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">iii</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
    </div>
    <div style="text-align: justify; line-height: 1.25;">
      <div style="background-color: rgb(255, 255, 255); line-height: 1.25; font-weight: normal; color: rgb(255, 0, 0); font-family: 'Times New Roman',Times,serif; font-style: normal; font-variant: normal; text-transform: none;">
        <div style="line-height: 1.25;">The information in this prospectus is not complete and may be changed. The selling shareholders may not sell these securities until the registration statement filed with the Securities and Exchange Commission is
          effective. This preliminary prospectus is not an offer to sell these securities and we are not soliciting an offer to buy these securities in any state or jurisdiction where the offer or sale is not permitted.</div>
      </div>
      &#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z5d21e24aa19d4debaed5bff7bdd928dd">

        <tr>
          <td style="width: 32.99%; vertical-align: top;">
            <div style="line-height: 1.25; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(255, 0, 0); font-family: 'Times New Roman',Times,serif; font-style: normal; font-variant: normal; text-transform: none;">PRELIMINARY PROSPECTUS</div>
          </td>
          <td style="width: 34%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(255, 0, 0); font-family: 'Times New Roman',Times,serif; font-style: normal; font-variant: normal; text-transform: none;">SUBJECT






              TO COMPLETION</div>
          </td>
          <td style="width: 33%; vertical-align: top;">
            <div style="text-align: right; line-height: 1.25; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(255, 0, 0); font-family: 'Times New Roman',Times,serif; font-style: normal; font-variant: normal; text-transform: none;">DATED
              AUGUST 20, 2020</div>
          </td>
        </tr>

    </table>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;</div>
    <div style="text-align: center; line-height: 1.25;"><img width="250" height="133" src="image0.jpg"></div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">25,897,198 Ordinary Shares</div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">This prospectus relates to the resale, by the selling shareholders identified in this prospectus, of up to an aggregate of 25,897,198 ordinary shares, par value NIS 2.40 per share
      of Check-Cap Ltd., consisting of (1) 20,388,864 ordinary shares consisting of (i) 19,265,068 ordinary shares issuable upon the exercise of warrants originally issued in a private placement on July 27, 2020, or the July 2020 Private Placement and (ii)
      1,123,796 ordinary shares issuable upon the exercise of placement agent warrants issued in the July 2020 Private Placement, and (2) 5,508,334 ordinary shares previously registered in a Registration Statement on Form F-1 (File No. 333-238532),
      consisting of (i) 833,333 ordinary shares issuable upon the exercise of warrants originally issued in a private placement on April 22, 2020, or the April 2020 Private Placement, (ii) 466,667 ordinary shares issuable upon the exercise of placement
      agent warrants issued in the April 2020 Private Placement, (iii) 1,666,667 ordinary shares issuable upon the exercise of warrants originally issued in a private placement on May 4, 2020, or the First May 2020 Private Placement, (iv) 525,000 ordinary
      shares issuable upon the exercise of placement agent warrants issued in the First May 2020 Private Placement, (v) 1,666,667 ordinary shares issuable upon the exercise of warrants originally issued in a private placement on May 13, 2020, or the Second
      May 2020 Private Placement, and (vi) 350,000 ordinary shares issuable upon the exercise of placement agent warrants issued in the Second May 2020 Private Placement.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The selling shareholders are identified in the table commencing on page 10. We will not receive any proceeds from the sale of the ordinary shares by the selling shareholders. All
      net proceeds from the sale of the ordinary shares covered by this prospectus will go to the selling shareholders. However, we may receive the proceeds from any exercise of warrants if the selling shareholders do not exercise the warrants on a
      cashless basis, if and when exercised. See &#8220;Use of Proceeds.&#8221;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The selling shareholders may sell all or a portion of the ordinary shares from time to time in market transactions through any market on which our ordinary shares are then traded,
      in negotiated transactions or otherwise, and at prices and on terms that will be determined by the then prevailing market price or at negotiated prices directly or through a broker or brokers, who may act as agent or as principal or by a combination
      of such methods of sale. We will bear all of the expenses incurred in connection with the registration of these shares. The selling shareholders will pay any underwriting discounts and selling commissions and/or similar charges incurred in connection
      with the sale of the shares. See &#8220;Plan of Distribution&#8221;.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">Our ordinary shares are listed on the Nasdaq Capital Market under the symbol &#8220;CHEK.&#8221; The last reported sale price of our ordinary shares on August 19, 2020 was $0.46 per share.</div>
    </div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-weight: bold;">The securities offered in this prospectus involve a high degree of risk. See &#8220;Risk Factors&#8221; beginning on page 6</font> <font style="font-weight: bold;">of this prospectus to read about factors you should consider before purchasing any of our securities.</font></div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold;">Neither the U.S. Securities and Exchange Commission, the Israel Securities Authority nor any state or other foreign securities commission has approved or
      disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: center; text-indent: 36pt; line-height: 1.25;">The date of this prospectus is August&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; , 2020.</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">iv</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: center; line-height: 1.25;">&#160; <br>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">TABLE OF CONTENTS</div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z980068932ee54ef6bf36fda34d81fcc0">

        <tr>
          <td style="width: 92%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;"><a href="#AboutThisProspectus">About this Prospectus</a></div>
          </td>
          <td style="width: 8%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="text-align: right; line-height: 1.25;">1<br>
            </div>
          </td>
        </tr>
        <tr>
          <td style="width: 92%; vertical-align: top; background-color: #FFFFFF;">
            <div style="line-height: 1.25;"><a href="#PROSPECTUSSUMMARY">Prospectus Summary</a></div>
          </td>
          <td style="width: 8%; vertical-align: top; background-color: #FFFFFF;">
            <div style="text-align: right; line-height: 1.25;">2<br>
            </div>
          </td>
        </tr>
        <tr>
          <td style="width: 92%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;"><a href="#RISKFACTORS">Risk Factors</a></div>
          </td>
          <td style="width: 8%; vertical-align: top; background-color: #CCEEFF;">
            <div style="text-align: right; line-height: 1.25;">6<br>
            </div>
          </td>
        </tr>
        <tr>
          <td style="width: 92%; vertical-align: top; background-color: #FFFFFF;">
            <div style="line-height: 1.25;"><a href="#SPECIALNOTEREGARDINGFORWA">Special Note Regarding Forward-Looking Statements</a></div>
          </td>
          <td style="width: 8%; vertical-align: top; background-color: #FFFFFF;">
            <div style="text-align: right; line-height: 1.25;">7<br>
            </div>
          </td>
        </tr>
        <tr>
          <td style="width: 92%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;"><a href="#USEOFPROCEEDS">Use of Proceeds</a></div>
          </td>
          <td style="width: 8%; vertical-align: top; background-color: #CCEEFF;">
            <div style="text-align: right; line-height: 1.25;">8<br>
            </div>
          </td>
        </tr>
        <tr>
          <td style="width: 92%; vertical-align: top; background-color: #FFFFFF;">
            <div style="line-height: 1.25;"><a href="#CAPITALIZATION">Capitalization</a></div>
          </td>
          <td style="width: 8%; vertical-align: top; background-color: #FFFFFF;">
            <div style="text-align: right; line-height: 1.25;">8<br>
            </div>
          </td>
        </tr>
        <tr>
          <td style="width: 92%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;"><a href="#SELLINGSHAREHOLDERS">Selling Shareholders</a></div>
          </td>
          <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: right;">10<br>
          </td>
        </tr>
        <tr>
          <td style="width: 92%; vertical-align: top; background-color: #FFFFFF;">
            <div style="line-height: 1.25;"><a href="#DESCRIPTIONOFSHARECAPITAL">Description of Share Capital</a></div>
          </td>
          <td style="width: 8%; vertical-align: top; background-color: rgb(255, 255, 255); text-align: right;">14<br>
          </td>
        </tr>
        <tr>
          <td style="width: 92%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;"><a href="#PLANOFDISTRIBUTION">Plan of Distribution</a></div>
          </td>
          <td style="width: 8%; vertical-align: top; background-color: #CCEEFF;">
            <div style="text-align: right; line-height: 1.25;">24<br>
            </div>
          </td>
        </tr>
        <tr>
          <td style="width: 92%; vertical-align: top; background-color: #FFFFFF;">
            <div style="line-height: 1.25;"><a href="#LEGALMATTERS">Legal Matters</a></div>
          </td>
          <td style="width: 8%; vertical-align: top; background-color: rgb(255, 255, 255); text-align: right;">26<br>
          </td>
        </tr>
        <tr>
          <td style="width: 92%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;"><a href="#EXPERTS">Experts</a></div>
          </td>
          <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: right;">26<br>
          </td>
        </tr>
        <tr>
          <td style="width: 92%; vertical-align: top; background-color: #FFFFFF;">
            <div style="line-height: 1.25;"><a href="#WHEREYOUCANFINDMOREINFORM">Where You Can Find More Information</a></div>
          </td>
          <td style="width: 8%; vertical-align: top; background-color: rgb(255, 255, 255); text-align: right;">26<br>
          </td>
        </tr>
        <tr>
          <td style="width: 92%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;"><a href="#INCORPORATIONOFCERTAININF">Incorporation By Reference</a></div>
          </td>
          <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: right;">27<br>
          </td>
        </tr>
        <tr>
          <td style="width: 92%; vertical-align: top; background-color: #FFFFFF;">
            <div style="line-height: 1.25;"><a href="#ENFORCEABILITYOFCIVILLIAB">Enforceability of Civil Liabilities</a></div>
          </td>
          <td style="width: 8%; vertical-align: top; background-color: rgb(255, 255, 255); text-align: right;">28<br>
          </td>
        </tr>

    </table>
    <div style="text-align: center; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">v</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <!--PROfilePageNumberReset%Num%1%%%-->
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="AboutThisProspectus"><!--Anchor--></a>About This Prospectus</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">This prospectus is part of a registration statement that we filed with the SEC. As permitted by the rules and regulations of the SEC, the registration statement filed by us
      includes additional information not contained in this prospectus. You may read the registration statement and the other reports we file with the SEC at the SEC&#8217;s website or its offices described below under the heading &#8220;Where You Can Find More
      Information&#8221;.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">You should rely only on the information that is contained in this prospectus or that is incorporated by reference into this prospectus. Neither we nor the selling shareholders have
      authorized anyone to provide you with information that is in addition to or different from that contained in, or incorporated by reference into, this prospectus. If anyone provides you with different or inconsistent information, you should not rely
      on it.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The information contained in this prospectus is accurate as of the date on the front of this prospectus only, regardless of the time of delivery of this prospectus or of any sale
      of our ordinary shares. Our business, financial condition, results of operations and prospects may have changed since that date.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We obtained statistical data, market data and other industry data and forecasts used or incorporated by reference in this prospectus from market research, publicly available
      information and industry publications.&#160; While we believe that the statistical data, industry data and forecasts and market research are reliable, we have not independently verified the data. While we are not aware of any misstatements regarding the
      industry data presented in this prospectus, our estimates involve risks and uncertainties and are subject to change based on various factors, including those discussed under the heading &#8220;Risk Factors&#8221; in this prospectus. Our financial statements are
      prepared and presented in accordance with generally accepted accounting principles in the United States of America, or U.S. GAAP. Our historical results do not necessarily indicate our expected results for any future periods.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Certain figures included in this prospectus have been subject to rounding adjustments. Accordingly, figures shown as totals in certain tables may not be an arithmetic aggregation
      of the figures that precede them</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In this prospectus, unless the context otherwise requires:</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z16118656071d47b88edd0a36d3e7a6b0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right;">&#9679;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>references to the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our&#8221; and &#8220;Check-Cap Ltd.&#8221; refer to Check-Cap Ltd.,&#160;an Israeli company, together with Check-Cap US, Inc., its U.S. subsidiary;</div>
          </td>
        </tr>

    </table>
    <div style="text-align: justify; text-indent: -18pt; margin-left: 54pt; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z159376afee8a4aab9c5929684448f615">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right;">&#9679;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>references to the &#8220;Companies Law&#8221; or &#8220;Israeli Companies Law&#8221; are to the Israeli Companies Law, 5759-1999, as amended;</div>
          </td>
        </tr>

    </table>
    <div style="text-align: justify; text-indent: -18pt; margin-left: 54pt; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z851601df2b884e9d87ab607ecb498d15">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right;">&#9679;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>references to &#8220;dollars,&#8221; &#8220;U.S. dollars&#8221; and &#8220;$&#8221; are to United States Dollars;</div>
          </td>
        </tr>

    </table>
    <div style="text-align: justify; text-indent: -18pt; margin-left: 54pt; line-height: 1.25;">&#160;&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb1300e1eac8049a887407276bb804ba3">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right;">&#9679;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>references to &#8220;ordinary shares,&#8221; &#8220;our shares&#8221; and similar expressions refer to the Registrant&#8217;s Ordinary Shares, NIS 2.40 nominal (par) value per share;</div>
          </td>
        </tr>

    </table>
    <div style="text-align: justify; text-indent: -18pt; margin-left: 54pt; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z59b65a82945544e98de0337b914de68f">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right;">&#9679;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>references to &#8220;shekels&#8221; and &#8220;NIS&#8221; are to New Israeli Shekels, the Israeli currency; and</div>
          </td>
        </tr>

    </table>
    <div style="text-align: justify; text-indent: -18pt; margin-left: 54pt; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3ffd080750db47bcb47ee65197109dc0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right;">&#9679;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>references to the &#8220;SEC&#8221; are to the United States Securities and Exchange Commission.</div>
          </td>
        </tr>

    </table>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">We effected a 1-for-12 reverse share split of our ordinary shares on April 4, 2018. Unless indicated otherwise by the context, all ordinary share, option, warrant and per share amounts as well as
        share prices appearing in this prospectus have been adjusted to give retroactive effect to the share split for all periods presented.</div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">1</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;<br>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="PROSPECTUSSUMMARY"><!--Anchor--></a>PROSPECTUS SUMMARY</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-style: italic;">This summary highlights information contained in other parts of this prospectus or incorporated by reference into this prospectus from our filings with the SEC, listed in the
      section of the prospectus entitled &#8220;Incorporation of Certain Information by Reference.&#8221; Because it is only a summary, it does not contain all of the information that you should consider before purchasing our securities in this offering and it is
      qualified in its entirety by, and should be read in conjunction with, the more detailed information appearing elsewhere or incorporated by reference into this prospectus.&#160; You should read the entire prospectus, the registration statement of which
      this prospectus is a part, and the information incorporated by reference herein in their entirety, including the &#8220;Risk Factors&#8221; and our financial statements and the related notes incorporated by reference into this prospectus, before making an
      investment decision.&#160; Some of the statements in this prospectus and the documents incorporated by reference herein constitute forward-looking statements that involve risks and uncertainties.&#160; See information set forth under the section &#8220;Cautionary
      Note Regarding Forward-Looking Statements.&#8221;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Our Company</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We are a clinical stage medical diagnostics company aiming to redefine colorectal cancer, or CRC, prevention through the introduction of C-Scan&#174;, the first and only
      patient-friendly preparation-free test designed to detect polyps&#160; before they may transform into cancer. The disruptive capsule-based screening technology aims to increase screening adherence worldwide and enable millions of people to stay healthy.
      The system utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps and other structural abnormalities. CRC is the third most commonly diagnosed cancer, with more than 1.8 million new cases identified every year
      globally. Nearly 881,000 deaths occur annually worldwide as a result of CRC.&#160; While approximately 0.5% of the average-risk screening population presents cancerous polyps in the colon and rectum at a given time, approximately 25% of the same
      population presents benign polyps that could potentially turn into cancer over time. It can take up to 10 years before a pre-cancerous polyp develops into invasive cancer. As such, there is a crucial detection window for the prevention of colorectal
      cancer, through the detection of these benign polyps. While routine screening is recommended by The American Cancer Society for healthy people aged 45 years and older, screening adherence remains low. About 1 in 3 adults among the targeted screening
      population avoids having a colonoscopy in the U.S., and adherence in other regions of the world such as Europe and Asia are even lower. Unlike other screening modalities that are designed for direct visualization and imaging of the internal colon,
      such as optical colonoscopy and other capsule-based technologies, C-Scan is designed to function without any laxative preparation, and to transit the gastrointestinal tract by natural motility while the patient continues his or her daily routine.
      Furthermore, the C-Scan system does not require fasting prior to or during capsule transit. C-Scan is comprised of three main components: (1) C-Scan Cap, a ingestible X-ray scanning capsule; (2) C-Scan Track, three miniaturized patches worn on the
      patient&#8217;s back for integrated positioning, control and data recording; and (3) C-Scan View, a proprietary software to process and represent 2D and 3D maps of the inner surface of the colon.&#160; We believe that this solution has the potential to become
      an alternative for both physicians and patients and, to increase the number of people completing CRC screening.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Since our formation, we have not generated any revenue. We do not anticipate generating any significant revenue for the foreseeable future and we do not yet have any specific
      launch dates for our product. We incurred net losses of $13.8 million in 2019, $10.6 million in 2018 and $9.8 million in 2017.&#160; As of June 30, 2020, we had an accumulated deficit of $83.5 million and a total shareholders&#8217; equity of $15.0 million.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Public health epidemics or outbreaks could adversely impact our business. In late 2019, a novel strain of COVID-19, also known as coronavirus, was reported in Wuhan, China. While
      initially the outbreak was largely concentrated in China, it has now spread globally, including to Israel and the United States. In March 2020, the World Health Organization declared COVID-19 a pandemic and&#160; recommended containment and mitigation
      measures worldwide. Accordingly, many countries around the world, including Israel, have implemented significant governmental measures to control the spread of the virus, including temporary closure of businesses, severe restrictions on travel and
      the movement of people, and other material limitations on the conduct of business. As a consequence, we have experienced temporary disruptions to our operations and we temporarily suspended our clinical studies. Further, in accordance with the
      directive of the Israel Ministry of Health, during the first wave of the COVID-19 pandemic in Israel, the majority of our employees worked remotely while a select few continued to work from our headquarters Also, we temporarily suspended interactions
      between hospitals and healthcare professionals and its employees and clinical trial patients. In addition, to manage this crisis, we implemented several cost reduction measures, including a temporary 15% reduction in salaries for all employees and
      management and the fees of the members of our board of directors and lowered monthly expenditures by temporarily placing a number of operational employees on unpaid leave. As a result of lowered infection rates in Israel in June 2020,&#160; which resulted
      in the lifting of many government restrictions to control the spread of the virus as well as our improved financial position following our financings in April and May 2020, we resumed near normal operations and restored salaries to their original
      levels.&#160;However, during July 2020, infection rates in Israel began to significantly increase and the country is in the midst of a &#8220;second wave&#8221;. Consequently, we have implemented several&#160; measures according to the Israel Ministry of Health&#8217;s
      guidelines, including remote working whenever possible, physical separation between employees and daily employee health monitoring.&#160; It is still too early to assess the full impact of the coronavirus outbreak, but coronavirus is affecting our ability
      to initiate our planned pivotal study and commence pilot sales in Israel and Europe in our original timeframe.&#160; The extent to which the COVID-19 pandemic shall impact our operations will depend on future developments, which are highly uncertain and
      cannot be predicted with confidence, including the duration and severity of the outbreak, the impact on the global economy, the impact of a second and third wave of COVID-19 and the actions that may be required to contain the coronavirus or treat its
      impact. In particular, the continued spread of the coronavirus globally, could materially adversely impact our operations and workforce, including our research and clinical trials and our ability to continue raise capital, could affect the operations
      of key governmental agencies, such as the FDA, which may delay our development plans, and could result in the inability of our suppliers to deliver components or raw materials on a timely basis or at all, each of which in turn could have a material
      adverse impact on our business, financial condition and results of operation.</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">2</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Corporate Information</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We are incorporated in Israel.&#160; Our principal executive offices are located at Check-Cap Building, 29 Abba Hushi Avenue, P.O. Box 1271, Isfiya, 3009000, Israel.&#160; Our telephone
      number is +972-4-8303400 and our website is located at www.check-cap.com (the information contained therein or linked thereto shall not be considered incorporated by reference in this prospectus).&#160; Our U.S. agent in connection with this offering is
      Puglisi &amp; Associates, located at 850 Library Avenue, Suite 204, Newark, Delaware 19711.</div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">April 2020 Financing</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">On April 22, 2020, we sold to certain institutional investors an aggregate of 6,666,669 ordinary shares in a registered direct offering at a purchase price of $0.60 per share,
      resulting in gross proceeds of approximately $4,000,000. In addition, we issued to the investors unregistered warrants to purchase up to an aggregate of 6,666,669 ordinary shares in a concurrent private placement. The warrants are immediately
      exercisable and will expire five and one-half years from the issuance date at an exercise price of $0.80 per ordinary share, subject to adjustment as set forth therein. The warrants may be exercised on a cashless basis if at the time of exercise
      thereof, there is no effective registration statement registering the ordinary shares underlying the warrants. We paid an aggregate of $280,000 in placement agent fees, a management fee equal to 1.0% of the gross proceeds raised in the offering, a
      non-accountable expense allowance of $65,000 and clearing expenses of $12,900. We also issued unregistered placement agent warrants to purchase up to an aggregate of 466,667 ordinary shares on the same terms as the warrants issued to the investors in
      the private placement, except they have a term of five years and an exercise price of $0.75 per share.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In connection with the April 2020 financing, the selling shareholders named in this prospectus may offer and sell up to an aggregate of 1,300,000 ordinary shares issuable upon
      exercise of these warrants.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">First May 2020 Financing</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">On May 4, 2020, we sold to certain institutional investors an aggregate of 7,500,001 ordinary shares in a registered direct offering at a purchase price of $0.60 per share,
      resulting in gross proceeds of approximately $4,500,000. In addition, we issued to the investors unregistered warrants to purchase up to an aggregate of 7,500,001 ordinary shares in a concurrent private placement. The warrants are immediately
      exercisable and will expire five and one-half years from the issuance date at an exercise price of $0.80 per ordinary share, subject to adjustment as set forth therein. The warrants may be exercised on a cashless basis if at the time of exercise
      thereof, there is no effective registration statement registering the ordinary shares underlying the warrants. We paid an aggregate of $315,000 in placement agent fees, a management fee equal to 1.0% of the gross proceeds raised in the offering, a
      non-accountable expense allowance of $65,000 and clearing expenses of $12,900. We also issued unregistered placement agent warrants to purchase up to an aggregate of 525,000 ordinary shares on the same terms as the warrants issued to the investors in
      the private placement, except they have a term of five years and an exercise price of $0.75 per share.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In connection with the First May 2020 financing, the selling shareholders named in this prospectus may offer and sell up to an aggregate of 2,191,667 ordinary shares issuable upon
      exercise of these warrants.</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">3</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Second May 2020 Financing</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">On May 13, 2020, we sold to certain institutional investors an aggregate of 5,000,000 ordinary shares in a registered direct offering at a purchase price of $0.60 per share,
      resulting in gross proceeds of $3,000,000. In addition, we issued to the investors unregistered warrants to purchase up to an aggregate of 5,000,000 ordinary shares in a concurrent private placement. The warrants are immediately exercisable and will
      expire five and one-half years from the issuance date at an exercise price of $0.80 per ordinary share, subject to adjustment as set forth therein. The warrants may be exercised on a cashless basis if at the time of exercise thereof, there is no
      effective registration statement registering the ordinary shares underlying the warrants. We paid an aggregate of $210,000 in placement agent fees, a management fee equal to 1.0% of the gross proceeds raised in the offering, a non-accountable expense
      allowance of $32,500 and clearing expenses of $12,900. We also issued unregistered placement agent warrants to purchase up to an aggregate of 350,000 ordinary shares on the same terms as the warrants issued to the investors in the private placement,
      except they have a term of five years and an exercise price of $0.75 per share.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In connection with the Second May 2020 financing, the selling shareholders named in this prospectus may offer and sell up to an aggregate of 2,016,667 ordinary shares issuable upon
      exercise of these warrants.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; margin-right: 0.1pt; line-height: 1.25; font-weight: bold;">July 2020 Financing</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-right: 0.1pt; margin-left: 0.2pt; line-height: 1.25;">On July 23, 2020, we entered into a warrant exercise agreement, or the Exercise Agreement, with several existing institutional investors
      who are the holders, or the Holders, of warrants issued in May 2020, April 2020, February 2019 and&#160; November 2017, or the Old Warrants, to purchase our ordinary shares, pursuant to which the Holders agreed to exercise in cash their Old Warrants to
      purchase up to an aggregate of 16,054,223 ordinary shares having exercise prices ranging from $15.00 to $0.80 per share issued by us, at a reduced exercise price of $0.60 per share, resulting in gross proceeds of approximately $9.6 million. Closing
      occurred on July 27, 2020. Under the Exercise Agreement, we also issued to the Holders new unregistered warrants to purchase up to 19,265,068 ordinary shares, or the Private Placement Warrants. The Private Placement Warrants are immediately
      exercisable, expire five and one-half years from issuance date and have an exercise price of $0.80 per share, subject to adjustment as set forth therein. The Private Placement Warrants may be exercised on a cashless basis if at the time of exercise
      thereof, there is no effective registration statement registering the ordinary shares underlying the warrants. We paid an aggregate of $674,277 in placement agent fees a management fee equal to 1.0% of the gross proceeds raised in the offering, a
      non-accountable expense allowance of $65,000 and clearing expenses of $12,900 and issued unregistered placement agent warrants to purchase up to an aggregate of 1,123,796 ordinary shares on the same terms as the warrants issued to the Holders, except
      that they have an exercise price of $0.75 per share.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-right: 0.1pt; margin-left: 0.1pt; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-right: 0.1pt; margin-left: 0.1pt; line-height: 1.25;">In connection with the July 2020 financing, the selling shareholders named in this prospectus may offer and sell up to an aggregate of
      20,388,864 ordinary shares.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Throughout this prospectus, when we refer to our ordinary shares being registered on behalf of the selling shareholders, we are referring to the ordinary shares that may be
      issuable upon exercise of warrants. Throughout this prospectus, when we refer to the selling shareholders, we are referring to the selling shareholders named herein and, as applicable, any donees, pledgees, transferees or other successors-in-interest
      selling shares received after the date of this prospectus from a selling shareholder as a gift, pledge, or other non-sale related transfer that may be identified in a supplement to this prospectus or, if required, a post-effective amendment to the
      registration statement of which this prospectus is a part.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-weight: bold;">Recent Developments</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">On June 5, 2020, we announced that we received a notification from the Nasdaq Listing Qualifications that we are not in compliance with the minimum bid price requirement for
      continued listing set forth in Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Further, on April 16, 2020, in response to the COVID-19 pandemic, and the resulting related market conditions, Nasdaq has elected to provide temporary relief from the bid price
      requirements by tolling compliance through June 30, 2020. As a result of the tolling of the bid price requirements, we have 180 calendar days from July 1, 2020, or until December 28, 2020, to regain compliance with the minimum bid price requirement.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We can regain compliance, if at any time during this 180 day period, the closing bid price of our ordinary shares is at least $1 for a minimum of ten consecutive business days, in
      which case we will be provided with a written confirmation of compliance and the matter will be closed.&#160; We may then be eligible for an additional 180 day grace period if we meets the Nasdaq Capital Market's initial listing standards with the
      exception of the minimum bid price requirement.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If we cannot demonstrate compliance by the end of the grace period, the Nasdaq's staff will notify us that our ordinary shares are subject to delisting.</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">4</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">The Offering</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zef3b7d2ee6a6451ea8d62bb98b3b6548">

        <tr>
          <td style="width: 25.99%; vertical-align: top;">
            <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Offered Shares</div>
          </td>
          <td style="width: 2.01%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 72%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">Up to an aggregate of 25,897,198 ordinary shares, par value NIS 2.40 per share,&#160; of Check-Cap Ltd., consisting of (1) 20,388,864 ordinary shares consisting of (i) 19,265,068 ordinary shares
              issuable upon the exercise of warrants originally issued in the July 2020 Private Placement and (ii) 1,123,796 ordinary shares issuable upon the exercise of placement agent warrants issued in the July 2020 Private Placement, and (2) 5,508,334
              ordinary shares previously registered in a Registration Statement on Form F-1 (File No. 333-238532), consisting of (i) 833,333 ordinary shares issuable upon the exercise of warrants originally issued in the April 2020 Private Placement, (ii)
              466,667 ordinary shares issuable upon the exercise of placement agent warrants issued in the April 2020 Private Placement, (iii) 1,666,667 ordinary shares issuable upon the exercise of warrants originally issued in the First May 2020 Private
              Placement, (iv) 525,000 ordinary shares issuable upon the exercise of placement agent warrants issued in the First May 2020 Private Placement, (v) 1,666,667 ordinary shares issuable upon the exercise of warrants originally issued in the
              Second May 2020 Private Placement, and (vi) 350,000 ordinary shares issuable upon the exercise of placement agent warrants issued in the Second May 2020 Private Placement. The selling shareholders are identified in the table commencing on
              page 10.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 25.99%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 2.01%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 72%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 25.99%; vertical-align: top;">
            <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Ordinary Shares Outstanding at August 19, 2020</div>
          </td>
          <td style="width: 2.01%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 72%; vertical-align: top;">
            <div style="line-height: 1.25;">46,231,661 ordinary shares.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 25.99%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 2.01%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 72%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 25.99%; vertical-align: top;">
            <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Use of proceeds</div>
          </td>
          <td style="width: 2.01%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 72%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">We will not receive any proceeds from the sale of the ordinary shares by the selling shareholders. All net proceeds from the sale of the ordinary shares covered by this prospectus will go to
              the selling shareholders. However, we may receive the proceeds from any exercise of investor warrants and placement agent warrants if the selling shareholders do not exercise the warrants on a cashless basis, if and when exercised. See the
              section of this prospectus titled &#8220;Use of Proceeds.&#8221;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 25.99%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 2.01%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 72%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 25.99%; vertical-align: top;">
            <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Nasdaq Capital Market Symbol</div>
          </td>
          <td style="width: 2.01%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 72%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">Our ordinary shares are listed on the Nasdaq Capital Market under the symbol &#8220;CHEK.&#8221;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 25.99%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 2.01%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 72%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 25.99%; vertical-align: top;">
            <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Risk factors</div>
          </td>
          <td style="width: 2.01%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 72%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">Before investing in our securities, you should carefully read and consider the &#8220;Risk Factors&#8221; beginning on page 6 of this prospectus.</div>
          </td>
        </tr>

    </table>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Unless otherwise indicated, the number of ordinary shares outstanding prior to and after this offering is based on 46,231,661 ordinary shares outstanding as of August 19, 2020, and
      excludes:</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zbddabaadd24b4e599ee27dcb677858b2">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right;">&#9679;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>30,662,392 ordinary shares issuable upon the exercise of outstanding warrants, with a weighted average exercise price of $2.44 per ordinary share;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zef8ba26e9a18428cb710482f584e480b">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right;">&#9679;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>1,110,022 ordinary shares issuable upon the exercise of outstanding options, with a weighted average exercise price of $4.82 per ordinary share, granted under our option and equity incentive plans;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;">
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">&#9679;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>
                <div style="line-height: 1.25;">81,094 restricted stock units issued to employees, consultants and directors; and</div>
              </div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25;">
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top; align: right;">&#9679;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="line-height: 1.25;">132,742 ordinary shares that are available for future option grants under our 2015 Equity Incentive Plan and 2015 U.S. Sub-Plan to the 2015 Equity Incentive Plan, or the 2015 Plan.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;">&#160;</div>
      </div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Unless otherwise indicated, all information in this prospectus assumes no exercise of the outstanding options or warrants described above.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">5</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="RISKFACTORS"><!--Anchor--></a>RISK FACTORS</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic;">An investment in our securities involves a high degree of risk, you should carefully consider the risk factors set forth in our most recent Annual Report on
      Form 20-F on file with the SEC, which is incorporated by reference into this prospectus, as well as the following risk factors, which supplement or augment the risk factors set forth in our Annual Report on Form 20-F. Before making an investment
      decision, you should carefully consider these risks as well as other information we include or incorporate by reference in this prospectus. The risks and uncertainties not presently known to us or that we currently deem immaterial may also materially
      harm our business, operating results and financial condition and could result in a complete loss of your investment.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold;">The sale of a substantial amount of our ordinary shares, including resale of the ordinary shares issuable upon the exercise of the warrants
      held by the selling shareholders in the public market could adversely affect the prevailing market price of our ordinary shares.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We are registering for resale an aggregate of 25,897,198 ordinary shares issuable upon the exercise of warrants held by the selling shareholders. Sales of substantial amounts of
      our ordinary shares in the public market, or the perception that such sales might occur, could adversely affect the market price of our ordinary shares, and the market value of our other securities. We cannot predict if and when selling shareholders
      may sell such shares in the public markets. Furthermore, in the future, we may issue additional ordinary shares or other equity or debt securities convertible into ordinary shares. Any such issuance could result in substantial dilution to our
      existing shareholders and could cause our share price to decline.</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">6</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25; font-weight: bold;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="SPECIALNOTEREGARDINGFORWA"><!--Anchor--></a>SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">This prospectus and the documents incorporated herein by reference contain statements that may be deemed to be &#8220;forward-looking statements&#8221; within the meaning of the federal
      securities laws.&#160; These statements relate to anticipated future events, future results of operations and/or future financial performance.&#160; In some cases, you can identify forward-looking statements by their use of terminology such as &#8220;anticipate,&#8221;
      &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;target&#8221;, &#8220;future,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;ought to,&#8221; &#8220;plan,&#8221; &#8220;possible,&#8221; &#8220;potentially,&#8221; &#8220;predicts,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; negatives of such terms or other similar terms.&#160; These forward-looking
      statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the
      forward-looking statements including, without limitation, the risks identified above in &#8220;Risk Factors&#8221; and those contained in our Annual Report on Form 20-F for the fiscal year ended December 31, 2019, or the 2019 Annual Report.&#160; The forward-looking
      statements in this prospectus and the documents incorporated herein by reference include, without limitation, statements relating to:&#160;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zc21f6b2bdcb2468e8d1888cb079707cc">

        <tr>
          <td style="width: 7.68%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.84%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 88.48%; vertical-align: top;">
            <div style="line-height: 1.25;">our history of losses and our ability to continue as a going concern;</div>
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7.68%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.84%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 88.48%; vertical-align: top;">
            <div style="line-height: 1.25;">our needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7.68%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.84%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 88.48%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7.68%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.84%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 88.48%; vertical-align: top;">
            <div style="line-height: 1.25;">the impact of the recent outbreak of coronavirus;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7.68%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.84%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 88.48%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7.68%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.84%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 88.48%; vertical-align: top;">
            <div style="line-height: 1.25;">the initiation, timing, progress and results of our clinical trials and other product development efforts;</div>
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7.68%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.84%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 88.48%; vertical-align: top;">
            <div style="line-height: 1.25;">our reliance on one product or product line;</div>
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7.68%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.84%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 88.48%; vertical-align: top;">
            <div style="line-height: 1.25;">the clinical development, commercialization and market acceptance of C-Scan;</div>
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7.68%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.84%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 88.48%; vertical-align: top;">
            <div style="line-height: 1.25;">our ability to receive de novo classification and other regulatory approvals for C-Scan;</div>
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7.68%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.84%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 88.48%; vertical-align: top;">
            <div style="line-height: 1.25;">our ability to successfully complete clinical trials;</div>
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7.68%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.84%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 88.48%; vertical-align: top;">
            <div style="line-height: 1.25;">our reliance on single-source suppliers;</div>
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7.68%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.84%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 88.48%; vertical-align: top;">
            <div style="line-height: 1.25;">our reliance on third parties, such as for purposes of our clinical trials and clinical development and the manufacturing, marketing and distribution of our C-Scan system;</div>
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7.68%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.84%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 88.48%; vertical-align: top;">
            <div style="line-height: 1.25;">our ability to establish and maintain strategic partnerships and other corporate collaborations;</div>
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7.68%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.84%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 88.48%; vertical-align: top;">
            <div style="line-height: 1.25;">our ability to achieve reimbursement and coverage from government and private third-party payors;</div>
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7.68%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.84%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 88.48%; vertical-align: top;">
            <div style="line-height: 1.25;">the implementation of our business model and strategic plans for our business;</div>
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7.68%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.84%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 88.48%; vertical-align: top;">
            <div style="line-height: 1.25;">the scope of protection we are able to establish and maintain for intellectual property rights covering C-Scan and our ability to operate our business without infringing the intellectual property rights of
              others;</div>
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7.68%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.84%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 88.48%; vertical-align: top;">
            <div style="line-height: 1.25;">competitive companies, technologies and our industry; and</div>
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7.68%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.84%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 88.48%; vertical-align: top;">
            <div style="line-height: 1.25;">statements as to the impact of the political and security situation in Israel on our business.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The preceding list is not intended to be an exhaustive list of all of our forward-looking statements.&#160; Forward-looking statements reflect our current views with respect to future
      events and are based on assumptions and subject to risks and uncertainties.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">You should not unduly rely on any forward-looking statements.&#160; Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot
      guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or will occur.&#160; Except as required by law, we undertake no obligation to update publicly any
      forward-looking statements for any reason after the date of this prospectus, to conform these statements to actual results or to changes in our expectations.<font style="font-weight: bold;">&#160;</font></div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">7</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="USEOFPROCEEDS"><!--Anchor--></a>USE OF PROCEEDS</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We will not receive any proceeds from the sale of the ordinary shares by the selling shareholders. All net proceeds from the sale of the ordinary shares covered by this prospectus
      will go to the selling shareholders. We expect that the selling shareholders will sell their ordinary shares as described under &#8220;Plan of Distribution.&#8221;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We may receive proceeds from the exercise of the warrants and placement agent warrants to the extent that these warrants are exercised for cash by the selling shareholders.
      Warrants, however, are exercisable on a cashless basis under certain circumstances. If all of the warrants mentioned above were exercised for cash in full, the proceeds would be approximately $20.6 million. We intend to use the net proceeds of such
      warrant exercise, if any, to advance the ongoing clinical development of C-Scan&#174;, including preparations for our U.S. pivotal study, and for general corporate purposes. Pending such uses, we intend to invest the net proceeds in short-term,
      interest-bearing securities, investment grade securities, certificates of deposit or direct or guaranteed obligations of the U.S. government. We can make no assurances that any of the warrants and placement agent warrants will be exercised, or if
      exercised, that they will be exercised for cash, the quantity which will be exercised or in the period in which they will be exercised.</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="CAPITALIZATION"><!--Anchor--></a>CAPITALIZATION</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The following table sets forth our capitalization:</div>
    <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z4dc14b9a65aa4f53851725feafaada6a">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right;">&#9679;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>on an actual basis as of June 30, 2020; and</div>
          </td>
        </tr>

    </table>
    <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">&#9679;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>
                <div style="line-height: 1.25;">on an adjusted basis, giving effect to the exercise of certain outstanding warrants to purchase up to an aggregate of 16,054,223 of our ordinary shares at an exercise price of $0.60 per share in the July 2020
                  financing, resulting in gross proceeds of approximately $9.6 million.</div>
              </div>
            </td>
          </tr>

      </table>
      <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The following depiction of our capitalization on an adjusted basis as of June 30, 2020 reflects the net proceeds from the July 2020 warrant exercise financing that closed on July
      27, 2020, and does not reflect the exercise of any other options or warrants or any other transactions impacting our capital structure subsequent to June 30, 2020. The adjusted amounts shown below are unaudited and represent management&#8217;s estimate.
      The information in this table should be read in conjunction with and is qualified by reference to the financial statements and notes thereto and other financial information incorporated by reference into this prospectus.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" id="z06c92ca6773c4aa0aead0e4cae134104" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">

        <tr>
          <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">
            <div style="text-align: center; line-height: 1.25;"><br>
              &#160;</div>
          </td>
          <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" colspan="2" style="vertical-align: bottom;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">As of<br>
              June 30,<br>
              2020</div>
          </td>
          <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">(Actual)</div>
          </td>
          <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">(Adjusted)</div>
          </td>
          <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">(U.S.$ in thousands)</div>
          </td>
          <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>
          <td valign="bottom" colspan="2" style="vertical-align: top;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom;">&#160;</td>
          <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>
          <td valign="bottom" colspan="2" style="vertical-align: top;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25; font-weight: bold;">Shareholders&#8217; equity:</div>
          </td>
          <td valign="bottom" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" colspan="2" style="vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom;">&#160;</td>
          <td valign="bottom" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" colspan="2" style="vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF; width: 76%;">
            <div style="line-height: 1.25;">Ordinary Share capital, 90,000,000&#160;shares authorized and 30,172,943&#160; shares issued, actual;&#160;46,227,166&#160; shares issued, as adjusted</div>
          </td>
          <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
          <td valign="bottom" colspan="1" style="background-color: #FFFFFF; vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" colspan="1" style="background-color: #FFFFFF; vertical-align: bottom; text-align: right; width: 9%;">
            <div style="line-height: 1.25;">20,348</div>
          </td>
          <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: #FFFFFF; vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
          <td valign="bottom" colspan="1" style="background-color: #FFFFFF; vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" colspan="1" style="background-color: #FFFFFF; vertical-align: bottom; text-align: right; width: 9%;">
            <div style="line-height: 1.25;">31,637</div>
          </td>
          <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: #FFFFFF; vertical-align: bottom; width: 1%;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF; width: 76%;">
            <div style="line-height: 1.25;">Additional Paid in Capital&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
          </td>
          <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
            <div style="line-height: 1.25;">78,110</div>
          </td>
          <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
            <div style="line-height: 1.25;">75,530</div>
          </td>
          <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF; width: 76%;">
            <div style="line-height: 1.25;">Accumulated deficit&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
          </td>
          <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
          <td valign="bottom" colspan="1" style="background-color: #FFFFFF; vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" colspan="1" style="background-color: #FFFFFF; vertical-align: bottom; text-align: right; width: 9%;">
            <div style="line-height: 1.25;">(83,456</div>
          </td>
          <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: #FFFFFF; vertical-align: bottom; width: 1%;">
            <div style="line-height: 1.25;">)</div>
          </td>
          <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
          <td valign="bottom" colspan="1" style="background-color: #FFFFFF; vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" colspan="1" style="background-color: #FFFFFF; vertical-align: bottom; text-align: right; width: 9%;">
            <div style="line-height: 1.25;">(83,456</div>
          </td>
          <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: #FFFFFF; vertical-align: bottom; width: 1%;">
            <div style="line-height: 1.25;">)</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF; width: 76%; padding-bottom: 2px;">
            <div style="line-height: 1.25;">Total shareholders&#8217; equity&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
          </td>
          <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td>
          <td valign="bottom" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;">
            <div style="line-height: 1.25;">15,002</div>
          </td>
          <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td>
          <td valign="bottom" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;">
            <div style="line-height: 1.25;">23,711</div>
          </td>
          <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF; width: 76%;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
          <td valign="bottom" colspan="1" style="background-color: #FFFFFF; vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" colspan="1" style="background-color: #FFFFFF; vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: #FFFFFF; vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
          <td valign="bottom" colspan="1" style="background-color: #FFFFFF; vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" colspan="1" style="background-color: #FFFFFF; vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
          <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: #FFFFFF; vertical-align: bottom; width: 1%;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF; width: 76%; padding-bottom: 4px;">
            <div style="line-height: 1.25; font-weight: bold;">Total capitalization</div>
          </td>
          <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td>
          <td valign="bottom" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;">
            <div style="line-height: 1.25;">15,002</div>
          </td>
          <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>
          <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td>
          <td valign="bottom" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;">
            <div style="line-height: 1.25;">23,711</div>
          </td>
          <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">8</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">The number of issued and outstanding shares as of June 30, 2020 in the table excludes as of such date:</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">&#9679;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>
                <div style="line-height: 1.25;">26,327,751 ordinary shares issuable upon the exercise of outstanding warrants, with a weighted average exercise price of $2.83 per ordinary share;</div>
              </div>
            </td>
          </tr>

      </table>
      <div style="text-indent: -18pt; margin-left: 54pt; line-height: 1.25;">&#160;</div>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z77a4cf29bcb84003946900dfd926226d">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right;">&#9679;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>524,854 ordinary shares issuable upon the exercise of outstanding options, with a weighted average exercise price of $9.52 per ordinary share, granted under our option and equity incentive plans;</div>
          </td>
        </tr>

    </table>
    <div style="text-align: justify; text-indent: -18pt; margin-left: 54pt; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z07b2cb51fd1941e5a4937146bb64b8b0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right;">&#9679;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>85,589 restricted stock units issued to employees, consultants and directors;</div>
          </td>
        </tr>

    </table>
    <div style="text-align: justify; text-indent: -18pt; margin-left: 54pt; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z865bf741ac97459da03220532c9287e8">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right;">&#9679;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>367,910 ordinary shares that are available for future option grants under the 2015 Plan;</div>
          </td>
        </tr>

    </table>
    <div style="text-align: justify; text-indent: -18pt; margin-left: 54pt; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z08ab8e0d9e594487afde5b6a325e78a8">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right;">&#9679;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>19,265,068 ordinary shares issuable upon exercise of the unregistered warrants issued to certain investors in the July 2020 Private Placement, at an exercise price of $0.80 per share;</div>
          </td>
        </tr>

    </table>
    <div style="text-align: justify; text-indent: -18pt; margin-left: 54pt; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zaa51f66e3c974076b80548ed85c1ac01">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right;">&#9679;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>1,123,796 ordinary shares issuable upon exercise of the placement agent warrants issued to the placement agent as compensation in connection with the July 2020 Private Placement, at an exercise price of $0.75 per share.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">9</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">SELLING SHAREHOLDERS<a name="SELLINGSHAREHOLDERS"><!--Anchor--></a></div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The ordinary shares being offered by the selling shareholders are those ordinary shares issuable upon exercise of warrants previously issued in connection with our private
      placements that closed on April 22, 2020, May 4, 2020, May 13, 2020&#160; and July 27, 2020. For additional information regarding the issuance of those warrants to purchase ordinary shares, see &#8220;Prospectus Summary &#8211; April&#160; 2020 Financing,&#8221; &#8220;Prospectus
      Summary &#8211; First May 2020 Financing,&#8221; &#8220;Prospectus Summary &#8211; Second May 2020 Financing,&#8221; and &#8220;Prospectus Summary &#8211; July&#160; 2020 Financing,&#8221; above. We are registering the ordinary shares in order to permit the selling shareholders to offer the ordinary
      shares for resale from time to time. Other than with respect to H.C. Wainwright &amp; Co. LLC, or H.C. Wainwright, which acted as our placement agent in each of the June 2017, November 2017, February 2019, April 2020, the First May 2020, the Second
      May 2020 and the July 2020 private placements, and as our underwriter in connection with our underwritten offering in May 2018, except for the ownership of the warrants and placement agent warrants issued, and the ordinary shares issued and issuable,
      pursuant to prior financings, the selling shareholders have not had any material relationship with us within the past three years.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The table below lists the selling shareholders and other information regarding the beneficial ownership of the ordinary shares by each of the selling shareholders. The second
      column lists the number of ordinary shares beneficially owned by each selling shareholder, based on its ownership of ordinary shares and investor warrants or placement agent warrants to purchase ordinary shares, as of August 19, 2020, assuming
      exercise of the investor warrants or placement agent warrants held by each selling shareholder on that date, without regard to any limitations on conversions or exercises. The third column lists the maximum number of ordinary shares being offered in
      this prospectus by the selling shareholders. The fourth and fifth columns list the amount of ordinary shares owned after the offering, by number of ordinary shares and percentage of outstanding ordinary shares, assuming in both cases the sale of all
      of the ordinary shares offered by the selling shareholders pursuant to this prospectus, and without regard to any limitations on conversions or exercises.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under the terms of the investor warrants and placement agent warrants issued in the April 2020 Private Placement, the First May 2020 Private Placement, the Second May 2020 Private
      Placement and the July 2020 Private Placement, a selling shareholder may not exercise the warrants to the extent such exercise would cause such selling shareholder, together with its affiliates, to beneficially own a number of ordinary shares which
      would exceed 4.99% or 9.99% of our then outstanding ordinary shares following such exercise, excluding for purposes of such determination ordinary shares not yet issuable upon exercise of the warrants and placement agent warrants which have not been
      exercised. The number of shares does not reflect this limitation. The selling shareholders may sell all, some or none of their ordinary shares or investor warrants or placement agent warrants in this offering. See &#8220;Plan of Distribution.&#8221;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z621cb24f7ba442acb52545262a27281d">

        <tr>
          <td style="width: 30%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25; font-weight: bold;">Selling Shareholder</div>
          </td>
          <td style="width: 0.57%; vertical-align: bottom;">
            <div style="line-height: 1.25; font-weight: bold;">&#160;</div>
          </td>
          <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Number of Ordinary Shares Owned Prior to Offering</div>
          </td>
          <td style="width: 3.7%; vertical-align: bottom;">
            <div style="line-height: 1.25; font-weight: bold;">&#160;</div>
          </td>
          <td style="width: 0.57%; vertical-align: bottom;">
            <div style="line-height: 1.25; font-weight: bold;">&#160;</div>
          </td>
          <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Maximum Number of Ordinary Shares to be Sold Pursuant to this Prospectus</div>
          </td>
          <td style="width: 3.7%; vertical-align: bottom;">
            <div style="line-height: 1.25; font-weight: bold;">&#160;</div>
          </td>
          <td style="width: 0.57%; vertical-align: bottom;">
            <div style="line-height: 1.25; font-weight: bold;">&#160;</div>
          </td>
          <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Number of Ordinary Shares Owned After the Offering</div>
          </td>
          <td style="width: 4.27%; vertical-align: bottom;">
            <div style="line-height: 1.25; font-weight: bold;">&#160;</div>
          </td>
          <td style="width: 0.57%; vertical-align: bottom;">
            <div style="line-height: 1.25; font-weight: bold;">&#160;</div>
          </td>
          <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Percentage of Ordinary Shares Owned After the Offering</div>
          </td>
          <td style="width: 2.4%; vertical-align: bottom;">
            <div style="line-height: 1.25; font-weight: bold;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">Armistice Capital Master Fund, Ltd. (1)</div>
          </td>
          <td style="width: 0.57%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="text-align: right; line-height: 1.25;">7,885,228</div>
          </td>
          <td style="width: 3.7%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">(2)</div>
          </td>
          <td style="width: 0.57%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="text-align: right; line-height: 1.25;">7,885,228</div>
          </td>
          <td style="width: 3.7%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">(2)</div>
          </td>
          <td style="width: 0.57%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="text-align: right; line-height: 1.25;">-</div>
          </td>
          <td style="width: 4.27%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
          <td style="width: 0.57%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="text-align: right; line-height: 1.25;">&#160;&#160; &#160; &#160; &#160; -</div>
          </td>
          <td style="width: 2.4%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: bottom; background-color: rgb(255, 255, 255);">
            <div style="line-height: 1.25;">Sabby Volatility Warrant Master Fund, Ltd. (3)</div>
          </td>
          <td style="width: 0.57%; vertical-align: bottom; background-color: #FFFFFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: bottom; background-color: rgb(255, 255, 255);">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12%; vertical-align: bottom; background-color: rgb(255, 255, 255);">
            <div style="text-align: right; line-height: 1.25;">1,571,940</div>
          </td>
          <td style="width: 3.7%; vertical-align: bottom; background-color: #FFFFFF;">
            <div style="line-height: 1.25;">(4)</div>
          </td>
          <td style="width: 0.57%; vertical-align: bottom; background-color: #FFFFFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: bottom; background-color: #FFFFFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12%; vertical-align: bottom; background-color: rgb(255, 255, 255);">
            <div style="text-align: right; line-height: 1.25;">1,200,000</div>
          </td>
          <td style="width: 3.7%; vertical-align: bottom; background-color: #FFFFFF;">
            <div style="line-height: 1.25;">(5)</div>
          </td>
          <td style="width: 0.57%; vertical-align: bottom; background-color: #FFFFFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: bottom; background-color: rgb(255, 255, 255);">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12%; vertical-align: bottom; background-color: rgb(255, 255, 255);">
            <div style="text-align: right; line-height: 1.25;">371,940</div>
          </td>
          <td style="width: 4.27%; vertical-align: bottom; background-color: #FFFFFF;">
            <div style="line-height: 1.25;">&#160;(6)</div>
          </td>
          <td style="width: 0.57%; vertical-align: bottom; background-color: #FFFFFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: bottom; background-color: #FFFFFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12%; vertical-align: bottom; background-color: rgb(255, 255, 255);">
            <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;*</div>
          </td>
          <td style="width: 2.4%; vertical-align: bottom; background-color: #FFFFFF;">
            <div style="line-height: 1.25;"><br>
            </div>
          </td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">Hudson Bay Master Fund Ltd. (7)</div>
          </td>
          <td style="width: 0.57%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="text-align: right; line-height: 1.25;">1,581,396</div>
          </td>
          <td style="width: 3.7%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">(8)</div>
          </td>
          <td style="width: 0.57%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="text-align: right; line-height: 1.25;">1,581,396</div>
          </td>
          <td style="width: 3.7%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">(8)</div>
          </td>
          <td style="width: 0.57%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="text-align: right; line-height: 1.25;">-</div>
          </td>
          <td style="width: 4.27%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
          <td style="width: 0.57%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="text-align: right; line-height: 1.25;">-</div>
          </td>
          <td style="width: 2.4%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: bottom; background-color: rgb(255, 255, 255);">
            <div style="line-height: 1.25;">Bigger Capital Fund, LP (9)</div>
          </td>
          <td style="width: 0.57%; vertical-align: bottom; background-color: #FFFFFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: bottom; background-color: rgb(255, 255, 255);">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12%; vertical-align: bottom; background-color: rgb(255, 255, 255);">
            <div style="text-align: right; line-height: 1.25;">2,067,069</div>
          </td>
          <td style="width: 3.7%; vertical-align: bottom; background-color: #FFFFFF;">
            <div style="line-height: 1.25;">(10)</div>
          </td>
          <td style="width: 0.57%; vertical-align: bottom; background-color: #FFFFFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: bottom; background-color: #FFFFFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12%; vertical-align: bottom; background-color: rgb(255, 255, 255);">
            <div style="text-align: right; line-height: 1.25;">2,000,000</div>
          </td>
          <td style="width: 3.7%; vertical-align: bottom; background-color: #FFFFFF;">
            <div style="line-height: 1.25;">(11)</div>
          </td>
          <td style="width: 0.57%; vertical-align: bottom; background-color: #FFFFFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: bottom; background-color: rgb(255, 255, 255);">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12%; vertical-align: bottom; background-color: rgb(255, 255, 255);">
            <div style="text-align: right; line-height: 1.25;">67,069</div>
          </td>
          <td style="width: 4.27%; vertical-align: bottom; background-color: #FFFFFF;">
            <div style="line-height: 1.25;">(12)</div>
          </td>
          <td style="width: 0.57%; vertical-align: bottom; background-color: #FFFFFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: bottom; background-color: #FFFFFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12%; vertical-align: bottom; background-color: rgb(255, 255, 255);">
            <div style="text-align: right; line-height: 1.25;">*</div>
          </td>
          <td style="width: 2.4%; vertical-align: bottom; background-color: #FFFFFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">District 2 Capital Fund LP (13)</div>
          </td>
          <td style="width: 0.57%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="text-align: right; line-height: 1.25;">1,008,230</div>
          </td>
          <td style="width: 3.7%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">(14)</div>
          </td>
          <td style="width: 0.57%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="text-align: right; line-height: 1.25;">1,000,001</div>
          </td>
          <td style="width: 3.7%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">(15)</div>
          </td>
          <td style="width: 0.57%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="text-align: right; line-height: 1.25;">8,229</div>
          </td>
          <td style="width: 4.27%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;(16)</div>
          </td>
          <td style="width: 0.57%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="text-align: right; line-height: 1.25;">*</div>
          </td>
          <td style="width: 2.4%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: bottom; background-color: rgb(255, 255, 255);">
            <div style="line-height: 1.25;">Intracoastal Capital, LLC (17)</div>
          </td>
          <td style="width: 0.57%; vertical-align: bottom; background-color: #FFFFFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: bottom; background-color: rgb(255, 255, 255);">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12%; vertical-align: bottom; background-color: rgb(255, 255, 255);">
            <div style="text-align: right; line-height: 1.25;">3,322,760</div>
          </td>
          <td style="width: 3.7%; vertical-align: bottom; background-color: #FFFFFF;">
            <div style="line-height: 1.25;">(18)</div>
          </td>
          <td style="width: 0.57%; vertical-align: bottom; background-color: #FFFFFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: bottom; background-color: #FFFFFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12%; vertical-align: bottom; background-color: rgb(255, 255, 255);">
            <div style="text-align: right; line-height: 1.25;">3,081,396</div>
          </td>
          <td style="width: 3.7%; vertical-align: bottom; background-color: #FFFFFF;">
            <div style="line-height: 1.25;">(19)</div>
          </td>
          <td style="width: 0.57%; vertical-align: bottom; background-color: #FFFFFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: bottom; background-color: rgb(255, 255, 255);">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12%; vertical-align: bottom; background-color: rgb(255, 255, 255);">
            <div style="text-align: right; line-height: 1.25;">241,364</div>
          </td>
          <td style="width: 4.27%; vertical-align: bottom; background-color: #FFFFFF;">
            <div style="line-height: 1.25;">(20)</div>
          </td>
          <td style="width: 0.57%; vertical-align: bottom; background-color: #FFFFFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: bottom; background-color: #FFFFFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12%; vertical-align: bottom; background-color: rgb(255, 255, 255);">
            <div style="text-align: right; line-height: 1.25;">*</div>
          </td>
          <td style="width: 2.4%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">KBB Asset Management, LLC (21)</div>
          </td>
          <td style="width: 0.57%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="text-align: right; line-height: 1.25;">1,000,001</div>
          </td>
          <td style="width: 3.7%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">(22)</div>
          </td>
          <td style="width: 0.57%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="text-align: right; line-height: 1.25;">1,000,001</div>
          </td>
          <td style="width: 3.7%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">(22)</div>
          </td>
          <td style="width: 0.57%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="text-align: right; line-height: 1.25;">-</div>
          </td>
          <td style="width: 4.27%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.57%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="text-align: right; line-height: 1.25;">*</div>
          </td>
          <td style="width: 2.4%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: bottom; background-color: rgb(255, 255, 255);">
            <div style="line-height: 1.25;">Anson Investments Master Fund LP (23)</div>
          </td>
          <td style="width: 0.57%; vertical-align: bottom; background-color: #FFFFFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: bottom; background-color: rgb(255, 255, 255);">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12%; vertical-align: bottom; background-color: rgb(255, 255, 255);">
            <div style="text-align: right; line-height: 1.25;">4,650,863</div>
          </td>
          <td style="width: 3.7%; vertical-align: bottom; background-color: #FFFFFF;">
            <div style="line-height: 1.25;">(24)</div>
          </td>
          <td style="width: 0.57%; vertical-align: bottom; background-color: #FFFFFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: bottom; background-color: #FFFFFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12%; vertical-align: bottom; background-color: rgb(255, 255, 255);">
            <div style="text-align: right; line-height: 1.25;">4,166,667</div>
          </td>
          <td style="width: 3.7%; vertical-align: bottom; background-color: #FFFFFF;">
            <div style="line-height: 1.25;">(25)</div>
          </td>
          <td style="width: 0.57%; vertical-align: bottom; background-color: #FFFFFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: bottom; background-color: rgb(255, 255, 255);">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12%; vertical-align: bottom; background-color: rgb(255, 255, 255);">
            <div style="text-align: right; line-height: 1.25;">484,196</div>
          </td>
          <td style="width: 4.27%; vertical-align: bottom; background-color: #FFFFFF;">
            <div style="line-height: 1.25;">(26)</div>
          </td>
          <td style="width: 0.57%; vertical-align: bottom; background-color: #FFFFFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: bottom; background-color: #FFFFFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12%; vertical-align: bottom; background-color: rgb(255, 255, 255);">
            <div style="text-align: right; line-height: 1.25;">1.0%</div>
          </td>
          <td style="width: 2.4%; vertical-align: bottom; background-color: #FFFFFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">CVI Investments, Inc. (27)</div>
          </td>
          <td style="width: 0.57%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="text-align: right; line-height: 1.25;">1,636,364</div>
          </td>
          <td style="width: 3.7%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">(28)</div>
          </td>
          <td style="width: 0.57%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="text-align: right; line-height: 1.25;">1,500,000</div>
          </td>
          <td style="width: 3.7%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">(29)</div>
          </td>
          <td style="width: 0.57%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="text-align: right; line-height: 1.25;">136,364</div>
          </td>
          <td style="width: 4.27%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">(30)</div>
          </td>
          <td style="width: 0.57%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="text-align: right; line-height: 1.25;">*</div>
          </td>
          <td style="width: 2.4%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: bottom;">
            <div style="line-height: 1.25;">Lincoln Park Capital Fund, LLC (31)</div>
          </td>
          <td style="width: 0.57%; vertical-align: bottom;">&#160;</td>
          <td style="width: 1%; vertical-align: bottom;">&#160;</td>
          <td style="width: 12%; vertical-align: bottom;">
            <div style="text-align: right; line-height: 1.25;">17,046</div>
          </td>
          <td style="width: 3.7%; vertical-align: bottom;">
            <div style="line-height: 1.25;">(32)</div>
          </td>
          <td style="width: 0.57%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12%; vertical-align: bottom;">
            <div style="text-align: right; line-height: 1.25;">17,046</div>
          </td>
          <td style="width: 3.7%; vertical-align: bottom;">
            <div style="line-height: 1.25;">(32)</div>
          </td>
          <td style="width: 0.57%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12%; vertical-align: bottom;">
            <div style="text-align: right; line-height: 1.25;">-</div>
          </td>
          <td style="width: 4.27%; vertical-align: bottom;">&#160;</td>
          <td style="width: 0.57%; vertical-align: bottom;">&#160;</td>
          <td style="width: 1%; vertical-align: bottom;">&#160;</td>
          <td style="width: 12%; vertical-align: bottom;">
            <div style="text-align: right; line-height: 1.25;">-</div>
          </td>
          <td style="width: 2.4%; vertical-align: bottom;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">Michael Vasinkevich (33)</div>
          </td>
          <td style="width: 0.57%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="text-align: right; line-height: 1.25;">1,718,309</div>
          </td>
          <td style="width: 3.7%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">(34)</div>
          </td>
          <td style="width: 0.57%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="text-align: right; line-height: 1.25;">1,580,978</div>
          </td>
          <td style="width: 3.7%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">(35)</div>
          </td>
          <td style="width: 0.57%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="text-align: right; line-height: 1.25;">137,331</div>
          </td>
          <td style="width: 4.27%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">(36)</div>
          </td>
          <td style="width: 0.57%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="text-align: right; line-height: 1.25;">*</div>
          </td>
          <td style="width: 2.4%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: bottom;">
            <div style="line-height: 1.25;">Noam Rubinstein (33)</div>
          </td>
          <td style="width: 0.57%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12%; vertical-align: bottom;">
            <div style="text-align: right; line-height: 1.25;">778,392</div>
          </td>
          <td style="width: 3.7%; vertical-align: bottom;">
            <div style="line-height: 1.25;">(37)</div>
          </td>
          <td style="width: 0.57%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12%; vertical-align: bottom;">
            <div style="text-align: right; line-height: 1.25;">776,621</div>
          </td>
          <td style="width: 3.7%; vertical-align: bottom;">
            <div style="line-height: 1.25;">(38)</div>
          </td>
          <td style="width: 0.57%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12%; vertical-align: bottom;">
            <div style="text-align: right; line-height: 1.25;">1,771</div>
          </td>
          <td style="width: 4.27%; vertical-align: bottom;">
            <div style="line-height: 1.25;">(39)</div>
          </td>
          <td style="width: 0.57%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12%; vertical-align: bottom;">
            <div style="text-align: right; line-height: 1.25;">*</div>
          </td>
          <td style="width: 2.4%; vertical-align: bottom;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">Craig Schwabe (33)</div>
          </td>
          <td style="width: 0.57%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="text-align: right; line-height: 1.25;">83,209</div>
          </td>
          <td style="width: 3.7%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">(40)</div>
          </td>
          <td style="width: 0.57%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="text-align: right; line-height: 1.25;">83,209</div>
          </td>
          <td style="width: 3.7%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">(40)</div>
          </td>
          <td style="width: 0.57%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="text-align: right; line-height: 1.25;">-</div>
          </td>
          <td style="width: 4.27%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.57%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="text-align: right; line-height: 1.25;">-</div>
          </td>
          <td style="width: 2.4%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: bottom;">
            <div style="line-height: 1.25;">Charles Worthman (33)</div>
          </td>
          <td style="width: 0.57%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12%; vertical-align: bottom;">
            <div style="text-align: right; line-height: 1.25;">26,784</div>
          </td>
          <td style="width: 3.7%; vertical-align: bottom;">
            <div style="line-height: 1.25;">(41)</div>
          </td>
          <td style="width: 0.57%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12%; vertical-align: bottom;">
            <div style="text-align: right; line-height: 1.25;">24,655</div>
          </td>
          <td style="width: 3.7%; vertical-align: bottom;">
            <div style="line-height: 1.25;">(42)</div>
          </td>
          <td style="width: 0.57%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12%; vertical-align: bottom;">
            <div style="text-align: right; line-height: 1.25;">2,129</div>
          </td>
          <td style="width: 4.27%; vertical-align: bottom;">
            <div style="line-height: 1.25;">(43)</div>
          </td>
          <td style="width: 0.57%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12%; vertical-align: bottom;">
            <div style="text-align: right; line-height: 1.25;">*</div>
          </td>
          <td style="width: 2.4%; vertical-align: bottom;">&#160;</td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">*&#160;&#160;Denotes less than 1%</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">10</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc824d47fea17466cbb45dfc0ca167be8">

        <tr>
          <td style="width: 27pt; vertical-align: top; align: right;">(1)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Armistice Capital, LLC, the investment manager of Armistice Capital Master Fund Ltd., or Armistice, and Steven J. Boyd, the managing member of Armistice Capital, LLC, hold shared voting and dispositive power over the ordinary shares held
              by Armistice. The principal business address of Armistice is c/o Armistice Capital, LLC, 510 Madison Avenue, 7th Floor, New York, NY, 10022.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zac33de4116644859bac6fb5e48d34ad9">

        <tr>
          <td style="width: 27pt; vertical-align: top; align: right;">(2)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Represents 7,885,228 ordinary shares issuable upon exercise of warrants issued in July 2020 Private Placement.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z4e58a7d2d5be4765bdf9853fbbb2392b">

        <tr>
          <td style="width: 27pt; vertical-align: top; align: right;">(3)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Sabby Management, LLC is the investment manager of Sabby Volatility Warrant Master Fund, Ltd., or Sabby VWMF, and shares voting and investment power with respect to these shares in this capacity. As manager of Sabby Management, LLC, Hal
              Mintz also shares voting and investment power on behalf of Sabby VWMF. Each of Sabby Management, LLC and Hal Mintz disclaims beneficial ownership over the securities listed except to the extent of their pecuniary interest therein. The address
              of principal business office of Sabby VWMF is 10 Mountainview Road, Suite 205, Upper Saddle River, New Jersey 07458.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z980176f40a7f4eaaa26cf4aac34bb4f8">

        <tr>
          <td style="width: 27pt; vertical-align: top; align: right;">(4)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Represents (i) 371,940 ordinary shares, and (ii) 1,200,000 ordinary shares issuable upon exercise of warrants issued in our July 2020 Private Placement.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8312436d0f9144d087de48b741fc2a3b">

        <tr>
          <td style="width: 27pt; vertical-align: top; align: right;">(5)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Represents 1,200,000 ordinary shares issuable upon exercise of warrants issued in our July 2020 Private Placement.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za08b362345ae486ea76b6d1dd162852a">

        <tr>
          <td style="width: 27pt; vertical-align: top; align: right;">(6)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Represents 371,940 ordinary shares.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z4e6fc6dd28f44fe4b4150ee2defa1f90">

        <tr>
          <td style="width: 27pt; vertical-align: top; align: right;">(7)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Hudson Bay Capital Management LP, the investment manager of Hudson Bay Master Fund Ltd., has voting and investment power over these securities. Sander Gerber is the managing member of Hudson Bay Capital GP LLC, which is the general partner
              of Hudson Bay Capital Management LP. Each of Hudson Bay Master Fund Ltd. and Sander Gerber disclaims beneficial ownership over these securities.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9c07be1cff714a8ba37b5eb9572f4a2f">

        <tr>
          <td style="width: 27pt; vertical-align: top; align: right;">(8)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Represents 1,581,396 ordinary shares issuable upon exercise of warrants issued in our July 2020 Private Placement.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zeb6d0610957843a4b2859c561291efe6">

        <tr>
          <td style="width: 27pt; vertical-align: top; align: right;">(9)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Michael Bigger has the power to vote or dispose of the shares owned by Bigger Capital Fund, LP, or Bigger. The investor&#8217;s address is 175 W Carver, Huntington, NY, 11743. Michael Bigger disclaims beneficial ownership over these securities.</div>
          </td>
        </tr>

    </table>
    <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2380de2852654624a88565758eeaaeb2">

        <tr>
          <td style="width: 27pt; vertical-align: top; align: right;">(10)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Represents (i) 2,000,000 ordinary shares issuable upon exercise of warrants issued in our July 2020 Private Placement, (ii)&#160; 2,983 ordinary shares issuable upon exercise of placement agent warrants originally issued in our November 2017
              private placement and assigned to Bigger prior to the date of this prospectus, and (iii) 64,086 ordinary shares issuable upon exercise of placement agent warrants originally issued in our February 2019 private placement and assigned to Bigger
              prior to the date of this prospectus.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z5d4188526d294369b72a4754bf419bfe">

        <tr>
          <td style="width: 27pt; vertical-align: top; align: right;">(11)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Represents 2,000,000 ordinary shares issuable upon exercise of warrants issued in our July 2020 Private Placement.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2e48da5dbc3048e2a5c14804976a6b8e">

        <tr>
          <td style="width: 27pt; vertical-align: top; align: right;">(12)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Represents (i) 2,983 ordinary shares issuable upon exercise of placement agent warrants originally issued in our November 2017 private placement and assigned to Bigger prior to the date of this prospectus, and (ii) 64,086 ordinary shares
              issuable upon exercise of placement agent warrants originally issued in our February 2019 private placement and assigned to Bigger prior to the date of this prospectus.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z5d639a3e251e444ea9540fa3fa427d6b">

        <tr>
          <td style="width: 27pt; vertical-align: top; align: right;">(13)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Michael Bigger has the power to vote or dispose of the shares owned by District 2 Capital Fund LP. The investor&#8217;s address is 175 W Carver, Huntington, New York 11743. Michael Bigger disclaims beneficial ownership over these securities.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z011469fd2e3744008ee3cc89418bff6f">

        <tr>
          <td style="width: 27pt; vertical-align: top; align: right;">(14)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Represents (i) 8,229 ordinary shares, and (ii) 1,000,001 ordinary shares issuable upon exercise of warrants issued in our July 2020 Private Placement.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">11</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z715e8d878dc143fba719cb5e6d172fe1">

        <tr>
          <td style="width: 27pt; vertical-align: top; align: right;">(15)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Represents 1,000,001 ordinary shares issuable upon exercise of warrants issued in our July 2020 Private Placement.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze5b6b37828484ce4beb129b067f9503d">

        <tr>
          <td style="width: 27pt; vertical-align: top; align: right;">(16)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Represents 8,229 ordinary shares.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z10358b6e1755444d8c5f71294acdb278">

        <tr>
          <td style="width: 27pt; vertical-align: top; align: right;">(17)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Mitchell P. Kopin, or Mr. Kopin, and Daniel B. Asher, or Mr. Asher, each of whom are managers of Intracoastal Capital, LLC, or Intracoastal, have shared voting control and investment discretion over the securities reported herein that are
              held by Intracoastal. As a result, each of Mr. Kopin and Mr. Asher may be deemed to have beneficial ownership (as determined under Section 13(d) of Exchange Act) of the securities reported herein that are held by Intracoastal.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb69e70398ae64a3fa656b7b278e5222c">

        <tr>
          <td style="width: 27pt; vertical-align: top; align: right;">(18)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Represents (i) 241,364 ordinary shares issuable upon exercise of previously issued warrants, and (ii) 3,081,396 ordinary shares issuable upon exercise of warrants issued in connection with our July 2020 Private Placement.</div>
          </td>
        </tr>

    </table>
    <div style="text-align: justify; line-height: 1.25;">&#160;&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd109cd3bcc65460a8de59f9baaa5d920">

        <tr>
          <td style="width: 27pt; vertical-align: top; align: right;">(19)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Represents 3,081,396 ordinary shares issuable upon exercise of warrants issued in connection with our July 2020 Private Placement.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z695858c2380f476087baad97ce16a244">

        <tr>
          <td style="width: 27pt; vertical-align: top; align: right;">(20)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Represents 241,364 ordinary shares issuable upon exercise of previously issued warrants.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z288b7a565ba441db92428594e633d69e">

        <tr>
          <td style="width: 27pt; vertical-align: top; align: right;">(21)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Steve Segal has the power to vote or dispose of the shares owned by KBB Asset Management, LLC. The investor&#8217;s address is 29 Maple Street, Essex Junction, Vermont 05452. Steve Segal disclaims beneficial ownership over these securities.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z80f89eea91c04b75a8d08d34af926d0f">

        <tr>
          <td style="width: 27pt; vertical-align: top; align: right;">(22)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Represents 1,000,001 ordinary shares issuable upon exercise of warrants issued in our July 2020 Private Placement.</div>
          </td>
        </tr>

    </table>
    <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7c4fc9c19009479aa664a76ca8268083">

        <tr>
          <td style="width: 27pt; vertical-align: top; align: right;">(23)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Anson Advisors Inc and Anson Funds Management LP, the Co-Investment Advisers of Anson Investments Master Fund LP, or Anson, hold voting and dispositive power over the Common Shares held by Anson. Bruce Winson is the managing member of
              Anson Management GP LLC, which is the general partner of Anson Funds Management LP. Moez Kassam and Amin Nathoo are directors of Anson Advisors Inc. Mr. Winson, Mr. Kassam and Mr. Nathoo each disclaim beneficial ownership of these Common
              Shares except to the extent of their pecuniary interest therein. The principal business address of Anson is 190 Elgin Ave; George Town, Grand Cayman.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd7523619d4044598aee7d0bf580bd09a">

        <tr>
          <td style="width: 27pt; vertical-align: top; align: right;">(24)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Represents (i) 484,196 ordinary shares issuable upon exercise of warrants issued in connection with our February 2019 private placement, (ii) 833,333 ordinary shares issuable upon exercise of warrants issued in connection with our April
              2020 Private Placement, (iii) 1,666,667 ordinary shares issuable upon exercise of warrants issued in connection with our First May 2020 Private Placement, and (iv) 1,666,667 ordinary shares issuable upon exercise of warrants issued in our
              Second May 2020 Private Placement.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z4f20427f148844168c0f775b902f2c53">

        <tr>
          <td style="width: 27pt; vertical-align: top; align: right;">(25)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Represents (i) 833,333 ordinary shares issuable upon exercise of warrants issued in connection with our April 2020 Private Placement, (ii) 1,666,667 ordinary shares issuable upon exercise of warrants issued in connection with our First May
              2020 Private Placement, and (iii) 1,666,667 ordinary shares issuable upon exercise of warrants issued in our Second May 2020 Private Placement.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za38236fa44e6485395becf42dd9d3ac8">

        <tr>
          <td style="width: 27pt; vertical-align: top; align: right;">(26)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Represents 484,196 ordinary shares issuable upon exercise of warrants issued in connection with our February 2019 private placement.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z275596593c2b4ceea3fa12defe9d84db">

        <tr>
          <td style="width: 27pt; vertical-align: top; align: right;">(27)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Heights Capital Management, Inc., the authorized agent of CVI Investments, Inc., or CVI, has discretionary authority to vote and dispose of the shares held by CVI and may be deemed to be the beneficial owner of these shares.&#160; Martin
              Kobinger, in his capacity as Investment Manager of Heights Capital Management, Inc., may also be deemed to have investment discretion and voting power over the shares held by CVI.&#160; Mr. Kobinger disclaims any such beneficial ownership of the
              shares.&#160; CVI Investments, Inc. is affiliated with one or more FINRA members, none of whom are currently expected to participate in the sale pursuant to this prospectus contained in the registration statement of common shares purchased by CVI.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z864adda0c46348d2a9c4aa1c0940963d">

        <tr>
          <td style="width: 27pt; vertical-align: top; align: right;">(28)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Represents (i) 136,364 ordinary shares issuable upon exercise of previously issued warrants, and (ii) 1,500,000 ordinary shares issuable upon exercise of warrants issued in connection with our July 2020 Private Placement.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">12</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zdd22288da058488ebab359188c98c85e">

        <tr>
          <td style="width: 27pt; vertical-align: top; align: right;">(29)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Represents 1,500,000 ordinary shares issuable upon exercise of warrants issued in connection with our July 2020 Private Placement.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zec65492c8d82404fa0687745e682524c">

        <tr>
          <td style="width: 27pt; vertical-align: top; align: right;">(30)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Represents 136,364 ordinary shares issuable upon exercise of previously issued warrants.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0ae864ed76a54ee8a03aba69e8374082">

        <tr>
          <td style="width: 27pt; vertical-align: top; align: right;">(31)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Joshua Scheinfeld and Jonathan Cope, the principals of Lincoln Park Capital Fund, LLC, or Lincoln Park, are deemed to be beneficial owners of all the ordinary shares owned by Lincoln Park.&#160; Messers, Scheinfeld and Cope have shared voting
              and disposition power. The address of Lincoln Park is 440 N. Wells Street, Suite 410, Chicago, IL 60654.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd6a5861974474fd79a9b876106121816">

        <tr>
          <td style="width: 27pt; vertical-align: top; align: right;">(32)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Represents 17,046 ordinary shares issuable upon exercise of placement agent warrants issued in our July 2020 Private Placement.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z96fb4917f4de4100bb1995b6d4c85307">

        <tr>
          <td style="width: 27pt; vertical-align: top; align: right;">(33)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Referenced person is affiliated with H.C. Wainwright, a registered broker dealer. H.C. Wainwright is a registered broker-dealer and acted as the placement agent in the April 2020 Private Placement, the First May 2020 Private Placement, the
              Second May 2020 Private Placement and the July 2020 Private Placement. The address of H.C. Wainwright &amp; Co., LLC, 430 Park Avenue, New York, NY 10022.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb28b8e7894504efaaeb4292810e68430">

        <tr>
          <td style="width: 27pt; vertical-align: top; align: right;">(34)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Represents (i) 137,331 ordinary shares issuable upon exercise of previously issued placement agent warrants, (ii) 299,250 ordinary shares issuable upon exercise of placement agent warrants issued in connection with our April 2020
              financing, (iii) 336,656 ordinary shares issuable upon exercise of placement agent warrants issued in connection with our First May 2020 Private Placement, (iv) 224,438 ordinary shares issuable upon exercise of placement agent warrants issued
              in our Second May 2020 Private Placement, and (v) 720,634 ordinary shares issuable upon exercise of placement agent warrants issued in our July 2020 Private Placement.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z97b614d937b6437dbd72662008ed1795">

        <tr>
          <td style="width: 27pt; vertical-align: top; align: right;">(35)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Represents (i) 299,250 ordinary shares issuable upon exercise of placement agent warrants issued in connection with our April 2020 Private Placement, (ii) 336,656 ordinary shares issuable upon exercise of placement agent warrants issued in
              connection with our First May 2020 Private Placement, (iii) 224,438 ordinary shares issuable upon exercise of placement agent warrants issued in connection with our Second May 2020 Private Placement, and (iv) 720,634 ordinary shares issuable
              upon exercise of placement agent warrants issued in our July 2020 Private Placement.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z6a78fa529d7049518f63b3149cf3b148">

        <tr>
          <td style="width: 27pt; vertical-align: top; align: right;">(36)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Represents 137,331 ordinary shares issuable upon exercise of previously issued placement agent warrants.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb2085c03f6de4b42b004d484db7b973b">

        <tr>
          <td style="width: 27pt; vertical-align: top; align: right;">(37)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Represents (i) 1,771 ordinary shares issuable upon exercise of previously issued placement agent warrants, (ii) 147,000 ordinary shares issuable upon exercise of placement agent warrants issued in connection with our April 2020 Private
              Placement, (iii) 165,375 ordinary shares issuable upon exercise of placement agent warrants issued in connection with our First May 2020 Private Placement, (iv) 110,250 ordinary shares issuable upon exercise of placement agent warrants issued
              in our Second May 2020 Private Placement, and (v) 353,996 ordinary shares issuable upon exercise of placement agent warrants issued in our July 2020 Private Placement.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zacef2052f5124d5fadbdd8133201aa47">

        <tr>
          <td style="width: 27pt; vertical-align: top; align: right;">(38)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Represents (i) 147,000 ordinary shares issuable upon exercise of placement agent warrants issued in connection with our April 2020 Private Placement, (ii) 165,375 ordinary shares issuable upon exercise of placement agent warrants issued in
              connection with our First May 2020 Private Placement, (iii) 110,250 ordinary shares issuable upon exercise of placement agent warrants issued in our Second May 2020 Private Placement, and (iv) 353,996 ordinary shares issuable upon exercise of
              placement agent warrants issued in our July 2020 Private Placement.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z46937432cd5548bebc10ab4bc81f14d3">

        <tr>
          <td style="width: 27pt; vertical-align: top; align: right;">(39)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Represents 1,771 ordinary shares issuable upon exercise of previously issued placement agent warrants.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9c0656c505604d61a820a79319e9602a">

        <tr>
          <td style="width: 27pt; vertical-align: top; align: right;">(40)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Represents (i) 15,750 ordinary shares issuable upon exercise of placement agent warrants issued in connection with our April 2020 Private Placement, (ii) 17,719 ordinary shares issuable upon exercise of placement agent warrants issued in
              connection with our First May 2020 Private Placement, (iii) 11,812 ordinary shares issuable upon exercise of placement agent warrants issued in our Second May 2020 Private Placement, and (iv) 37,928 ordinary shares issuable upon exercise of
              placement agent warrants issued in our July 2020 Private Placement.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z5805edbea4d648fe9e38e70264db114c">

        <tr>
          <td style="width: 27pt; vertical-align: top; align: right;">(41)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Represents (i) 2,129 ordinary shares issuable upon exercise of previously issued placement agent warrants, (ii) 4,667 ordinary shares issuable upon exercise of placement agent warrants issued in connection with our April 2020 Private
              Placement, (iii) 5,250 ordinary shares issuable upon exercise of placement agent warrants issued in connection with our First May 2020 Private Placement, (iv) 3,500 ordinary shares issuable upon exercise of placement agent warrants issued in
              our Second May 2020 Private Placement, and (v) 11,238 ordinary shares issuable upon exercise of placement agent warrants issued in our July 2020 Private Placement.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7fd340b5243f47f6a00a9e0d26d7ea80">

        <tr>
          <td style="width: 27pt; vertical-align: top; align: right;">(42)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Represents (i) 4,667 ordinary shares issuable upon exercise of placement agent warrants issued in connection with our April 2020 Private Placement, (ii) 5,250 ordinary shares issuable upon exercise of placement agent warrants issued in
              connection with our First May 2020 Private Placement, (iii) 3,500 ordinary shares issuable upon exercise of placement agent warrants issued in our Second May 2020 Private Placement and (iv) 11,238 ordinary shares issuable upon exercise of
              placement agent warrants issued in our July 2020 Private Placement.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z6b2c8664638d4f90b25b619133d30b4a">

        <tr>
          <td style="width: 27pt; vertical-align: top; align: right;">(43)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Represents 2,129 ordinary shares issuable upon exercise of previously issued placement agent warrants.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">13</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="DESCRIPTIONOFSHARECAPITAL"><!--Anchor--></a>DESCRIPTION OF SHARE CAPITAL</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The following description of our share capital summarizes certain provisions of our amended articles of association. Such summaries do not purport to be complete and are subject
      to, and are qualified in their entirety by reference to, all of the provisions of our amended articles of association, copies of which have been filed as exhibits to the registration statement of which this prospectus forms a part.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Ordinary Shares</div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">As of August 19, 2020, our authorized share capital consists of 90,000,000 ordinary shares, par value NIS 2.40 per share, of which 46,231,661are outstanding.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Memorandum and Articles of Association</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Registration Number and Purposes of the Company</div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our registration number with the Israeli Registrar of Companies is 51-425981-1. Our purpose as set forth in our amended articles of association is to engage in any lawful activity.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Voting Rights and Conversion</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">All ordinary shares have identical voting and other rights in all respects.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">Transfer of Shares</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our fully paid ordinary shares are issued in registered form and may be freely transferred under our amended articles of association, unless the transfer is restricted or
      prohibited by another instrument, applicable law or the rules of a stock exchange on which the shares are listed for trade. The ownership or voting of our ordinary shares by non-residents of Israel is not restricted in any way by our amended articles
      of association or the laws of the State of Israel, except for ownership by nationals of some countries that are, or have been, in a state of war with Israel, according to applicable Israeli law&#8217;s requirements.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our Board of Directors may, to the extent it deems necessary in its discretion, close the register of shareholders of registration of transfers of shares for a period determined by
      the Board of Directors, and no registrations of transfers of shares shall be made by us during any such period during which the register of shareholders is so closed.&#160; We shall notify shareholders with respect to such suspension of registration in
      such manner as shall be determined by our Board of Directors.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">Election of Directors</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under our amended articles of association, our board of directors must consist of not less than four but no more than eleven directors, including (if any) external directors
      (within the meaning of the Israeli Companies Law).&#160; Pursuant to our amended articles of association, each of our directors will be appointed by a simple majority vote of holders of our voting shares, participating and voting at an annual general
      meeting of our shareholders (subject to the special approval requirements under the Israeli Companies Law for the election of external directors, if any). Our ordinary shares do not have cumulative voting rights for the election of directors.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Each director (other than external directors, if any) will hold office until the next annual general meeting following the annual general meeting at which they were elected and
      until his or her successor is elected and qualified, or until the occurrence of certain events, in accordance with the Israeli Companies Law and our amended articles of association, including his or her earlier resignation, death or removal by a vote
      of the majority of the voting power of our shareholders at a general meeting of until his or her office expires by operation of law. In addition, our amended articles of association allow our board of directors to appoint directors (other than
      external directors) to fill vacancies on the board of directors to serve for a term of office equal to the remaining period of the term of office of the directors(s) whose office(s) have been vacated.</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">14</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-weight: bold;">Dividend and Liquidation Rights</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We may declare a dividend to be paid to the holders of our ordinary shares in proportion to their respective shareholdings. Under the Israeli Companies Law, dividend distributions
      are determined by the board of directors and do not require the approval of the shareholders of a company unless the company&#8217;s articles of association provide otherwise. Our amended articles of association do not require shareholder approval of a
      dividend distribution and provide that dividend distributions may be determined by our board of directors.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Pursuant to the Israeli Companies Law, we may declare and pay dividends only if, upon the determination of our board of directors, there is no reasonable concern that the
      distribution will prevent us from being able to meet the terms of our existing and foreseeable obligations as they become due. Under the Israeli Companies Law, the distribution amount is further limited to the greater of retained earnings or earnings
      generated over the two most recent years legally available for distribution according to our then last reviewed or audited financial statements (less the amount of previously distributed dividends, if not reduced from the earnings), provided that the
      date of the financial statements is not more than six months prior to the date of distribution. In the event that we do not have retained earnings or earnings generated over the two most recent years legally available for distribution, we must seek
      the approval of the court in order to distribute a dividend. The court may approve our request if it is convinced that there is no reasonable concern that the payment of a dividend will prevent us from satisfying our existing and foreseeable
      obligations as they become due.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In the event of our liquidation, after satisfaction of liabilities to creditors, our assets will be distributed to the holders of our ordinary shares in proportion to the nominal
      value of their shareholdings. This right, as well as the right to receive dividends, may be affected by the grant of preferential dividend or distribution rights to the holders of a class of shares with preferential rights that may be authorized in
      the future.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">Exchange Controls</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">There are currently no Israeli currency control restrictions on remittances of dividends on our ordinary shares, proceeds from the sale of the shares or interest or other payments
      to non-residents of Israel, except for shareholders who are subjects of countries that are, or have been, in a state of war with Israel.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">Shareholder Meetings</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under Israeli law, we are required to hold an annual general meeting of our shareholders once every calendar year that must be held no later than 15 months after the date of the
      previous annual general meeting. All meetings other than the annual general meeting of shareholders are referred to in our amended articles of association as special general meetings. Our board of directors may call special general meetings whenever
      it sees fit, at such time and place, within or outside of Israel, as it may determine. In addition, the Israeli Companies Law provides that our board of directors is required to convene a special general meeting upon the written request of (i) any
      two of our directors or one-quarter of the serving members of our board of directors; or (ii) one or more shareholders holding, in the aggregate, either (a) 5% or more of our outstanding shares and 1% of our outstanding voting power or (b) 5% or more
      of our outstanding voting power.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Furthermore, the Israeli Companies Law requires that resolutions regarding the following matters be approved by our shareholders at a general meeting:</div>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z723c31804db24e918209f124781cd6d1">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>amendments to our articles of association;</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7a275b7ae3734963b99c706bbf88b7c5">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>appointment, terms of service and termination of service of our auditors;</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zbaee72460e5844f1b976f43b349f03fe">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>appointment of external directors;</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z59b2ce6f3af84db0bd7b4f104750afb3">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>approval of certain related party transactions;</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc88903e2fd804ec9ab5a55d2be96880d">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>increases or reductions of our authorized share capital;</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z33a269256aa04436a229e68188e58bf8">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>mergers; and</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zefcb1d5334334e78b2a6dfaa3ac0d077">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>the exercise of our board of director&#8217;s powers by a general meeting, if our board of directors is unable to exercise its powers and the exercise of any of its powers is essential for our proper management.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">15</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Subject to the provisions of the Israeli Companies Law and regulations promulgated thereunder, shareholders entitled to participate and vote at general meetings are the
      shareholders of record on a date to be decided by the board of directors, which, as a company listed on an exchange outside Israel, may be between four and 40 days prior to the date of the meeting.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Israeli Companies Law requires that a notice of any annual general meeting or special general meeting be provided to shareholders at least 21 days prior to the meeting and if
      the agenda of the meeting includes, among other things, the appointment or removal of directors, the approval of transactions with office holders or interested or related parties, an approval of a merger or the approval of the compensation policy,
      notice must be provided at least 35 days prior to the meeting.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under the Israeli Companies Law, our shareholders are not permitted to take action via written consent in lieu of a meeting.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">Voting rights</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">Quorum Requirements</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Pursuant to our amended articles of association, holders of our ordinary shares have one vote for each ordinary share held on all matters submitted to a vote before the
      shareholders at a general meeting. The quorum required for general meetings of our shareholders is at least two shareholders present in person, by proxy or written ballot, who hold or represent between them at least 25% of the total outstanding
      voting rights (or if a higher percentage is required by law, such higher percentage), within half an hour of the time fixed for the commencement of the meeting. A meeting adjourned for lack of a quorum is adjourned either to the same day in the
      following week at the same time and place or to such day, time and place as specified in the notice of the meeting or to such day, time and place as the chairman of the general meeting shall determine. At the reconvened meeting, at least two
      shareholders present in person or by proxy shall constitute a lawful quorum, unless the meeting of shareholders was convened at the demand of shareholders, in which case, the quorum shall be the presence of one or more shareholders holding at least
      5% of our issued share capital and at least one percent of the voting power of our shares, or one or more shareholders with at least 5% of the voting power of our shares.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">Vote Requirements</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our amended articles of association provide that all resolutions of our shareholders require a simple majority vote, unless otherwise required by the Israeli Companies Law or by
      our amended articles of association. Under the Israeli Companies Law, certain actions require a special majority, including: (i) approval of an extraordinary transaction with a controlling shareholder or in which the controlling shareholder has a
      personal interest and the terms of employment or other engagement of the controlling shareholder or a relative of the controlling shareholder (even if not extraordinary), requiring the approval described in Item 6C to the 2019 Annual Report
      &#8220;Directors, Senior Management and Employees &#8212;Board Practices&#8212;Approval of Related Party Transactions under Israeli Law&#8212; Disclosure of Personal Interests of Controlling Shareholders and Approval of Certain Transactions&#8221;; (ii) approval of a compensation
      policy, requiring the approval described in Item 6C to the 2019 Annual Report &#8220;Directors, Senior Management and Employees&#8212; Board Practices&#8212; Compensation Committee and Compensation Policy&#8221;; and (iii) approval of executive officer compensation
      inconsistent with our office holder compensation policy or the compensation of our chief executive officer (subject to limited exceptions), requiring the approval described in Item 6C to the 2019 Annual Report &#8220;Directors, Senior Management and
      Employees&#8212; Board Practices&#8212; Approval of Related Party Transactions under Israeli Law&#8212; Disclosure of Personal Interests of an Office Holder and Approval of Certain Transactions.&#8221;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In addition, under the Israeli Companies Law the appointment of external directors requires the approval of a majority vote of the shares present and voting on the matter, provided
      that either: (i) such majority includes a majority of the shares held by all shareholders who are non-controlling shareholders and shareholders who do not have a personal interest in the election of the external director (other than a personal
      interest not deriving from a relationship with a controlling shareholder) that are voted at the meeting, excluding abstentions; or (ii) the total number of shares held by shareholders who are non-controlling shareholders and shareholders who do not
      have a personal interest in the election of the external director (other than a personal interest not derived from a relationship with a controlling shareholder) voted against the election of the external director does not exceed 2% of the aggregate
      voting rights in the company.</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">16</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Furthermore, under the Israeli Companies Law the authorization of the chairman of the board to assume the role or responsibilities of the chief executive officer, or the
      authorization of the chief executive officer or his or her relative thereof to assume the role or responsibilities of the chairman of the board, for periods of no longer than three years each, is subject to receipt of the approval of a majority of
      the shares voting on the matter, provided that either (i) included in such majority are at least two-thirds of the shares of shareholders who are non-controlling shareholders and shareholders who do not have a personal interest in the resolution that
      are voted at the meeting on the matter (excluding any abstentions); or (ii) the total number of shares of shareholders specified in clause (i) who voted against the resolution does not 2% of the voting rights in the company.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Another exception to the simple majority vote requirement is a resolution for the voluntary winding up, or an approval of a scheme of arrangement or reorganization, of the company
      pursuant to Section 350 of the Israeli Companies Law, which requires the approval of holders of 75% of the voting rights represented at the meeting and voting on the resolution.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">Access to Corporate Records</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under the Israeli Companies Law, shareholders are provided access to: minutes of the general meetings of our shareholders; our shareholders register and principal shareholders
      register, articles of association and financial statements; and any document that we are required by law to file publicly with the Israeli Companies Registrar or the Israel Securities Authority. In addition, shareholders may request to be provided
      with any document in the company&#8217;s possession related to an action or transaction requiring shareholder approval under the related party transaction provisions of the Israeli Companies Law. We may deny this request if we believe it has not been made
      in good faith or if such denial is necessary to protect our interest or protect a trade secret or patent.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">Modification of Class Rights</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under the Israeli Companies Law and our amended articles of association, the rights attached to any class of shares, such as voting, liquidation and dividend rights, may be
      modified or cancelled by adoption of a resolution by the holders of a majority of all shares as one class, without any required separate resolution of any class of shares, or otherwise in accordance with the rights attached to such class of shares,
      as set forth in our amended articles of association.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">Acquisitions under Israeli Law</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">Full Tender Offer</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">A person wishing to acquire shares of an Israeli public company, and who would as a result hold over 90% of the target company&#8217;s voting rights or issued and outstanding share
      capital, is required by the Israeli Companies Law to make a tender offer to all of the company&#8217;s shareholders for the purchase of all of the issued and outstanding shares of the company. A person wishing to acquire shares of a Israeli public company,
      and who would as a result hold over 90% of the target company&#8217;s voting rights or issued and outstanding share capital of a certain class of shares of the company, is required to make a tender offer to all of the shareholders who hold shares of the
      relevant class for the purchase of all of the issued and outstanding shares of that class. If the shareholders who do not accept the offer hold less than 5% of the issued and outstanding share capital of the company or of the applicable class, and
      more than half of the shareholders who do not have a personal interest in the offer accept the offer, all of the shares that the acquirer offered to purchase will be transferred to the acquirer by operation of law. However, a tender offer will also
      be accepted if the shareholders who do not accept the offer hold less than 2% of the issued and outstanding share capital of the company or of the applicable class of shares.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Upon a successful completion of such a full tender offer, any shareholder that was an offeree in such tender offer, whether such shareholder accepted the tender offer or not, may,
      within six months from the date of acceptance of the tender offer, petition an Israeli court to determine whether the tender offer was for less than fair value and that the fair value should be paid as determined by the court. However, under certain
      conditions, the offeror may include in the terms of the tender offer that an offeree who accepted the offer will not be entitled to petition the Israeli court as described above.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If (a) the shareholders who did not respond or accept the tender offer hold at least 5% of the issued and outstanding share capital of the company, or of the applicable class, or
      the shareholders who accept the offer constitute less than a majority of the offerees that do not have a personal interest in the acceptance of the tender offer, or (b) the shareholders who did not accept the tender offer hold 2% or more of the
      issued and outstanding share capital of the company (or of the applicable class), the acquirer may not acquire shares of the company that will increase its holdings to more than 90% of the company&#8217;s issued and outstanding share capital or of the
      applicable class from shareholders who accepted the tender offer.</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">17</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">Special Tender Offer</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Israeli Companies Law provides that an acquisition of shares of an Israeli public company must be made by means of a special tender offer if as a result of the acquisition the
      purchaser would become a holder of 25% or more of the voting rights in the company, if there is no other shareholder that holds 25% or more of the voting rights in the company, subject to exceptions. Similarly, the Israeli Companies Law provides that
      an acquisition of shares in an Israeli public company must be made by means of a special tender offer if as a result of the acquisition the purchaser would become a holder of more than 45% of the voting rights in the company, if there is no other
      shareholder of the company who holds more than 45% of the voting rights in the company, subject to certain exceptions. No tender offer is required if the acquisition of shares: (i) occurs in the context of a private placement, that was approved by
      the company&#8217;s shareholders and whose purpose is to give the acquirer at least 25% of the voting rights in the company if there is no person who holds 25% or more of the voting rights in the company, or as a private placement whose purpose is to give
      the acquirer 45% of the voting rights in the company, if there is no person who holds 45% of the voting rights in the company; (ii) was from a holder of 25% or more of the voting rights in the company following which the purchaser will hold 25% or
      more of the voting rights in the company; or (iii) was from a holder of more than 45% of the voting rights in the company following which the purchaser will hold more than 45% of the voting rights in the company.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">A special tender offer must be extended to all shareholders of a company (but the offeror is not required to purchase shares representing more than 5% of the voting power attached
      to the company&#8217;s outstanding shares, regardless of how many shares are tendered by shareholders). A special tender offer may be consummated only if (i) at least 5% of the voting power attached to the company&#8217;s outstanding shares will be acquired by
      the offeror; and (ii) the number of shares tendered in the offer exceeds the number of shares whose holders objected to the offer (excluding the purchaser, its controlling shareholders, holders of 25% or more of the voting rights in the company or
      any person having a personal interest in the acceptance of the tender offer, or anyone on their behalf, including any such person&#8217;s relatives and entities under their control). If a special tender offer is accepted, then the purchaser or any person
      or entity controlling it, at the time of the offer, and any person or entity under common control with the purchaser or such controlling person or entity may not make a subsequent tender offer for the purchase of shares of the target company and may
      not enter into a merger with the target company for a period of one year from the date of the offer, unless the purchaser or such person or entity undertook to effect such an offer or merger in the initial special tender offer.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">Merger</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Israeli Companies Law permits merger transactions if approved by each party&#8217;s board of directors and, unless certain requirements described under the Israeli Companies Law are
      met, by a majority vote of each party&#8217;s shares, and, in the case of the target company, a majority vote of each class of its shares, voted on the proposed merger at a shareholders meeting. The board of directors of a merging company may not approve
      the merger if it determines that there exists a reasonable concern that, as a result of the merger, the surviving company will be unable to satisfy the obligations of the merging entities.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">For purposes of the shareholder vote of a merging company whose shares are held by the other merging company or a person or entity holding 25% or more of any of the means of
      control of the other merging entity, unless a court rules otherwise, the merger will not be deemed approved if a majority of the votes of shares voting on the matter at the shareholders meeting (excluding abstentions) that are held by parties other
      than the other party to the merger, or by any other person or entity who holds 25% or more of the voting rights or the right to appoint 25% or more of the directors of the other party, or any one on their behalf including their relatives or
      corporations controlled by any of them, vote against the merger. If, however, the merger involves a merger with a company&#8217;s own controlling shareholder or if the controlling shareholder has a personal interest in the merger, then the merger is
      instead subject to the same Special Majority approval that governs all extraordinary transactions with controlling shareholders (as described in Item 6C to the 2019 Annual Report &#8220;Directors, Senior Management and Employees&#8212;Board Practices&#8212; Approval
      of Related Party Transactions under Israeli Law &#8212; Disclosure of Personal Interests of Controlling Shareholders and Approval of Certain Transactions&#8221;).</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">18</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If the transaction would have been approved by the shareholders of a merging company but for the separate approval of each class or the exclusion of the votes of certain
      shareholders as provided above, a court may still approve the merger upon the request of holders of at least 25% of the voting rights of a company, if the court holds that the merger is fair and reasonable, taking into account the valuation of the
      merging companies and the consideration offered to the shareholders.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Upon the request of a creditor of either party to the proposed merger, the court may delay or prevent the merger if it concludes that there exists a reasonable concern that, as a
      result of the merger, the surviving company will be unable to satisfy the obligations of the merging entities, and may further give instructions to secure the rights of creditors.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In addition, a merger may not be consummated unless at least 50 days have passed from the date on which a proposal for approval of the merger was filed by each party with the
      Israeli Registrar of Companies and at least 30 days have passed from the date on which the merger was approved by the shareholders of each party.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">Anti-Takeover Measures under Israeli Law</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Israeli Companies Law allow us to create and issue shares having rights different from those attached to our ordinary shares, including shares providing certain preferred
      rights with respect to voting, distributions or other matters and shares having preemptive rights. No preferred shares are currently authorized under our amended articles of association. In the future, if we do authorize, create and issue a specific
      class of preferred shares, such class of shares, depending on the specific rights that may be attached to it, may have the ability to frustrate or prevent a takeover or otherwise prevent our shareholders from realizing a potential premium over the
      market value of their ordinary shares. The authorization and designation of a class of preferred shares will require an amendment to our amended articles of association, which requires the prior approval of the holders of a majority of the voting
      power attached to our issued and outstanding shares at a general meeting. The convening of the meeting, the shareholders entitled to participate and the majority vote required to be obtained at such a meeting will be subject to the requirements set
      forth in the Israeli Companies Law and our amended articles of association as described above in &#8220;&#8212; Voting Rights.&#8221;</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">Borrowing Powers</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Pursuant to the Israeli Companies Law and our amended articles of association, our board of directors may exercise all powers and take all actions that are not required under law
      or under our amended articles of association to be exercised or taken by our shareholders, including the power to borrow money for company purposes.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">Changes in Capital</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our amended articles of association enable us to increase or reduce our share capital. Any such changes are subject to the provisions of the Israeli Companies Law and must be
      approved by a resolution duly passed by our shareholders at a general meeting by voting on such change in the capital. In addition, transactions that have the effect of reducing capital, such as the declaration and payment of dividends in the absence
      of sufficient retained earnings or profits, require the approval of both our board of directors and an Israeli court.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Description of the Warrants</div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">&#160;</div>
    <div style="line-height: 1.25; font-style: italic;">April 2020 Warrants</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The following is a brief summary of the investor warrants and placement agent warrants issued in connection with our April 2020 Private Placement and is subject in all respects to
      the provisions contained in the investor warrants, in the form filed as an exhibit to our Current Report on Form 6-K dated April 22, 2020 and the placement agent warrants, in the form filed as an exhibit to the registration statement, of which this
      prospectus forms a part. Unless otherwise stated, references to warrants in this section include the investor warrants and placement agent warrants.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-style: italic;">Exercisability</font>. Holders may exercise warrants at any time after April 22, 2020 until close of business on October 22, 2025, except that the
      placement agent warrants are exercisable until close of business on April 20, 2025. The warrants are exercisable, at the option of each holder, in whole or in part, by delivering to us a duly executed exercise notice accompanied by payment in full
      for the number of shares of ordinary shares purchased upon such exercise (except in the case of a cashless exercise in limited circumstances discussed below).</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">19</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-style: italic;">Cashless Exercise</font>. If at the time of exercise of the warrants there is no effective registration statement registering the ordinary shares
      underlying the warrants, the holder may, at its option, exercise its warrants on a cashless basis. When exercised on a cashless basis, a portion of the warrant is cancelled in payment of the purchase price payable in respect of the number of our
      ordinary shares purchasable upon such exercise.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-style: italic;">Exercise Price</font>. The exercise price of ordinary shares purchasable upon exercise of the investor warrants is $0.80 per share, and the
      exercise price of ordinary shares purchasable upon exercise of the placement agent warrants is $0.75. The exercise price and the number of shares issuable upon exercise of the warrants is subject to appropriate adjustment in the event of
      recapitalization events, stock dividends, stock splits, stock combinations, reclassifications or similar events affecting our ordinary shares, and also upon any distributions of assets, including cash, stock or other property to our shareholders.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-style: italic;">Transferability</font>. Subject to certain transfer restrictions, the warrants may be transferred at the option of the holder upon surrender of
      the warrants with the appropriate instruments of transfer. In addition, the holder (or permitted assignees under FINRA Rule 5110(g)(1)) of the placement agent warrants may not sell, transfer, assign, pledge, or hypothecate the warrants or the
      securities underlying these warrants, nor may they engage in any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of the warrants or the underlying securities for a period of 180 days
      from the effective date or commencement of sales of the public offering of the ordinary shares issuable upon exercise of the warrants, subject to limited exceptions.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-style: italic;">Purchase Rights, Fundamental Transactions and Change of Control</font>. If we sell or grant any rights to purchase shares, warrants or securities
      or other property to our shareholders on a pro rata basis, we will provide the holders of warrants with the right to acquire, upon the same terms, the securities subject to such purchase rights as though the warrant had been exercised immediately
      prior to the declaration of such rights. If we consummate any fundamental transaction, as described in the warrants and generally including any consolidation or merger into another corporation, the consummation of a transaction whereby another entity
      acquires more than 50% of our outstanding ordinary shares, the sale of all or substantially all of our assets, any tender offer or exchange offer or another transaction in which our ordinary shares are converted into or exchanged for other securities
      or other consideration, the holder of warrants will thereafter receive upon exercise of the warrants the securities or other consideration to which a holder of the number of ordinary shares then deliverable upon the exercise or conversion of such
      warrants would have been entitled upon such consolidation, merger or other transaction. In addition, in the event of a fundamental transaction which is approved by our board of directors, the holders of the warrants have the right to require us or a
      successor entity to redeem the warrants for cash in the amount of the Black-Scholes value of the unexercised portion of the warrants as of the date of the consummation of the fundamental transaction; provided, however, in the event of a fundamental
      transaction which is not within the our control (including not approved by our board of directors), we will only be required to pay the same type of consideration, at the Black-Scholes value of the unexercised portion of the warrant, that is being
      offered and paid to the holders of our shares in connection with the Fundamental Transaction.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-style: italic;">Exchange Listing</font>. We do not plan on making an application to list the warrants on the Nasdaq Capital Market, any national securities
      exchange or other nationally recognized trading system. Our ordinary shares underlying the warrants will be listed on the Nasdaq Capital Market and our ordinary shares are traded on the Nasdaq Capital Market.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-style: italic;">Rights as Shareholder</font>. Except as otherwise provided in the warrants (such as the rights described above of a warrant holder upon our sale
      or grant of any rights to purchase shares, warrants or securities or other property to our shareholders on a pro rata basis) or by virtue of such holder&#8217;s ownership of our ordinary shares, the holders of the warrants do not have the rights or
      privileges of holders of our ordinary shares, including any voting rights, until they exercise their warrants.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-style: italic;">First May 2020 Warrants</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The following is a brief summary of the investor warrants and placement agent warrants issued in connection with our First May 2020 financing and is subject in all respects to the
      provisions contained in the investor warrants, in the form filed as an exhibit to our Current Report on Form 6-K dated May 4, 2020 and the placement agent warrants, in the form filed as an exhibit to the registration statement, of which this
      prospectus forms a part. Unless otherwise stated, references to warrants in this section include the investor warrants and placement agent warrants.</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">20</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-style: italic;">Exercisability</font>. Holders may exercise warrants at any time after May 4, 2020 until close of business on November 4, 2025, except that the
      placement agent warrants are exercisable until close of business on April 30, 2025. The warrants are exercisable, at the option of each holder, in whole or in part, by delivering to us a duly executed exercise notice accompanied by payment in full
      for the number of shares of ordinary shares purchased upon such exercise (except in the case of a cashless exercise in limited circumstances discussed below).</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-style: italic;">Cashless Exercise</font>. If at the time of exercise of the warrants there is no effective registration statement registering the ordinary shares
      underlying the warrants, the holder may, at its option, exercise its warrants on a cashless basis. When exercised on a cashless basis, a portion of the warrant is cancelled in payment of the purchase price payable in respect of the number of our
      ordinary shares purchasable upon such exercise.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-style: italic;">Exercise Price</font>. The exercise price of ordinary shares purchasable upon exercise of the investor warrants is $0.80 per share, and the
      exercise price of ordinary shares purchasable upon exercise of the placement agent warrants is $0.75. The exercise price and the number of shares issuable upon exercise of the warrants is subject to appropriate adjustment in the event of
      recapitalization events, stock dividends, stock splits, stock combinations, reclassifications or similar events affecting our ordinary shares, and also upon any distributions of assets, including cash, stock or other property to our shareholders.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-style: italic;">Transferability</font>. Subject to certain transfer restrictions, the warrants may be transferred at the option of the holder upon surrender of
      the warrants with the appropriate instruments of transfer. In addition, the holder (or permitted assignees under FINRA Rule 5110(g)(1)) of the placement agent warrants may not sell, transfer, assign, pledge, or hypothecate the warrants or the
      securities underlying these warrants, nor may they engage in any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of the warrants or the underlying securities for a period of 180 days
      from the effective date or commencement of sales of the public offering of the ordinary shares issuable upon exercise of the warrants, subject to limited exceptions.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-style: italic;">Purchase Rights, Fundamental Transactions and Change of Control</font>. If we sell or grant any rights to purchase shares, warrants or securities
      or other property to our shareholders on a pro rata basis, we will provide the holders of warrants with the right to acquire, upon the same terms, the securities subject to such purchase rights as though the warrant had been exercised immediately
      prior to the declaration of such rights. If we consummate any fundamental transaction, as described in the warrants and generally including any consolidation or merger into another corporation, the consummation of a transaction whereby another entity
      acquires more than 50% of our outstanding ordinary shares, the sale of all or substantially all of our assets, any tender offer or exchange offer or another transaction in which our ordinary shares are converted into or exchanged for other securities
      or other consideration, the holder of warrants will thereafter receive upon exercise of the warrants the securities or other consideration to which a holder of the number of ordinary shares then deliverable upon the exercise or conversion of such
      warrants would have been entitled upon such consolidation, merger or other transaction. In addition, in the event of a fundamental transaction which is approved by our board of directors, the holders of the warrants have the right to require us or a
      successor entity to redeem the warrants for cash in the amount of the Black-Scholes value of the unexercised portion of the warrants as of the date of the consummation of the fundamental transaction; provided, however, in the event of a fundamental
      transaction which is not within the our control (including not approved by our board of directors), we will only be required to pay the same type of consideration, at the Black-Scholes value of the unexercised portion of the warrant, that is being
      offered and paid to the holders of our shares in connection with the Fundamental Transaction.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-style: italic;">Exchange Listing</font>. We do not plan on making an application to list the warrants on the Nasdaq Capital Market, any national securities
      exchange or other nationally recognized trading system. Our ordinary shares underlying the warrants will be listed on the Nasdaq Capital Market and our ordinary shares are traded on the Nasdaq Capital Market.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-style: italic;">Rights as Shareholder</font>. Except as otherwise provided in the warrants (such as the rights described above of a warrant holder upon our sale
      or grant of any rights to purchase shares, warrants or securities or other property to our shareholders on a pro rata basis) or by virtue of such holder&#8217;s ownership of our ordinary shares, the holders of the warrants do not have the rights or
      privileges of holders of our ordinary shares, including any voting rights, until they exercise their warrants.</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">21</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;"><font style="font-style: italic;">Second May 2020</font>&#160;<font style="font-style: italic;">Warrants</font></div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The following is a brief summary of the investor warrants and placement agent warrants issued in connection with our Second May 2020 financing and is subject in all respects to the
      provisions contained in the investor warrants, in the form filed as an exhibit to our Current Report on Form 6-K dated May 12, 2020 and the placement agent warrants, in the form filed as an exhibit to the registration statement, of which this
      prospectus forms a part. Unless otherwise stated, references to warrants in this section include the investor warrants and placement agent warrants.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-style: italic;">Exercisability</font>. Holders may exercise warrants at any time after May 13, 2020 until close of business on November 13, 2025, except that the
      placement agent warrants are exercisable until close of business on May&#160; 8, 2025. The warrants are exercisable, at the option of each holder, in whole or in part, by delivering to us a duly executed exercise notice accompanied by payment in full for
      the number of shares of ordinary shares purchased upon such exercise (except in the case of a cashless exercise in limited circumstances discussed below).</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-style: italic;">Cashless Exercise</font>. If at the time of exercise of the warrants there is no effective registration statement registering the ordinary shares
      underlying the warrants, the holder may, at its option, exercise its warrants on a cashless basis. When exercised on a cashless basis, a portion of the warrant is cancelled in payment of the purchase price payable in respect of the number of our
      ordinary shares purchasable upon such exercise.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-style: italic;">Exercise Price</font>.&#160; The exercise price of ordinary shares purchasable upon exercise of the investor warrants is $0.80 per share, and the
      exercise price of ordinary shares purchasable upon exercise of the placement agent warrants is $0.75. The exercise price and the number of shares issuable upon exercise of the warrants is subject to appropriate adjustment in the event of
      recapitalization events, stock dividends, stock splits, stock combinations, reclassifications or similar events affecting our ordinary shares, and also upon any distributions of assets, including cash, stock or other property to our shareholders.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-style: italic;">Transferability</font>. Subject to certain transfer restrictions, the warrants may be transferred at the option of the holder upon surrender of
      the warrants with the appropriate instruments of transfer. In addition, the holder (or permitted assignees under FINRA Rule 5110(g)(1)) of the placement agent warrants may not sell, transfer, assign, pledge, or hypothecate the warrants or the
      securities underlying these warrants, nor may they engage in any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of the warrants or the underlying securities for a period of 180 days
      from the effective date or commencement of sales of the public offering of the ordinary shares issuable upon exercise of the warrants, subject to limited exceptions.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-style: italic;">Purchase Rights, Fundamental Transactions and Change of Control</font>. If we sell or grant any rights to purchase shares, warrants or securities
      or other property to our shareholders on a pro rata basis, we will provide the holders of warrants with the right to acquire, upon the same terms, the securities subject to such purchase rights as though the warrant had been exercised immediately
      prior to the declaration of such rights. If we consummate any fundamental transaction, as described in the warrants and generally including any consolidation or merger into another corporation, the consummation of a transaction whereby another entity
      acquires more than 50% of our outstanding ordinary shares, the sale of all or substantially all of our assets, any tender offer or exchange offer or another transaction in which our ordinary shares are converted into or exchanged for other securities
      or other consideration, the holder of warrants will thereafter receive upon exercise of the warrants the securities or other consideration to which a holder of the number of ordinary shares then deliverable upon the exercise or conversion of such
      warrants would have been entitled upon such consolidation, merger or other transaction. In addition, in the event of a fundamental transaction which is approved by our board of directors, the holders of the warrants have the right to require us or a
      successor entity to redeem the warrants for cash in the amount of the Black-Scholes value of the unexercised portion of the warrants as of the date of the consummation of the fundamental transaction; provided, however, in the event of a fundamental
      transaction which is not within the our control (including not approved by our board of directors), we will only be required to pay the same type of consideration, at the Black-Scholes value of the unexercised portion of the warrant, that is being
      offered and paid to the holders of our shares in connection with the Fundamental Transaction..</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-style: italic;">Exchange Listing</font>. We do not plan on making an application to list the warrants on the Nasdaq Capital Market, any national securities
      exchange or other nationally recognized trading system. Our ordinary shares underlying the warrants will be listed on the Nasdaq Capital Market and our ordinary shares are traded on the Nasdaq Capital Market.</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">22</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-style: italic;">Rights as Shareholder</font>. Except as otherwise provided in the warrants (such as the rights described above of a warrant holder upon our sale
      or grant of any rights to purchase shares, warrants or securities or other property to our shareholders on a pro rata basis) or by virtue of such holder&#8217;s ownership of our ordinary shares, the holders of the warrants do not have the rights or
      privileges of holders of our ordinary shares, including any voting rights, until they exercise their warrants.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;"><font style="font-style: italic;">July 2020</font>&#160;<font style="font-style: italic;">Warrants</font></div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The following is a brief summary of the investor warrants and placement agent warrants issued in connection with our July 2020 financing and is subject in all respects to the
      provisions contained in the investor warrants, in the form filed as an exhibit to our Current Report on Form 6-K dated July 24, 2020 and the placement agent warrants, in the form filed as an exhibit to the registration statement, of which this
      prospectus forms a part. Unless otherwise stated, references to warrants in this section include the investor warrants and placement agent warrants.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-style: italic;">Exercisability</font>. Holders may exercise warrants at any time after July 27, 2020 until close of business on January 27, 2026. The warrants are
      exercisable, at the option of each holder, in whole or in part, by delivering to us a duly executed exercise notice accompanied by payment in full for the number of shares of ordinary shares purchased upon such exercise (except in the case of a
      cashless exercise in limited circumstances discussed below).</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-style: italic;">Cashless Exercise</font>. If at the time of exercise of the warrants there is no effective registration statement registering the ordinary shares
      underlying the warrants, the holder may, at its option, exercise its warrants on a cashless basis. When exercised on a cashless basis, a portion of the warrant is cancelled in payment of the purchase price payable in respect of the number of our
      ordinary shares purchasable upon such exercise.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-style: italic;">Exercise Price</font>.&#160; The exercise price of ordinary shares purchasable upon exercise of the investor warrants is $0.80 per share, and the
      exercise price of ordinary shares purchasable upon exercise of the placement agent warrants is $0.75. The exercise price and the number of shares issuable upon exercise of the warrants is subject to appropriate adjustment in the event of
      recapitalization events, stock dividends, stock splits, stock combinations, reclassifications or similar events affecting our ordinary shares, and also upon any distributions of assets, including cash, stock or other property to our shareholders.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-style: italic;">Transferability</font>. Subject to certain transfer restrictions, the warrants may be transferred at the option of the holder upon surrender of
      the warrants with the appropriate instruments of transfer.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-style: italic;">Purchase Rights, Fundamental Transactions and Change of Control</font>. If we sell or grant any rights to purchase shares, warrants or securities
      or other property to our shareholders on a pro rata basis, we will provide the holders of warrants with the right to acquire, upon the same terms, the securities subject to such purchase rights as though the warrant had been exercised immediately
      prior to the declaration of such rights. If we consummate any fundamental transaction, as described in the warrants and generally including any consolidation or merger into another corporation, the consummation of a transaction whereby another entity
      acquires more than 50% of our outstanding ordinary shares, the sale of all or substantially all of our assets, any tender offer or exchange offer or another transaction in which our ordinary shares are converted into or exchanged for other securities
      or other consideration, the holder of warrants will thereafter receive upon exercise of the warrants the securities or other consideration to which a holder of the number of ordinary shares then deliverable upon the exercise or conversion of such
      warrants would have been entitled upon such consolidation, merger or other transaction. In addition, in the event of a fundamental transaction which is approved by our board of directors, the holders of the warrants have the right to require us or a
      successor entity to redeem the warrants for cash in the amount of the Black-Scholes value of the unexercised portion of the warrants as of the date of the consummation of the fundamental transaction; provided, however, in the event of a fundamental
      transaction which is not within the our control (including not approved by our board of directors), we will only be required to pay the same type of consideration, at the Black-Scholes value of the unexercised portion of the warrant, that is being
      offered and paid to the holders of our shares in connection with the Fundamental Transaction..</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-style: italic;">Exchange Listing</font>. We do not plan on making an application to list the warrants on the Nasdaq Capital Market, any national securities
      exchange or other nationally recognized trading system. Our ordinary shares underlying the warrants will be listed on the Nasdaq Capital Market and our ordinary shares are traded on the Nasdaq Capital Market.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-style: italic;">Rights as Shareholder</font>. Except as otherwise provided in the warrants (such as the rights described above of a warrant holder upon our sale
      or grant of any rights to purchase shares, warrants or securities or other property to our shareholders on a pro rata basis) or by virtue of such holder&#8217;s ownership of our ordinary shares, the holders of the warrants do not have the rights or
      privileges of holders of our ordinary shares, including any voting rights, until they exercise their warrants.</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">23</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="PLANOFDISTRIBUTION"><!--Anchor--></a>PLAN OF DISTRIBUTION</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We are registering the ordinary shares issuable upon exercise of the warrants and placement agent warrants issued in our April 2020 Private Placement, our First May 2020 Private
      Placement, our Second May 2020 Private Placement and our July 2020 Private Placement to permit the resale of these ordinary shares by the holders of these warrants from time to time after the date of this prospectus. We will not receive any of the
      proceeds from the sale by the selling shareholders of the ordinary shares other than proceeds from the cash exercise of the warrants and placement agent warrants, if and when exercised. We will bear all fees and expenses incident to our obligation to
      register the ordinary shares.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The selling shareholders may sell all or a portion of the ordinary shares beneficially owned by them and offered hereby from time to time directly or through one or more
      underwriters, broker-dealers or agents. If the ordinary shares are sold through underwriters or broker-dealers, the selling shareholders will be responsible for underwriting discounts or commissions or agent&#8217;s commissions. The ordinary shares may be
      sold in one or more transactions at fixed prices, at prevailing market prices at the time of the sale, at varying prices determined at the time of sale, or at negotiated prices. These sales may be effected in transactions, which may involve crosses
      or block transactions,</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1484b8d55fa648c58c139a4eb8002d24">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right;">&#9679;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>on any national securities exchange or quotation service on which the securities may be listed or quoted at the time of sale;</div>
          </td>
        </tr>

    </table>
    <div style="text-align: justify; text-indent: -18pt; margin-left: 54pt; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8e02252bb0ba4312b633a80277e3f19b">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right;">&#9679;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>in the over-the-counter market;</div>
          </td>
        </tr>

    </table>
    <div style="text-align: justify; text-indent: -18pt; margin-left: 54pt; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z6ecdf922a25146a0b9192b49e591a43d">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right;">&#9679;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>in transactions otherwise than on these exchanges or systems or in the over-the-counter market;</div>
          </td>
        </tr>

    </table>
    <div style="text-align: justify; text-indent: -18pt; margin-left: 54pt; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf1766208127c4b19b74c85e7b022c7f2">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right;">&#9679;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>through the writing of options, whether such options are listed on an options exchange or otherwise;</div>
          </td>
        </tr>

    </table>
    <div style="text-align: justify; text-indent: -18pt; margin-left: 54pt; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z5ca15d4739e243d58a8edf8af7d9dbda">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right;">&#9679;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;</div>
          </td>
        </tr>

    </table>
    <div style="text-align: justify; text-indent: -18pt; margin-left: 54pt; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z75a9fe5b50984fcbb39c515fa1d8decb">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right;">&#9679;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>block trades in which the broker-dealer will attempt to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the transaction;</div>
          </td>
        </tr>

    </table>
    <div style="text-align: justify; text-indent: -18pt; margin-left: 54pt; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb7bcdd844fc444b2a462ebdc9fc2ea69">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right;">&#9679;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>purchases by a broker-dealer as principal and resale by the broker-dealer for its account;</div>
          </td>
        </tr>

    </table>
    <div style="text-align: justify; text-indent: -18pt; margin-left: 54pt; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3c281f8436114a3581fd021945e2e275">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right;">&#9679;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>an exchange distribution in accordance with the rules of the applicable exchange;</div>
          </td>
        </tr>

    </table>
    <div style="text-align: justify; text-indent: -18pt; margin-left: 54pt; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2583d272f4624f1bb4d10aa68ca4c95a">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right;">&#9679;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>privately negotiated transactions;</div>
          </td>
        </tr>

    </table>
    <div style="text-align: justify; text-indent: -18pt; margin-left: 54pt; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf51c0020e9954744886dcdce4ff90fbc">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right;">&#9679;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>short sales;</div>
          </td>
        </tr>

    </table>
    <div style="text-align: justify; text-indent: -18pt; margin-left: 54pt; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd0c9a2aaf06a4db59a8574e333b25d3e">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right;">&#9679;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>sales pursuant to Rule 144;</div>
          </td>
        </tr>

    </table>
    <div style="text-align: justify; text-indent: -18pt; margin-left: 54pt; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze3c0e6abb78d4c2ebb25641751f87278">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right;">&#9679;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>broker-dealers may agree with the selling security holders to sell a specified number of such shares at a stipulated price per share;</div>
          </td>
        </tr>

    </table>
    <div style="text-align: justify; text-indent: -18pt; margin-left: 54pt; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0753d980105042e7860c83fe008ceef3">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right;">&#9679;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>a combination of any such methods of sale; and</div>
          </td>
        </tr>

    </table>
    <div style="text-align: justify; text-indent: -18pt; margin-left: 54pt; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd642a1b18017433da7b80921876a7a4d">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right;">&#9679;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>any other method permitted pursuant to applicable law.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If the selling shareholders effect such transactions by selling ordinary shares to or through underwriters, broker-dealers or agents, such underwriters, broker-dealers or agents
      may receive commissions in the form of discounts, concessions or commissions from the selling shareholders or commissions from purchasers of the ordinary shares for whom they may act as agent or to whom they may sell as principal (which discounts,
      concessions or commissions as to particular underwriters, broker-dealers or agents may be in excess of those customary in the types of transactions involved). In connection with sales of ordinary shares or otherwise, the selling shareholders may
      enter into hedging transactions with broker-dealers, which may in turn engage in short sales of the ordinary shares in the course of hedging in positions they assume. The selling shareholders may also sell ordinary shares short and deliver ordinary
      shares covered by this prospectus to close out short positions and to return borrowed shares in connection with such short sales. The selling shareholders may also loan or pledge ordinary shares to broker-dealers that in turn may sell such shares.</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">24</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The selling shareholders may pledge or grant a security interest in some or all of the warrants, placement agent warrants or ordinary shares owned by them and, if they default in
      the performance of their secured obligations, the pledgees or secured parties may offer and sell the ordinary shares from time to time pursuant to this prospectus or any amendment to this prospectus under Rule 424(b)(3) or other applicable provision
      of the Securities Act of 1933, as amended, amending, if necessary, the list of selling shareholders to include the pledgee, transferee or other successors in interest as selling shareholders under this prospectus. The selling shareholders also may
      transfer and donate the ordinary shares in other circumstances in which case the transferees, donees, pledgees or other successors in interest will be the selling beneficial owners for purposes of this prospectus.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The selling shareholders and any broker-dealer participating in the distribution of the ordinary shares may be deemed to be &#8220;underwriters&#8221; within the meaning of the Securities Act,
      and any commission paid, or any discounts or concessions allowed to, any such broker-dealer may be deemed to be underwriting commissions or discounts under the Securities Act. At the time a particular offering of the ordinary shares is made, a
      prospectus supplement, if required, will be distributed which will set forth the aggregate amount of ordinary shares being offered and the terms of the offering, including the name or names of any broker-dealers or agents, any discounts, commissions
      and other terms constituting compensation from the selling shareholders and any discounts, commissions or concessions allowed or reallowed or paid to broker-dealers.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under the securities laws of some states ordinary shares may be sold in such states only through registered or licensed brokers or dealers. In addition, in some states ordinary
      shares may not be sold unless such ordinary shares have been registered or qualified for sale in such state or an exemption from registration or qualification is available and is complied with.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">There can be no assurance that any selling shareholder will sell any or all of the ordinary shares registered pursuant to the registration statement, of which this prospectus forms
      a part.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The selling shareholders and any other person participating in such distribution will be subject to applicable provisions of the Exchange Act, and the rules and regulations
      thereunder, including, without limitation, Regulation M of the Exchange Act, which may limit the timing of purchases and sales of any of the ordinary shares by the selling shareholders and any other participating person. Regulation M may also
      restrict the ability of any person engaged in the distribution of the ordinary shares to engage in market-making activities with respect to the ordinary shares. All of the foregoing may affect the marketability of the ordinary shares and the ability
      of any person or entity to engage in market-making activities with respect to the ordinary shares.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We will pay all expenses of the registration of the ordinary shares, estimated to be $20,000 in total, including, without limitation, Securities and Exchange Commission filing fees
      and expenses of compliance with state securities or &#8220;blue sky&#8221; laws; provided, however, that each selling shareholder will pay all underwriting discounts and selling commissions, if any,&#160;and any related legal expenses incurred by it.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Once sold under the registration statement, of which this prospectus forms a part, the ordinary shares will be freely tradable in the hands of persons other than our affiliates.</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">25</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="LEGALMATTERS"><!--Anchor--></a>LEGAL MATTERS</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">McDermott Will &amp; Emery LLP, New York, New York, has passed upon certain legal matters regarding the securities offered hereby under U.S. law, and Fischer Behar Chen Well Orion
      &amp; Co., Tel Aviv, Israel, has passed upon certain legal matters regarding the securities offered hereby under Israeli law. If the securities are distributed in an underwritten offering, certain legal matters will be passed upon for the
      underwriters by counsel identified in the applicable prospectus supplement.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="EXPERTS"><!--Anchor--></a>EXPERTS</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The consolidated financial statements of Check-Cap Ltd. and its subsidiaries as of December 31, 2019 and 2018 and for each of the three years in the period ended December 31, 2019
      incorporated by reference in this prospectus have been audited by Brightman Almagor Zohar &amp; Co., a firm in the Deloitte Global Network, an independent registered accounting firm, as set forth in their report thereon, included therein, and
      incorporated herein by reference in reliance upon such report given on the authority of such firm as experts in accounting and auditing.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="WHEREYOUCANFINDMOREINFORM"><!--Anchor--></a>WHERE YOU CAN FIND MORE INFORMATION</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We have filed with the SEC a registration statement on Form F-1, including amendments and relevant exhibits and schedules, under the Securities Act covering the ordinary shares to
      be sold in this offering. This prospectus, which constitutes a part of the registration statement, summarizes material provisions of contracts and other documents that we refer to in the prospectus. Since this prospectus does not contain all of the
      information contained in the registration statement, you should read the registration statement and its exhibits and schedules for further information with respect to us and our ordinary shares. You may review and copy the registration statement,
      reports and other information we file at the SEC&#8217;s public reference room at 100 F Street, N.E., Washington, D.C. 20549. You may also request copies of these documents upon payment of a duplicating fee by writing to the SEC. For further information on
      the public reference facility, please call the SEC at 1-800-SEC-0330. Our SEC filings, including the registration statement, are also available to you on the SEC&#8217;s Web site at http://www.sec.gov.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">You may read and copy the registration statement, including the related exhibits and schedules, and any document we file with the SEC without charge at the SEC&#8217;s public reference
      room at 100 F Street, N.E., Room 1580, Washington, DC 20549. You may also obtain copies of the documents at prescribed rates by writing to the Public Reference Section of the SEC at 100 F Street, N.E., Room 1580, Washington, DC 20549. Please call the
      SEC at 1-800-SEC-0330 for further information on the public reference room. The SEC also maintains an Internet website that contains reports and other information regarding issuers that file electronically with the SEC. Our filings with the SEC are
      also available to the public through the SEC&#8217;s website at <u>http://www.sec.gov</u>.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We are subject to the information reporting requirements of the Exchange Act that are applicable to foreign private issuers, and under those requirements are filing reports with
      the SEC. Those other reports or other information may be inspected without charge at the locations described above. As a foreign private issuer, we are exempt from the rules under the Exchange Act related to the furnishing and content of proxy
      statements, and our officers, directors and principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act. In addition, we are not required under the Exchange Act to file
      annual, quarterly and current reports and financial statements with the SEC as frequently or as promptly as United States companies whose securities are registered under the Exchange Act. However, we will file with the SEC, within 120 days after the
      end of each fiscal year, or such applicable time as required by the SEC, an annual report on Form 20-F containing financial statements audited by an independent registered public accounting firm, and will submit to the SEC, on Form 6-K, unaudited
      quarterly financial information.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We maintain a corporate website at https://www.check-cap.com. Information contained on, or that can be accessed through, our website does not constitute a part of this prospectus.
      We have included our website address in this prospectus solely as an inactive textual reference. We post on our website any materials required to be so posted on such website under applicable corporate or securities laws and regulations, including,
      posting any XBRL interactive financial data required to be filed with the SEC and any notices of general meetings of our shareholders.</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">26</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="INCORPORATIONOFCERTAININF"><!--Anchor--></a>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We are allowed to incorporate by reference the information we file with the SEC, which means that we can disclose important information to you by referring to those documents. The
      information incorporated by reference is considered to be part of this prospectus. We incorporate by reference in this prospectus the documents listed below:</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z6591f69641f04e00b273e78bc84ac8aa">

        <tr>
          <td style="width: 3.83%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.84%; vertical-align: top;">
            <div style="line-height: 1.25;">(1)</div>
          </td>
          <td style="width: 92.32%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">Our Annual Report on Form 20-F for the year ended December 31, 2019 filed with the SEC on March 6, 2020;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z68eff7af3c20439194916d7d6803f874">

        <tr>
          <td style="width: 3.83%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.84%; vertical-align: top;">
            <div style="line-height: 1.25;">(2)</div>
          </td>
          <td style="width: 92.32%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">Our Form 6-K filed with the SEC on March 6, 2020, April 6, 2020, April 20, 2020, April 22, 2020, April 30, 2020, May 4, 2020, May 12, 2020, May 27, 2020, June 5, 2020, July 23, 2020, July 24,
              2020 and August 6, 2020 (to the extent expressly incorporated by reference into our effective registration statements filed by us under the Securities Act); and</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zf9f2c06361e14beba9dc3d0bee69177f">

        <tr>
          <td style="width: 3.83%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.84%; vertical-align: top;">
            <div style="line-height: 1.25;">(3)</div>
          </td>
          <td style="width: 92.32%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">The description of our ordinary shares contained in our Registration Statement on Form F-1, as amended, under the Securities Act, as originally filed with the SEC on December 23, 2014
              (Registration No. 333- 201250) under the heading &#8220;Description of Securities&#8221; and as incorporated into our Registration Statement on Form 8-A12B, filed with the SEC February 11, 2015.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The information relating to us contained in this prospectus does not purport to be comprehensive and should be read together with the information contained in the documents
      incorporated or deemed to be incorporated by reference in this prospectus.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">As you read the above documents, you may find inconsistencies in information from one document to another. If you find inconsistencies between the documents and this prospectus,
      you should rely on the statements made in the most recent document. All information appearing in this prospectus is qualified in its entirety by the information and financial statements, including the notes thereto, contained in the documents
      incorporated by reference herein.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Potential investors, including any beneficial owner, may obtain a copy of any of the documents summarized herein (subject to certain restrictions because of the confidential nature
      of the subject matter) or any of our SEC filings incorporated by reference herein without charge by written or oral request directed to Mira Rosenzweig, Chief Financial Officer; at Check-Cap Building, 29 Abba Hushi Avenue, P.O. Box 1271, Isfiya,
      3009000, Israel; Our telephone number is +972-4-8303400.&#160;</div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">You also may access the incorporated reports and other documents referenced above on our website at <font style="font-style: italic;">www.</font>&#160;<font style="font-style: italic;">check-cap.com</font>.
      The information contained on, or that can be accessed through, our website is not part of this prospectus.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">You should rely only on the information contained or incorporated by reference in this prospectus or a prospectus supplement. We have not authorized any other person to provide you
      with different information. If anyone provides you with different or inconsistent information, you should not rely on it. We are not making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should
      assume that the information appearing in this prospectus is accurate only as of the date on the front cover of this prospectus, or such earlier date, that is indicated in this prospectus. Our business, financial condition, results of operations and
      prospects may have changed since that date.</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">27</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="ENFORCEABILITYOFCIVILLIAB"><!--Anchor--></a>ENFORCEABILITY OF CIVIL LIABILITIES</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We are incorporated under the laws of the State of Israel. All of our current executive officers, the Israeli experts and the majority of our directors reside outside the United
      States, and substantially all of our assets and a substantial portion of the assets of these persons are located outside the United States. Therefore, service of process upon us and upon our directors and officers and the Israeli experts named in
      this prospectus, substantially all of whom reside outside the United States, may be difficult to obtain within the United States. Furthermore, because substantially all of our assets, and a substantial portion of those of our officers and directors
      who reside outside the United States and the Israeli experts named herein, are located outside the United States, any judgment obtained in the United States against us or any of these persons may not be collectible within the United States.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We have appointed Puglisi &amp; Associates as our agent to receive service of process in any action against us in any United States federal or state court arising out of this
      offering or any purchase or sale of securities in connection with this offering. The address of Puglisi &amp; Associates is 850 Library Avenue, Suite 204, Newark, Delaware 19711.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We have been informed by our legal counsel in Israel, Fischer Behar Chen Well Orion &amp; Co., that there is doubt as to the enforceability of civil liabilities under U.S.
      securities laws pursuant to original actions instituted in Israel. Israeli courts may refuse to hear a claim based on an alleged violation of U.S. securities laws on the grounds that Israel is not the most appropriate forum to bring such a claim. In
      addition, even if an Israeli court agrees to hear a claim, it may determine that Israeli law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable, the content of applicable U.S. law must be proved as a fact by expert
      witnesses, which can be a time-consuming and costly process. Certain matters of procedure may also be governed by Israeli law.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Subject to certain time limitations and legal procedures, Israeli courts may enforce a U.S. judgment in a civil matter, including a judgment based upon the civil liability
      provisions of the Securities Act and the Exchange Act and including a monetary or compensatory judgment in a non-civil matter, provided that, among other things:&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 7.68%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 3.84%; vertical-align: top;" rowspan="1">&#9679;</td>
            <td style="width: 88.48%; vertical-align: top;" rowspan="1">
              <div>
                <div>
                  <div>the judgment was rendered by a court which was, according to the laws of the state of the court, competent to render the judgment;</div>
                </div>
              </div>
            </td>
          </tr>
          <tr>
            <td style="width: 7.68%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 3.84%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 88.48%; vertical-align: top;" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 7.68%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 3.84%; vertical-align: top;">
              <div style="line-height: 1.25;">&#9679;</div>
            </td>
            <td style="width: 88.48%; vertical-align: top;">
              <div style="line-height: 1.25;">
                <div>the judgment may no longer be appealed;</div>
              </div>
            </td>
          </tr>
          <tr>
            <td style="width: 7.68%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 3.84%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 88.48%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 7.68%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 3.84%; vertical-align: top;">
              <div style="line-height: 1.25;">&#9679;</div>
            </td>
            <td style="width: 88.48%; vertical-align: top;">
              <div>the obligation imposed by the judgment is enforceable according to the rules relating to the enforceability of judgments in Israel and the substance of the judgment is not contrary to public policy; and</div>
            </td>
          </tr>
          <tr>
            <td style="width: 7.68%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 3.84%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 88.48%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 7.68%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 3.84%; vertical-align: top;">
              <div style="line-height: 1.25;">&#9679;</div>
            </td>
            <td style="width: 88.48%; vertical-align: top;">
              <div style="line-height: 1.25;">
                <div>the judgment is executory in the state in which it was given.</div>
              </div>
            </td>
          </tr>

      </table>
      <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">Even if such conditions are met, an Israeli court may not declare a foreign civil judgment enforceable if:</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zf4355176a2484da9a053280dbb044feb">

        <tr>
          <td style="width: 7.68%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 3.84%; vertical-align: top;" rowspan="1">&#9679;</td>
          <td style="width: 88.48%; vertical-align: top;" rowspan="1">
            <div>the judgment was given in a state whose laws do not provide for the enforcement of judgments of Israeli courts (subject to exceptional cases);</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7.68%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 3.84%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 88.48%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 7.68%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.84%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 88.48%; vertical-align: top;">
            <div style="line-height: 1.25;">the enforcement of the judgment is likely to prejudice the sovereignty or security of the State of Israel;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7.68%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.84%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 88.48%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7.68%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.84%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 88.48%; vertical-align: top;">
            <div style="line-height: 1.25;">the judgment was obtained by fraud;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7.68%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.84%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 88.48%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7.68%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.84%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 88.48%; vertical-align: top;">
            <div style="line-height: 1.25;">the opportunity given to the defendant to bring its arguments and evidence before the court was not reasonable in the opinion of the Israeli court;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7.68%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.84%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 88.48%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7.68%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.84%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 88.48%; vertical-align: top;">
            <div style="line-height: 1.25;">the judgment was rendered by a court not competent to render it according to the laws of private international law as they apply in Israel;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7.68%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.84%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 88.48%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7.68%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.84%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 88.48%; vertical-align: top;">
            <div style="line-height: 1.25;">the judgment is contradictory to another judgment that was given in the same matter between the same parties and that is still valid; or</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7.68%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.84%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 88.48%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7.68%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.84%; vertical-align: top;">
            <div style="line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 88.48%; vertical-align: top;">
            <div style="line-height: 1.25;">at the time the action was brought in the foreign court, a lawsuit in the same matter and between the same parties was pending before a court or tribunal in Israel.</div>
          </td>
        </tr>

    </table>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Foreign judgments enforced by Israeli courts generally will be payable in Israeli currency, which can then be converted into non-Israeli currency and transferred out of Israel. The
      usual practice in an action before an Israeli court to recover an amount in a non-Israeli currency is for the Israeli court to render a judgment for the equivalent amount in Israeli currency at the rate of exchange in force on the date of the
      judgment, but the judgment debtor may make payment in foreign currency. Pending collection, the amount of the judgment of an Israeli court stated in Israeli currency ordinarily will be linked to the Israeli consumer price index plus interest at the
      annual statutory rate set by Israeli regulations prevailing at the time. Judgment creditors must bear the risk of unfavorable exchange rates.&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">28</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25;"><img width="250" height="133" src="image0.jpg"></div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">, 2020</font></div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <!--PROfilePageNumberReset%Num%1%II - %%-->
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">PART II</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">INFORMATION NOT REQUIRED IN PROSPECTUS</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Item 6. Indemnification of Directors, Officers and Employees</div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under the Israeli Companies Law, a company may not exculpate an office holder from liability for a breach of the duty of loyalty. An Israeli company may exculpate an office holder
      in advance from liability to the company, in whole or in part, for damages caused to the company as a result of a breach of duty of care, but only if a provision authorizing such exculpation is included in its articles of association. Our amended
      articles of association include such a provision, to the fullest extent permitted by law. The company may not exculpate in advance a director from liability arising out of a prohibited dividend or other distribution to shareholders.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under the Israeli Companies Law and the Israeli Securities Law, 5728-1968, or the Israeli Securities Law, a company may indemnify an office holder in respect of the following
      liabilities and expenses incurred for acts performed by him or her as an office holder, either pursuant to an undertaking made in advance of any such event or following an event, provided its articles of association include a provision authorizing
      such indemnification:</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a financial liability imposed on him or her in favor of another person pursuant to a judgment, including a settlement or arbitrator&#8217;s award approved by a court.
      However, if an undertaking to indemnify an office holder with respect to such liability is provided in advance, then such an undertaking must be limited to events which, in the opinion of the board of directors, can be foreseen based on the company&#8217;s
      activities when the undertaking to indemnify is given, and to an amount or according to criteria determined by the board of directors as reasonable under the circumstances, and such undertaking shall detail the abovementioned foreseen events and
      amount or criteria;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;reasonable litigation expenses, including attorneys&#8217; fees, incurred by the office holder (1) as a result of an investigation or proceeding instituted against him or her
      by an authority authorized to conduct such investigation or proceeding, provided that (i) no indictment was filed against such office holder as a result of such investigation or proceeding; and (ii) no financial liability was imposed upon him or her
      as a substitute for the criminal proceeding as a result of such investigation or proceeding or, if such financial liability was imposed, it was imposed with respect to an offense that does not require proof of criminal intent; and (2) in connection
      with a monetary sanction;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;reasonable litigation expenses, including attorneys&#8217; fees, incurred by the office holder or imposed by a court in proceedings instituted against him or her by the
      company, on its behalf, or by a third party, or in connection with criminal proceedings in which the office holder was acquitted, or as a result of a conviction for an offense that does not require proof of criminal intent; and</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;expenses, including reasonable litigation expenses and legal fees, incurred by an office holder in relation to an administrative proceeding instituted against such
      office holder, or certain compensation payments made to an injured party imposed on an office holder by an administrative proceeding, pursuant to certain provisions of the Israeli Securities Law.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under the Israeli Companies Law and the Israeli Securities Law, a company may insure an office holder against the following liabilities incurred for acts performed by him or her as
      an office holder if and to the extent provided in the company&#8217;s articles of association:</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a breach of the duty of loyalty to the company, provided that the office holder acted in good faith and had a reasonable basis to believe that the act would not harm
      the company;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a breach of the duty of care to the company or to a third party, to the extent such a breach arises out of the negligent conduct of the office holder;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a financial liability imposed on the office holder in favor of a third party; and</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160; expenses, including reasonable litigation expenses and legal fees, incurred by an office holder in relation to an administrative proceeding instituted against such office
      holder or certain compensation payments to an injured party imposed on an office holder by an administrative proceeding, pursuant to certain provisions of the Securities Law.</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">II - 1</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under the Israeli Companies Law, a company may not indemnify, exculpate or enter into an insurance contract for office holder liability, for any of the following:</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a breach of the duty of loyalty, except for indemnification and insurance for a breach of the duty of loyalty to the company to the extent that the office holder acted
      in good faith and had a reasonable basis to believe that the act would not prejudice the company;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a breach of the duty of care committed intentionally or recklessly, excluding a breach arising out of the negligent conduct of the office holder;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;an act or omission committed with intent to derive illegal personal benefit; or</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a fine, monetary sanction or forfeit levied against the office holder.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under the Israeli Companies Law, exculpation, indemnification and insurance of office holders in a public company must be approved by the compensation committee and the board of
      directors and, with respect to the chief executive officer and a director or (under certain circumstances), also by the shareholders. See Item 6C to the 2019 Annual Report &#8220;Directors, Senior Management and Employees &#8212;Board Practices&#8212;Approval of
      Related Party Transactions under Israeli Law.&#8221; However, the insurance of office holders shall not require shareholder approval and may be approved only by the compensation committee, if the engagement terms are determined in the company&#8217;s
      compensation policy and that policy was approved by the shareholders by a special majority (as described in Item 6C to the 2019 Annual Report &#8220;Directors, Senior Management and Employees &#8212;Board Practices&#8212;Approval of Related Party Transactions under
      Israeli Law&#8221;), provided that the policy is on market terms and is not likely to materially impact the company&#8217;s profitability, assets or obligations.&#160;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our amended articles of association permit us to exculpate, indemnify and insure our office holders to the fullest extent permitted under the Israeli Companies Law and the Israeli
      Securities Law. We have obtained directors&#8217; and officers&#8217; liability insurance for the benefit of our office holders and intend to continue to maintain such coverage and pay all premiums thereunder to the fullest extent permitted by the Israeli
      Companies Law.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We have entered into indemnification and exculpation agreements with each of our current officers and directors exculpating them from a breach of their duty of care to us to the
      fullest extent permitted by the Israeli Companies Law and undertaking to indemnify them to the fullest extent permitted by the Israeli Companies Law and the Israeli Securities Law, to the extent that these liabilities are not covered by insurance.
      This indemnification is limited to events determined as foreseeable by our board of directors based on our activities, as set forth in the indemnification agreements. Under such indemnification agreements, the maximum aggregate amount of
      indemnification that we may pay to any and all of our currently serving or future officers and directors together may not exceed the higher of $5 million and 25% of our shareholders equity according to our most recent financial statements at the time
      of payment. In the opinion of the SEC, however, indemnification of directors and office holders for liabilities arising under the Securities Act of 1933, as amended, is against public policy and therefore unenforceable.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">II - 2</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Item 7. Recent Sales of Unregistered Securities</div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Set forth below are the sales of all unregistered securities of ours sold by us within the past three years (i.e., since August 1, 2017, up to the date of this registration
      statement) which were not registered under the Securities Act:</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">On November 22, 2017, we consummated a registered direct offering of 189,387 ordinary shares at a price of $13.20 per share and a simultaneous private placement of five-year
      warrants to purchase an aggregate of up to 142,042 ordinary shares. The warrants have an exercise price of $15.00 per share and are immediately exercisable. We received approximately $2.5 million gross proceeds from the November 2017 registered
      direct offering. During the year ended December 31, 2018, 56,812 warrants were cashless exercised into 13,574 ordinary shares. As part of the July 2020 financing, all of the remaining warrants in the amount of 85,228 warrants were exercised. We also
      issued unregistered placement agent warrants to purchase up to an aggregate of 9,741 ordinary shares on the same terms as the warrants issued to the investors in the private placement, except they have an exercise price of $16.5 per share.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">On February 6, 2019, we consummated a registered direct offering of 1,881,500 units at a purchase price of $2.58 per unit and 1,024,876 pre-funded units, at a purchase price of
      $2.57 per pre-funded unit. Each unit consisted of one ordinary share and one Series D Warrant to purchase 0.5 ordinary share. Each pre-funded unit consisted of one pre-funded warrant to purchase one ordinary share and one Series D Warrant to purchase
      0.5 ordinary share. The exercise price of each pre-funded warrant included in the pre-funded unit was $0.01 per share. The Series D warrants have an exercise price of $2.58 per ordinary share, are immediately exercisable and will expire five years
      from the date of issuance. We received gross proceeds of approximately of $7.5 million from the offering. As part of the July 2020 financing, 968,992 of the warrants were exercised, and 484,196 warrants remain outstanding. We also issued unregistered
      placement agent warrants to purchase up to an aggregate of 203,446 ordinary shares on the same terms as the warrants issued to the investors in the private placement, except they have an exercise price of $3.225 per share.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">On February 4, 2020, we consummated a private placement of 2,720,178 ordinary shares at a purchase price of $1.75 per share.&#160; We received gross proceeds of approximately $4.76
      million from the private placement.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">On April 22, 2020, we consummated a registered direct offering of 6,666,669 ordinary shares at a price of $0.60 per share and a simultaneous private placement of five and a
      half-year warrants to purchase an aggregate of up to 6,666,669 ordinary shares. The warrants have an exercise price of $0.80 per share and are immediately exercisable. We received gross proceeds from the April 22, 2020 registered direct offering of
      approximately $4.0 million. As part of the July 2020 financing, 5,833,336 of the warrants were exercised and 833,333 warrants remain outstanding. We also issued unregistered placement agent warrants to purchase up to an aggregate of 466,667 ordinary
      shares on the same terms as the warrants issued to the investors in the private placement, except they have a term of five years and an exercise price of $0.75 per share.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">On May 4, 2020, we consummated a registered direct offering of 7,500,001 ordinary shares at a price of $0.60 per share and a simultaneous private placement of five and a half-year
      warrants to purchase an aggregate of up to 7,500,001 ordinary shares. The warrants have an exercise price of $0.80 per share and are immediately exercisable. We received gross proceeds from the May 4, 2020 registered direct offering of approximately
      $4.5 million. As part of the July 2020 financing, 5,833,334 of the warrants were exercised and 1,666,667 warrants remain outstanding.]We also issued unregistered placement agent warrants to purchase up to an aggregate of 525,000 ordinary shares on
      the same terms as the warrants issued to the investors in the private placement, except they have a term of five years and an exercise price of $0.75 per share.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">On May 13, 2020, we consummated a registered direct offering of 5,000,000 ordinary shares at a price of $0.60 per share and a simultaneous private placement of five and a half-year
      warrants to purchase an aggregate of up to 5,000,000 ordinary shares. The warrants have an exercise price of $0.80 per share and are immediately exercisable. We received gross proceeds from the May 13, 2020 registered direct offering of $3.0 million.
      As part of the July 2020 financing, 3,333,333 of the warrants were exercised and 1,666,667 warrants remain outstanding. We also issued unregistered placement agent warrants to purchase up to an aggregate of 350,000 ordinary shares on the same terms
      as the warrants issued to the investors in the private placement, except they have a term of five years and an exercise price of $0.75 per share.</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">II - 3</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-right: 0.1pt; margin-left: 0.2pt; line-height: 1.25;">On July 23, 2020, we entered into the Exercise Agreement with Holders of our Old Warrants, pursuant to which the Holders agreed to exercise
      in cash their Old Warrants to purchase up to an aggregate of 16,054,223 ordinary shares having exercise prices ranging from $15.00 to $0.80 per share, at a reduced exercise price of $0.60 per share, resulting in gross proceeds of approximately $9.6
      million. The warrants exercised in the transaction include warrants to purchase up to 15,000,003 ordinary shares at an exercise price of $0.80 per share issued in May 2020 and April 2020, warrants to purchase up to 968,992 ordinary shares at an
      exercise price of $2.58 per share issued in February 2019, and warrants to purchase up to 85,228 ordinary shares at an exercise price of $15.00 per share issued in November 2017. Closing occurred on July 27, 2020. Under the Exercise Agreement, we
      also issued to the Holders the Private Placement Warrants. The Private Placement Warrants are immediately exercisable, expire five and one-half years from issuance date and have an exercise price of $0.80 per share, subject to adjustment as set forth
      therein. The Private Placement Warrants may be exercised on a cashless basis if at the time of exercise thereof, there is no effective registration statement registering the ordinary shares underlying the warrants. We also issued unregistered
      placement agent warrants to purchase up to an aggregate 1,123,796 ordinary shares on the same terms as the Private Placement Warrants issued to the Holders, except that they have an exercise price of $0.75 per share.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The privately placed securities above were offered and sold pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act and Rule 506 of
      Regulation D promulgated thereunder since, among other things, the transactions did not involve a public offering and the securities were acquired for investment purposes only and not with a view to or for sale in connection with any distribution
      thereof.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Item 8. Exhibits and Financial Statement Schedules</div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0e84848688244befb8a53bc32cc49741">

        <tr>
          <td style="width: 27pt; vertical-align: top; align: right;">(a)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-style: italic; font-weight: bold;">Exhibits</div>
          </td>
        </tr>

    </table>
    <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zc5f7af3ba1d54dcfb2cadbb8ee8d0ca9">

        <tr>
          <td style="width: 9.01%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Exhibit No.</div>
          </td>
          <td style="width: 1%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 90%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Exhibit Description</div>
          </td>
        </tr>
        <tr>
          <td style="width: 9.01%; vertical-align: top; background-color: #CCEEFF;">
            <div style="text-align: justify; line-height: 1.25;"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891320000745/exhibit_1-1.htm">3.1</a></div>
          </td>
          <td style="width: 1%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: #CCEEFF;">
            <div style="text-align: justify; line-height: 1.25;"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891320000745/exhibit_1-1.htm">Amended and Restated Articles of Association of Check-Cap Ltd. (1)</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 9.01%; vertical-align: top; background-color: #FFFFFF;">
            <div style="text-align: justify; line-height: 1.25;"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891314003928/exhibit_10-14.htm">4.1</a></div>
          </td>
          <td style="width: 1%; vertical-align: top; background-color: #FFFFFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: #FFFFFF;">
            <div style="line-height: 1.25;"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891314003928/exhibit_10-14.htm">Form of Registrant&#8217;s Ordinary Share Certificate (2)</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 9.01%; vertical-align: top; background-color: #CCEEFF;">
            <div style="text-align: justify; line-height: 1.25;"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891315000567/exhibit_4-6.htm">4.2</a></div>
          </td>
          <td style="width: 1%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891315000567/exhibit_4-6.htm">Form of Long Term Incentive Warrant Certificate (2)</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 9.01%; vertical-align: top; background-color: #FFFFFF;">
            <div style="text-align: justify; line-height: 1.25;"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891315000567/exhibit_4-6.htm">4.3</a></div>
          </td>
          <td style="width: 1%; vertical-align: top; background-color: #FFFFFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: #FFFFFF;">
            <div style="line-height: 1.25;"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891315000567/exhibit_4-6.htm">Form of Warrant Agreement dated as of February 24, 2015 between Check-Cap Ltd. and American Stock Transfer &amp; Trust
                Company LLC, as Warrant Agent (2)</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 9.01%; vertical-align: top; background-color: #CCEEFF;">
            <div style="text-align: justify; line-height: 1.25;"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891315002104/exhibit_4-1.htm">4.4</a></div>
          </td>
          <td style="width: 1%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891315002104/exhibit_4-1.htm">Amendment No.1 dated as of June 24, 2015, to Warrant Agreement dated as of February 24, 2015 between Check-Cap Ltd. and
                American Stock Transfer &amp; Trust Company LLC, as Warrant Agent (3)</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 9.01%; vertical-align: top; background-color: #FFFFFF;">
            <div style="text-align: justify; line-height: 1.25;"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891315000567/exhibit_1-1.htm">4.5</a></div>
          </td>
          <td style="width: 1%; vertical-align: top; background-color: #FFFFFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: #FFFFFF;">
            <div style="line-height: 1.25;"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891315000567/exhibit_1-1.htm">Form of 2014 Underwriter Warrants (2)</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 9.01%; vertical-align: top; background-color: #CCEEFF;">
            <div style="text-align: justify; line-height: 1.25;"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891317001696/exhibit_4-2.htm">4.6</a></div>
          </td>
          <td style="width: 1%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891317001696/exhibit_4-2.htm">Form of June 2017 Warrants (4)</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 9.01%; vertical-align: top; background-color: #FFFFFF;">
            <div style="text-align: justify; line-height: 1.25;"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891317001696/exhibit_4-2.htm">4.7</a></div>
          </td>
          <td style="width: 1%; vertical-align: top; background-color: #FFFFFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: #FFFFFF;">
            <div style="line-height: 1.25;"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891317001696/exhibit_4-2.htm">Form of June 2017 Placement Agent Warrants (4)</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 9.01%; vertical-align: top; background-color: #CCEEFF;">
            <div style="text-align: justify; line-height: 1.25;"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891317003232/exhibit_4-1.htm">4.8</a></div>
          </td>
          <td style="width: 1%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891317003232/exhibit_4-1.htm">Form of November 2017 Warrants (5)</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 9.01%; vertical-align: top; background-color: #FFFFFF;">
            <div style="text-align: justify; line-height: 1.25;"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891317003232/exhibit_4-2.htm">4.9</a></div>
          </td>
          <td style="width: 1%; vertical-align: top; background-color: #FFFFFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: #FFFFFF;">
            <div style="line-height: 1.25;"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891317003232/exhibit_4-2.htm">Form of November 2017 Placement Agent Warrants (5)</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 9.01%; vertical-align: top; background-color: #CCEEFF;">
            <div style="text-align: justify; line-height: 1.25;"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891317003232/exhibit_4-2.htm">4.10</a></div>
          </td>
          <td style="width: 1%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891317003232/exhibit_4-2.htm">Form of Ordinary Shares Warrant Certificate issued pursuant to a certain Credit Line Agreement dated as of August 20,
                2014 (2)</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 9.01%; vertical-align: top; background-color: #FFFFFF;">
            <div style="text-align: justify; line-height: 1.25;"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891318001272/exhibit_4-14.htm">4.11</a></div>
          </td>
          <td style="width: 1%; vertical-align: top; background-color: #FFFFFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: #FFFFFF;">
            <div style="line-height: 1.25;"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891318001272/exhibit_4-14.htm">Form of Series C Warrant (6)</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 9.01%; vertical-align: top; background-color: #CCEEFF;">
            <div style="text-align: justify; line-height: 1.25;"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891318001272/exhibit_4-15.htm">4.12</a></div>
          </td>
          <td style="width: 1%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891318001272/exhibit_4-15.htm">Form of Warrant Agent Agreement between Check-Cap Ltd. and American Stock Transfer &amp; Trust Company LLC, as Warrant
                Agent (6)</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 9.01%; vertical-align: top; background-color: #FFFFFF;">
            <div style="text-align: justify; line-height: 1.25;"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891319000303/exhibit_4-1.htm">4.13</a></div>
          </td>
          <td style="width: 1%; vertical-align: top; background-color: #FFFFFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: #FFFFFF;">
            <div style="line-height: 1.25;"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891319000303/exhibit_4-1.htm">Form of February 2019 Series D Warrant (7)</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 9.01%; vertical-align: top; background-color: #CCEEFF;">
            <div style="text-align: justify; line-height: 1.25;"><a href="exhibit_5-1.htm">5.1</a></div>
          </td>
          <td style="width: 1%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;"><a href="exhibit_5-1.htm"><br>
              </a> </div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;"><a href="exhibit_5-1.htm">Opinion of Fischer Behar Chen Well Orion &amp; Co., Israeli counsel to the Registrant*</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 9.01%; vertical-align: top; background-color: #FFFFFF;">
            <div style="text-align: justify; line-height: 1.25;"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891319000303/exhibit_4-3.htm">10.1</a></div>
          </td>
          <td style="width: 1%; vertical-align: top; background-color: #FFFFFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: #FFFFFF;">
            <div style="line-height: 1.25;"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891319000303/exhibit_4-3.htm">Form of the February 2019 Placement Agent Warrant (8)</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 9.01%; vertical-align: top; background-color: #CCEEFF;">
            <div style="text-align: justify; line-height: 1.25;"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891320001161/exhiibit_10-2.htm">10.2</a></div>
          </td>
          <td style="width: 1%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891320001161/exhiibit_10-2.htm">Form of Warrant issued by Check-Cap Ltd. on April 22, 2020 (9)</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 9.01%; vertical-align: top; background-color: #FFFFFF;">
            <div style="text-align: justify; line-height: 1.25;"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891320001286/exhibit_10-2.htm">10.3</a></div>
          </td>
          <td style="width: 1%; vertical-align: top; background-color: #FFFFFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: #FFFFFF;">
            <div style="line-height: 1.25;"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891320001286/exhibit_10-2.htm">Form of Warrant issued by Check-Cap Ltd. on May 4, 2020 (10)</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 9.01%; vertical-align: top; background-color: #CCEEFF;">
            <div style="text-align: justify; line-height: 1.25;"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891320001436/exhibit_10-2.htm">10.4</a></div>
          </td>
          <td style="width: 1%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891320001436/exhibit_10-2.htm">Form of Warrant issued by Check-Cap Ltd. on May 13, 2020 (11)</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 9.01%; vertical-align: top; background-color: #CCEEFF;">
            <div style="text-align: justify; line-height: 1.25;"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891320002081/exhibit_10-2.htm">10.5</a></div>
          </td>
          <td style="width: 1%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
          <td style="width: 90%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891320002081/exhibit_10-2.htm">Form of Warrant issued by Check-Cap Ltd. on July 27, 2020 (12)</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 9.01%; vertical-align: top; background-color: #FFFFFF;">
            <div style="text-align: justify; line-height: 1.25;"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891320001553/exhibit_10-5.htm">10.6</a></div>
          </td>
          <td style="width: 1%; vertical-align: top; background-color: #FFFFFF;">
            <div style="line-height: 1.25;"><br>
            </div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: #FFFFFF;">
            <div style="line-height: 1.25;"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891320001553/exhibit_10-5.htm">Form of Placement Agent Warrant issued by Check-Cap Ltd. on April 22, 2020(13)</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 9.01%; vertical-align: top; background-color: #CCEEFF;">
            <div style="text-align: justify; line-height: 1.25;"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891320001553/exhibit_10-6.htm">10.7</a></div>
          </td>
          <td style="width: 1%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;"><br>
            </div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891320001553/exhibit_10-6.htm">Form of Placement Agent Warrant issued by Check-Cap Ltd. on May 4, 2020(13)</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 9.01%; vertical-align: top; background-color: #FFFFFF;">
            <div style="text-align: justify; line-height: 1.25;"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891320001553/exhibit_10-7.htm">10.8</a></div>
          </td>
          <td style="width: 1%; vertical-align: top; background-color: #FFFFFF;">
            <div style="line-height: 1.25;"><br>
            </div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: #FFFFFF;">
            <div style="line-height: 1.25;"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891320001553/exhibit_10-7.htm">Form of Placement Agent Warrant issued by Check-Cap Ltd. on May 13, 2020(13)</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 9.01%; vertical-align: top; background-color: #FFFFFF;">
            <div style="text-align: justify; line-height: 1.25;"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891320002081/exhibit_10-3.htm">10.9</a></div>
          </td>
          <td style="width: 1%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
          <td style="width: 90%; vertical-align: top; background-color: #FFFFFF;">
            <div style="line-height: 1.25;"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891320002081/exhibit_10-3.htm">Form of Placement Agent Warrant issued by Check-Cap Ltd. on July 27, 2020(12)</a></div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">II - 4</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 9.01%; vertical-align: top; background-color: #CCEEFF;">
            <div style="text-align: justify; line-height: 1.25;"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891314003928/exhibit_10-15.htm">10.10</a></div>
          </td>
          <td style="width: 1%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891314003928/exhibit_10-15.htm">Forms of Ordinary Shares Warrant Certificate issued to the Pontifax entities (2)</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 9.01%; vertical-align: top; background-color: #FFFFFF;">
            <div style="text-align: justify; line-height: 1.25;"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891316006206/exhibit_10-2.htm">10.11</a></div>
          </td>
          <td style="width: 1%; vertical-align: top; background-color: #FFFFFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: #FFFFFF;">
            <div style="line-height: 1.25;"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891316006206/exhibit_10-2.htm">Placement Agent Agreement dated August 5, 2016 by and between Check-Cap Ltd. and Chardan Capital Markets LLC (14)</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 9.01%; vertical-align: top; background-color: #CCEEFF;">
            <div style="text-align: justify; line-height: 1.25;"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891317001696/exhibit_10-1.htm">10.12</a></div>
          </td>
          <td style="width: 1%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891317001696/exhibit_10-1.htm">Securities Purchase Agreement dated as of May 30, 2017 by and among Check-Cap Ltd. and the Purchasers named therein
                (15)</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 9.01%; vertical-align: top; background-color: #FFFFFF;">
            <div style="text-align: justify; line-height: 1.25;"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891317001696/exhibit_10-1.htm">10.1</a>3</div>
          </td>
          <td style="width: 1%; vertical-align: top; background-color: #FFFFFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: #FFFFFF;">
            <div style="line-height: 1.25;"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891317001696/exhibit_10-1.htm">Securities Purchase Agreement dated as of November 20, 2017 by and among Check-Cap Ltd. and the Purchasers named
                therein (16)</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 9.01%; vertical-align: top; background-color: #CCEEFF;">
            <div style="text-align: justify; line-height: 1.25;"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891318001462/exhibit_1-1.htm">10.14</a></div>
          </td>
          <td style="width: 1%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891318001462/exhibit_1-1.htm">Underwriting Agreement, dated as of May 4, 2018, by and between Check-Cap Ltd. and H.C. Wainwright &amp; Co., LLC (17)</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 9.01%; vertical-align: top; background-color: #FFFFFF;">
            <div style="text-align: justify; line-height: 1.25;"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891319000303/exhibit_10-1.htm">10.15</a></div>
          </td>
          <td style="width: 1%; vertical-align: top; background-color: #FFFFFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: #FFFFFF;">
            <div style="line-height: 1.25;"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891319000303/exhibit_10-1.htm">Form of Securities Purchase Agreement dated as of February 4, 2019 by and between Check-Cap Ltd. and the Purchasers
                named therein (18)</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 9.01%; vertical-align: top; background-color: #CCEEFF;">
            <div style="text-align: justify; line-height: 1.25;"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891319000303/exhibit_10-1.htm">10.16</a></div>
          </td>
          <td style="width: 1%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891319000303/exhibit_10-1.htm">Form of Securities Purchase Agreement dated as of December 19, 2019 by and between Check-Cap Ltd. and the Purchasers
                named therein (19)</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 9.01%; vertical-align: top; background-color: #FFFFFF;">
            <div style="text-align: justify; line-height: 1.25;"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891320001161/exhibit_10-1.htm">10.17</a></div>
          </td>
          <td style="width: 1%; vertical-align: top; background-color: #FFFFFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: #FFFFFF;">
            <div style="line-height: 1.25;"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891320001161/exhibit_10-1.htm">Form of Securities Purchase Agreement dated as of April 20, 2020 by and between Check-Cap Ltd. and the Purchasers
                signatory thereto (2)</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 9.01%; vertical-align: top; background-color: #CCEEFF;">
            <div style="text-align: justify; line-height: 1.25;"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891320001286/exhibit_10-1.htm">10.18</a></div>
          </td>
          <td style="width: 1%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891320001286/exhibit_10-1.htm">Form of Securities Purchase Agreement dated as of April 30, 2020 by and between Check-Cap Ltd. and the Purchasers
                signatory thereto (3)</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 9.01%; vertical-align: top; background-color: #FFFFFF;">
            <div style="text-align: justify; line-height: 1.25;"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891320001436/exhibit_10-1.htm">10.19</a></div>
          </td>
          <td style="width: 1%; vertical-align: top; background-color: #FFFFFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: #FFFFFF;">
            <div style="line-height: 1.25;"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891320001436/exhibit_10-1.htm">Form of Securities Purchase Agreement dated as of May 8, 2020 by and between Check-Cap Ltd. and the Purchasers
                signatory thereto (4)</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 9.01%; vertical-align: top; background-color: #FFFFFF;">
            <div style="text-align: justify; line-height: 1.25;"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891320001436/exhibit_10-1.htm">10.20</a></div>
          </td>
          <td style="width: 1%; vertical-align: top; background-color: #FFFFFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: #FFFFFF;">
            <div style="line-height: 1.25;"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891320001436/exhibit_10-1.htm">Form of Warrant Exercise Agreement dated as of July 23, 2020 by and between Check-Cap Ltd. and the Purchasers signatory
                thereto (12)</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 9.01%; vertical-align: top; background-color: #CCEEFF;">
            <div style="text-align: justify; line-height: 1.25;"><a href="exhibit_23-1.htm">23.1</a></div>
          </td>
          <td style="width: 1%; vertical-align: top; background-color: #CCEEFF;"> <br>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: #CCEEFF;">
            <div style="text-align: justify; line-height: 1.25;"><a href="exhibit_23-1.htm">Consent of Brightman Almagor Zohar &amp; Co.*</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 9.01%; vertical-align: top; background-color: #FFFFFF;">
            <div style="text-align: justify; line-height: 1.25;"><a href="exhibit_5-1.htm">23.2</a></div>
          </td>
          <td style="width: 1%; vertical-align: top; background-color: #FFFFFF;">
            <div style="line-height: 1.25;"><a href="exhibit_5-1.htm"><br>
              </a> </div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: #FFFFFF;">
            <div style="line-height: 1.25;"><a href="exhibit_5-1.htm">Consent of Fischer Behar Chen Well Orion &amp; Co. (included in Exhibit 5.1)*</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 9.01%; vertical-align: top; background-color: #CCEEFF;">
            <div style="text-align: justify; line-height: 1.25;"><a href="#SIGNATURES">24.1</a></div>
          </td>
          <td style="width: 1%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;"><br>
            </div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: #CCEEFF;">
            <div style="text-align: justify; line-height: 1.25;"><a href="#SIGNATURES">Power of Attorney (included in signature page)</a></div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

          <tr>
            <td style="width: 18pt; vertical-align: top; align: right;">*</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>
                <div>&#160;Filed herewith.</div>
              </div>
            </td>
          </tr>

      </table>
    </div>
    <br>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z23dbc4527e0145798c1591b26d0939b9">

        <tr>
          <td style="width: 18pt; vertical-align: top; align: right;">(1)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#160;Incorporated herein by reference to the Annual Report on Form 20-F filed with the SEC on March 6, 2020.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z65a5dab267304240845c387d08cbfe19">

        <tr>
          <td style="width: 18pt; vertical-align: top; align: right;">(2)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#160;Incorporated by reference to the Registration Statement on Form F-1 of the Registrant (File No. 333-201250).</div>
          </td>
        </tr>

    </table>
    <div style="text-align: justify; text-indent: -18pt; margin-left: 18pt; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z6731711dc83d4693ba0c4f374307e8b7">

        <tr>
          <td style="width: 18pt; vertical-align: top; align: right;">(3)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#160;Incorporated by reference to the Form 6-K filed by the Registrant with the SEC on June 24, 2015.</div>
          </td>
        </tr>

    </table>
    <div style="text-align: justify; text-indent: -18pt; margin-left: 18pt; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za65d51966d464f99987fb9c613b31482">

        <tr>
          <td style="width: 18pt; vertical-align: top; align: right;">(4)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#160;Incorporated by reference to the Form 6-K filed by the Registrant with the SEC on June 2, 2017.</div>
          </td>
        </tr>

    </table>
    <div style="text-align: justify; line-height: 1.25;">&#160;
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

          <tr>
            <td style="width: 18pt; vertical-align: top; align: right;">(5)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>
                <div style="line-height: 1.25;">&#160;Incorporated by reference to the Form 6-K filed by the Registrant with the SEC on November 22, 2017.</div>
              </div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;">&#160;
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 18pt; vertical-align: top; align: right;">(6)</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="text-indent: -27pt; margin-left: 27pt; line-height: 1.25;">&#160;Incorporated by reference to the Registration Statement on Form F-1/A by the Registrant with the SEC on April 25, 2018.</div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;">&#160;
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

              <tr>
                <td style="width: 18pt; vertical-align: top; align: right;">(7)</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>
                    <div style="line-height: 1.25;">&#160;Incorporated by reference to the Form 6-K filed by the Registrant with the SEC on February 6, 2019.</div>
                  </div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">&#160;
            <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                <tr>
                  <td style="width: 18pt; vertical-align: top; align: right;">(8)</td>
                  <td style="width: auto; vertical-align: top; text-align: justify;">
                    <div>
                      <div style="text-indent: -27pt; margin-left: 27pt; line-height: 1.25;">&#160;Incorporated by reference to the Form 6-K filed by the Registrant with the SEC on February 6, 2019.</div>
                    </div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25;">&#160;
              <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                  <tr>
                    <td style="width: 18pt; vertical-align: top; align: right;">(9)</td>
                    <td style="width: auto; vertical-align: top; text-align: justify;">
                      <div>
                        <div style="line-height: 1.25;">&#160;Incorporated herein by reference to the Form 6-K filed by the Registrant with the SEC on April 22, 2020.</div>
                      </div>
                    </td>
                  </tr>

              </table>
              <div style="line-height: 1.25;">&#160;
                <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                    <tr>
                      <td style="width: 18pt; vertical-align: top; align: right;">(10)</td>
                      <td style="width: auto; vertical-align: top; text-align: justify;">
                        <div>
                          <div style="text-indent: -27pt; margin-left: 27pt; line-height: 1.25;">&#160;Incorporated herein by reference to the Form 6-K filed by the Registrant with the SEC on May 4, 2020.</div>
                        </div>
                      </td>
                    </tr>

                </table>
                <div style="line-height: 1.25;">&#160;
                  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                      <tr>
                        <td style="width: 18pt; vertical-align: top; align: right;">(11)</td>
                        <td style="width: auto; vertical-align: top; text-align: justify;">
                          <div>
                            <div style="text-indent: -27pt; margin-left: 27pt; line-height: 1.25;">&#160;Incorporated herein by reference to the Form 6-K filed by the Registrant with the SEC on May 12, 2020.</div>
                          </div>
                        </td>
                      </tr>

                  </table>
                  <div style="line-height: 1.25;">&#160;
                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                        <tr>
                          <td style="width: 18pt; vertical-align: top; align: right;">(12)</td>
                          <td style="width: auto; vertical-align: top; text-align: justify;">
                            <div>
                              <div style="text-indent: -27pt; margin-left: 27pt; line-height: 1.25;">&#160;Incorporated by reference to the Form 6-K filed by the Registrant with the SEC on July 24, 2020.</div>
                            </div>
                          </td>
                        </tr>

                    </table>
                    <div style="line-height: 1.25;">&#160;
                      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                          <tr>
                            <td style="width: 18pt; vertical-align: top; align: right;">(13)</td>
                            <td style="width: auto; vertical-align: top; text-align: justify;">
                              <div>
                                <div style="text-indent: -27pt; margin-left: 27pt; line-height: 1.25;">&#160;Incorporated by reference to the Form 6-K filed by the Registrant with the SEC on July 24, 2020.</div>
                              </div>
                            </td>
                          </tr>

                      </table>
                      <div style="line-height: 1.25;">&#160;
                        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                            <tr>
                              <td style="width: 18pt; vertical-align: top; align: right;">(14)</td>
                              <td style="width: auto; vertical-align: top; text-align: justify;">
                                <div>
                                  <div style="text-align: left; line-height: 1.25;">&#160;Incorporated by reference to the Registration Statement on Form F-1 by the Registrant with the SEC on May 20, 2020.</div>
                                </div>
                              </td>
                            </tr>

                        </table>
                        <div style="line-height: 1.25;">&#160;<br>
                          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                              <tr>
                                <td style="width: 18pt; vertical-align: top; align: right;">(15)</td>
                                <td style="width: auto; vertical-align: top; text-align: justify;">
                                  <div>
                                    <div style="text-align: left; line-height: 1.25;">
                                      <div style="text-align: justify; text-indent: -27pt; margin-left: 27pt; line-height: 1.25;">&#160;Incorporated by reference to the Form 6-K filed by the Registrant with the SEC on June 2, 2017.</div>
                                    </div>
                                  </div>
                                </td>
                              </tr>

                          </table>
                          <div style="line-height: 1.25;">&#160;</div>
                        </div>
                      </div>
                    </div>
                  </div>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">II - 5</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div> <br>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

          <tr>
            <td style="width: 18pt; vertical-align: top; align: right;">(16)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-family: 'Times New Roman',Times,serif;">
                <div style="text-align: left; line-height: 1.25;">
                  <div style="text-align: justify; line-height: 1.25;">
                    <div style="line-height: 1.25;">&#160;Incorporated by reference to the Form 6-K filed by the Registrant with the SEC on November 22, 2017.</div>
                  </div>
                </div>
              </div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; line-height: 1.25;">&#160;<br>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

            <tr>
              <td style="width: 18pt; vertical-align: top; align: right;">(17)</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>
                  <div style="text-align: left; line-height: 1.25;">
                    <div style="text-align: justify; text-indent: -27pt; margin-left: 27pt; line-height: 1.25;">
                      <div style="line-height: 1.25;">&#160;Incorporated by reference to the Form 6-K filed by the Registrant with the SEC on May 4, 2018.</div>
                    </div>
                  </div>
                </div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;">&#160;<br>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

              <tr>
                <td style="width: 18pt; vertical-align: top; align: right;">(18)</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>
                    <div style="text-align: left; line-height: 1.25;">
                      <div style="text-align: justify; text-indent: -27pt; margin-left: 27pt; line-height: 1.25;">
                        <div style="line-height: 1.25;">&#160;Incorporated by reference to the Form 6-K filed by the Registrant with the SEC on February 6, 2019.</div>
                      </div>
                    </div>
                  </div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">&#160;<br>
            <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                <tr>
                  <td style="width: 18pt; vertical-align: top; align: right;">(19)</td>
                  <td style="width: auto; vertical-align: top; text-align: justify;">
                    <div>
                      <div style="text-align: left; line-height: 1.25;">
                        <div style="text-align: justify; text-indent: -27pt; margin-left: 27pt; line-height: 1.25;">
                          <div style="line-height: 1.25;">&#160;Incorporated by reference to the Annual Report on Form 20-F filed by the Registrant with the SEC on March 6, 2020.</div>
                        </div>
                      </div>
                    </div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25;">&#160;</div>
          </div>
        </div>
      </div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The agreements included as exhibits to this registration statement contain representations and warranties by each of the parties to the applicable agreement. These representations
      and warranties were made solely for the benefit of the other parties to the applicable agreement and (i) were not intended to be treated as categorical statements of fact, but rather as a way of allocating the risk to one of the parties if those
      statements prove to be inaccurate; (ii) may have been qualified in such agreement by disclosures that were made to the other party in connection with the negotiation of the applicable agreement; (iii) may apply contract standards of &#8220;materiality&#8221;
      that are different from &#8220;materiality&#8221; under the applicable securities laws; and (iv) were made only as of the date of the applicable agreement or such other date or dates as may be specified in the agreement.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Registrant acknowledges that, notwithstanding the inclusion of the foregoing cautionary statements, the registrant is responsible for considering whether additional specific
      disclosures of material information regarding material contractual provisions are required to make the statements in this registration statement not misleading.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z0f52c7bbbb434ed3af381b0ff4a58513">

        <tr>
          <td style="width: 3.82%; vertical-align: top;">
            <div style="line-height: 1.25;">(b)</div>
          </td>
          <td style="width: 96.18%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Financial Statement Schedules</div>
          </td>
        </tr>

    </table>
    <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">All schedules have been omitted because either they are not required, are not applicable or the information is otherwise set forth in the consolidated financial statements and
      related notes thereto.</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">II - 6</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Item 9. Undertakings</div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1500cd88f4f04103937c02288db6d457">

        <tr>
          <td style="width: 27pt; vertical-align: top; align: right;">(a)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>The undersigned Registrant hereby undertakes:</div>
          </td>
        </tr>

    </table>
    <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zdd3c45f247d14fbb9d22f25e6e7e73d0">

        <tr>
          <td style="width: 27pt; vertical-align: top; align: right;">(1)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zae7f9bafd470431c9c85de238372d719">

        <tr>
          <td style="width: 27pt; vertical-align: top; align: right;">i.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>To include any prospectus required by section 10(a)(3) of the Securities Act of 1933;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z696cc11bdf2a47448ab0f5ec76e78385">

        <tr>
          <td style="width: 27pt; vertical-align: top; align: right;">ii.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post- effective amendment thereof) which, individually or in the aggregate, represent a fundamental change
              in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered)
              and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no
              more than 20% change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective registration statement;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z180eddb9b4fa480cb79cd1a8a9727a4f">

        <tr>
          <td style="width: 27pt; vertical-align: top; align: right;">iii.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf1d1d68484f747d8a0b2949a0df467b3">

        <tr>
          <td style="width: 27pt; vertical-align: top; align: right;">(2)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>That for the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered
              therein, and this offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc1fc28e4a9914a2d98d172bb950f3564">

        <tr>
          <td style="width: 27pt; vertical-align: top; align: right;">(3)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z588d622e6b894d9a91bf2ab479aed38b">

        <tr>
          <td style="width: 27pt; vertical-align: top; align: right;">(4)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>To file a post-effective amendment to the registration statement to include any financial statements required by Item 8.A. of Form 20-F at the start of any delayed offering or throughout a continuous offering. Financial statements and
              information otherwise required by Section 10(a)(3) of the Act need not be furnished, provided that the registrant includes in the prospectus, by means of a post-effective amendment, financial statements required pursuant to this paragraph
              (a)(4) and other information necessary to ensure that all other information in the prospectus is at least as current as the date of those financial statements. Notwithstanding the foregoing, with respect to registration statements on Form
              F-3, a post-effective amendment need not be filed to include financial statements and information required by Section 10(a)(3) of the Act or Rule 3-19 of this chapter if such financial statements and information are contained in periodic
              reports filed with or furnished to the Commission by the registrant pursuant to section 13 or section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the Form F-3.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z28a22f3a88344575bb4caedffd1e9f9a">

        <tr>
          <td style="width: 27pt; vertical-align: top; align: right;">(5)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>That for purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of
              prospectus filed by the Registrant pursuant to Rule 424(b)(1) or (4), or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8279180dc4e843f787255bed22c5b910">

        <tr>
          <td style="width: 27pt; vertical-align: top; align: right;">(6)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>For the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein,
              and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zdcbf44eb15304611830be5c757d7f1c3">

        <tr>
          <td style="width: 27pt; vertical-align: top; align: right;">(b)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the Registrant pursuant to the provisions described in Item 6 hereof, or otherwise, the
              Registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other
              than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling
              person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such
              indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">II - 7</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">SIGNATURES<a name="SIGNATURES"><!--Anchor--></a></div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on
      Form F-1 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Isfiya, State of Israel on this 20<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> day of August 2020.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zdbdd259a9ce14dfb8fde822aa6327e1f">

        <tr>
          <td style="width: 49.68%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td colspan="2" style="vertical-align: top;">
            <div style="line-height: 1.25; font-weight: bold;">CHECK-CAP LTD.</div>
          </td>
          <td style="width: 12%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.68%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td colspan="2" style="vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.68%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3%; vertical-align: top;">
            <div style="line-height: 1.25;">By:</div>
          </td>
          <td style="width: 34.56%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">/s/ Alex Ovadia</div>
          </td>
          <td style="width: 12%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.68%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3%; vertical-align: top;">
            <div style="line-height: 1.25;">Name:&#160;</div>
          </td>
          <td style="width: 34.56%; vertical-align: top;">
            <div style="line-height: 1.25;">Alex Ovadia</div>
          </td>
          <td style="width: 12%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.68%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3%; vertical-align: top;">
            <div style="line-height: 1.25;">Title:</div>
          </td>
          <td style="width: 34.56%; vertical-align: top;">
            <div style="line-height: 1.25; font-style: italic;">Chief Executive Officer</div>
          </td>
          <td style="width: 12%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>

    </table>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed below by the following persons in the capacities and on the dates indicated.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z9cd0a35d7fc149ca80849c01e0af7dee">

        <tr>
          <td style="width: 37.75%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="text-align: center; line-height: 1.25;">Name</div>
          </td>
          <td style="width: 1.11%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 42.24%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="text-align: center; line-height: 1.25;">Title</div>
          </td>
          <td style="width: 1.12%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 17.78%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="text-align: center; line-height: 1.25;">Date</div>
          </td>
        </tr>
        <tr>
          <td style="width: 37.75%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.11%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 42.24%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.12%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 17.78%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 37.75%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">/s/ Alex Ovadia</div>
          </td>
          <td style="width: 1.11%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 42.24%; vertical-align: bottom;">
            <div style="line-height: 1.25;">Chief Executive Officer and Director</div>
          </td>
          <td style="width: 1.12%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 17.78%; vertical-align: bottom;">
            <div style="text-align: center; line-height: 1.25;">August 20, 2020</div>
          </td>
        </tr>
        <tr>
          <td style="width: 37.75%; vertical-align: top;">
            <div style="line-height: 1.25;">Alex Ovadia</div>
          </td>
          <td style="width: 1.11%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 42.24%; vertical-align: top;">
            <div style="line-height: 1.25;">(principal executive officer)</div>
          </td>
          <td style="width: 1.12%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 17.78%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 37.75%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.11%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 42.24%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.12%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 17.78%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 37.75%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">/s/ Mira Rosenzweig</div>
          </td>
          <td style="width: 1.11%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 42.24%; vertical-align: top;">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">Chief Financial Officer</div>
            </div>
          </td>
          <td style="width: 1.12%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 17.78%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">August 20, 2020</div>
          </td>
        </tr>
        <tr>
          <td style="width: 37.75%; vertical-align: top;">
            <div style="line-height: 1.25;">Mira Rosenzweig</div>
          </td>
          <td style="width: 1.11%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 42.24%; vertical-align: top;">
            <div style="line-height: 1.25;">(principal financial officer and principal accounting officer)</div>
          </td>
          <td style="width: 1.12%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 17.78%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 37.75%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.11%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 42.24%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.12%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 17.78%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 37.75%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">/s/ Steven Hanley</div>
          </td>
          <td style="width: 1.11%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 42.24%; vertical-align: top;">
            <div style="line-height: 1.25;">Chairman of the Board</div>
          </td>
          <td style="width: 1.12%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 17.78%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">August 20, 2020</div>
          </td>
        </tr>
        <tr>
          <td style="width: 37.75%; vertical-align: top;">
            <div style="line-height: 1.25;">Steven Hanley</div>
          </td>
          <td style="width: 1.11%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 42.24%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.12%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 17.78%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 37.75%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.11%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 42.24%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.12%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 17.78%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 37.75%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">/s/ Clara Ezed</div>
          </td>
          <td style="width: 1.11%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 42.24%; vertical-align: top;">
            <div style="line-height: 1.25;">Director</div>
          </td>
          <td style="width: 1.12%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 17.78%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">August 20, 2020</div>
          </td>
        </tr>
        <tr>
          <td style="width: 37.75%; vertical-align: top;">
            <div style="line-height: 1.25;">Clara Ezed</div>
          </td>
          <td style="width: 1.11%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 42.24%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.12%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 17.78%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 37.75%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.11%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 42.24%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.12%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 17.78%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 37.75%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">/s/ Mary Jo Gorman</div>
          </td>
          <td style="width: 1.11%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 42.24%; vertical-align: top;">
            <div style="line-height: 1.25;">Director</div>
          </td>
          <td style="width: 1.12%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 17.78%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">August 20, 2020</div>
          </td>
        </tr>
        <tr>
          <td style="width: 37.75%; vertical-align: top;">
            <div style="line-height: 1.25;">Mary Jo Gorman</div>
          </td>
          <td style="width: 1.11%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 42.24%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.12%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 17.78%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 37.75%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.11%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 42.24%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.12%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 17.78%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 37.75%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">/s/ XiangQian (XQ) Lin</div>
          </td>
          <td style="width: 1.11%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 42.24%; vertical-align: top;">
            <div style="line-height: 1.25;">Director</div>
          </td>
          <td style="width: 1.12%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 17.78%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">August 20, 2020</div>
          </td>
        </tr>
        <tr>
          <td style="width: 37.75%; vertical-align: top;">
            <div style="line-height: 1.25;">XiangQian (XQ) Lin</div>
          </td>
          <td style="width: 1.11%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 42.24%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.12%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 17.78%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 37.75%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.11%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 42.24%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.12%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 17.78%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 37.75%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">/s/ Yuval Yanai</div>
          </td>
          <td style="width: 1.11%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 42.24%; vertical-align: top;">
            <div style="line-height: 1.25;">Director</div>
          </td>
          <td style="width: 1.12%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 17.78%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">August 20, 2020</div>
          </td>
        </tr>
        <tr>
          <td style="width: 37.75%; vertical-align: top;">
            <div style="line-height: 1.25;">Yuval Yanai</div>
          </td>
          <td style="width: 1.11%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 42.24%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.12%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 17.78%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">II - 8</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">SIGNATURE OF AUTHORIZED REPRESENTATIVE IN THE UNITED STATES</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Pursuant to the Securities Act of 1933, as amended, the undersigned, the duly authorized representative in the United States of Check-Cap Ltd., has signed this registration
      statement on August 20, 2020.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z990ea0cd832449748caee0ec7599b64c">

        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td colspan="2" style="vertical-align: top;">
            <div style="line-height: 1.25;">Puglisi &amp; Associates</div>
          </td>
          <td style="width: 12%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 12%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3%; vertical-align: top;">
            <div style="line-height: 1.25;">By:</div>
          </td>
          <td style="width: 35%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">/s/ Donald J. Puglisi</div>
          </td>
          <td style="width: 12%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3%; vertical-align: top;">
            <div style="line-height: 1.25;">Name:&#160;</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div style="line-height: 1.25;">Donald J. Puglisi</div>
          </td>
          <td style="width: 12%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3%; vertical-align: top;">
            <div style="line-height: 1.25;">Title:</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div style="line-height: 1.25;">Authorized Representative</div>
          </td>
          <td style="width: 12%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>

    </table>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">II - 9</font></div>
  </div>
  <div id="DSPFPageNumberArea" style="text-align: center;">
    <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; margin-left: auto; margin-right: auto;"></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>exhibit_5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: ZKG
         Document created using EDGARfilings PROfile 7.0.1.0
         Copyright 1995 - 2020 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div style="text-align: right;"> <u><font style="font-weight: bold;">Exhibit 5.1</font></u><br>
    </div>
    <div style="text-align: center;"> <img src="image00002.jpg"></div>
    <div> <br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="ze7c9dba558a945469156fee2dc709acd" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 85%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 15%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Tel. 972-3-69441111</div>
            </td>
          </tr>
          <tr>
            <td style="width: 85%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 15%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Fax. 972-3-6091116</div>
            </td>
          </tr>
          <tr>
            <td style="width: 85%; vertical-align: top; padding-bottom: 2px;" colspan="1">&#160;</td>
            <td style="width: 15%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">fbc@fbclawyers.com</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div>
      <div style="text-align: center; line-height: 1.25;">August 20, 2020</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25;">To:</div>
      <div style="line-height: 1.25;">Check-Cap Ltd.</div>
      <div style="line-height: 1.25;">Check-Cap Building</div>
      <div style="line-height: 1.25;">29 Abba Hushi Avenue</div>
      <div style="line-height: 1.25;">P.O. Box 1271</div>
      <div style="line-height: 1.25;">Isfiya, 3009000, Israel</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25;">Re: <u>Check-Cap Ltd.</u></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25;">Ladies and Gentlemen:</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We have acted as Israeli counsel to Check-Cap Ltd., a company organized under the laws of the State of Israel (the
        &#8220;<font style="font-weight: bold;">Company</font>&#8221;), in connection with the Registration Statement on Form F-1 (the &#8220;<font style="font-weight: bold;">Registration Statement</font>&#8221;) being filed by the Company with the U.S. Securities and Exchange Commission (the &#8220;<font style="font-weight: bold;">SEC</font>&#8221;)
        pursuant to the Securities Act of 1933, as amended (the &#8220;<font style="font-weight: bold;">Securities Act</font>&#8221;), which registers the resale, from time to time, by certain selling
        shareholders named in the Registration Statement of up to an aggregate of 25,897,198 ordinary shares, par value NIS 2.40 per share of the Company (the &#8220;<font style="font-weight: bold;">Ordinary
          Shares</font>&#8221;), consisting of (1) 20,388,864 Ordinary Shares consisting of (i) 19,265,068 Ordinary Shares issuable upon the exercise of warrants issued in a private placement on July 27, 2020 (the &#8220;<font style="font-weight: bold;">July 2020 Private Placement</font>&#8221;) and (ii) 1,123,796 Ordinary Shares issuable upon the exercise of placement agent warrants issued in the July 2020 Private Placement, and (2) 5,508,334
        Ordinary Shares previously registered on a Registration Statement on Form F-1 (File No. 333-238532), consisting of (i) 833,333 Ordinary Shares issuable upon the exercise of warrants issued in a private placement on April 22, 2020 (the &#8220;<font style="font-weight: bold;">April 2020 Private Placement</font>&#8221;), (ii) 466,667 Ordinary Shares issuable upon the exercise of placement agent warrants issued in the April 2020 Private
        Placement, (iii) 1,666,667 Ordinary Shares issuable upon the exercise of warrants issued in a private placement on May 4, 2020 (the &#8220;<font style="font-weight: bold;">First May 2020
          Private Placement</font>&#8221;), (iv) 525,000 Ordinary Shares issuable upon the exercise of placement agent warrants issued in the First May 2020 Private Placement, (v) 1,666,667 Ordinary Shares issuable upon the exercise of warrants issued in a
        private placement on May 13, 2020 (the &#8220;<font style="font-weight: bold;">Second May 2020 Private Placement</font>&#8221;), and (vi) 350,000 Ordinary Shares issuable upon the exercise of
        placement agent warrants issued in the Second May 2020 Private Placement. The warrants under (1) and (2) above are collectively referred to herein as the &#8220;<font style="font-weight: bold;">Warrants</font>&#8221;, and the Ordinary Shares underlying the Warrants are collectively referred to herein as the &#8220;<font style="font-weight: bold;">Warrant Shares</font>&#8221;.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In connection herewith, we have examined the originals, or photocopies or copies, certified or otherwise identified
        to our satisfaction, of: (i) the form of the Registration Statement, to which this opinion is attached as an exhibit; (ii) a copy of the articles of association of the Company, as currently in effect (the &#8220;<font style="font-weight: bold;">Articles</font>&#8221;); (iii) resolutions of committees of the board of directors of the Company and of the board of directors of the Company (the &#8220;<font style="font-weight: bold;">Board</font>&#8221;) that have heretofore been approved and which relate to the offering and sale of the Warrants and the Warrant Shares; and (iv) such other corporate records, agreements, documents and
        other instruments, and such certificates or comparable documents of public officials and of officers and representatives of the Company as we have deemed relevant and necessary as a basis for the opinions hereafter set forth.&#160; We have also made
        inquiries of such officers and representatives as we have deemed relevant and necessary as a basis for the opinions hereafter set forth.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In such examination, we have assumed the genuineness of all signatures, the legal capacity of all natural persons,
        the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as reproduced or certified copies and the authenticity of the originals of such latter documents.&#160; We have assumed
        the same to have been properly given and to be accurate.&#160; We have also assumed the truth of all facts communicated to us by the Company and that all consents and minutes of meetings of committees of the Board, the Board and the shareholders of the
        Company that have been provided to us are true and accurate and have been properly prepared in accordance with the Articles and all applicable laws.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-indent: 36pt; line-height: 1.25;">Based upon and subject to the foregoing, we are of the opinion that the Warrant Shares, when issued, delivered and
        paid for in accordance with the terms of the applicable Warrants upon due exercise thereof, will be validly issued, fully paid and non-assessable.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Members of our firm are admitted to the Bar in the State of Israel, and we do not express any opinion as to the
        laws of any other jurisdiction.&#160; This opinion is limited to the matters stated herein and no opinion is implied or may be inferred beyond the matters expressly stated.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We hereby consent to the filing of this opinion as an exhibit to the Registration Statement and to the reference to
        this firm under the caption &#8220;Legal Matters&#8221; and &#8220;Enforceability of Civil Liabilities&#8221; in the prospectus forming part of the Registration Statement.&#160; In giving this consent, we do not thereby admit that we are within the category of persons whose
        consent is required under Section 7 of the Securities Act, the rules and regulations of the SEC promulgated thereunder or Item 509 of the SEC&#8217;s Regulation S-K promulgated under the Securities Act.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">This opinion letter is rendered as of the date hereof and we disclaim any obligation to advise you of facts,
        circumstances, events or developments that may be brought to our attention after the date hereof that may alter, affect or modify the opinions expressed herein.</div>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" id="z04dd2e7d89744c1ea36a6fc9c6e695fe" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 50%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Very truly yours,</div>
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"> <br>
              </div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 50%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><u>/s/ Fischer Behar Chen Well Orion &amp; Co.</u></div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 50%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Fischer Behar Chen Well Orion &amp; Co.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; text-align: center;">&#160;2
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; margin-left: auto; margin-right: auto;"></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25">&#160;</div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>exhibit_23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: ZKG
         Document created using EDGARfilings PROfile 7.0.1.0
         Copyright 1995 - 2020 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div style="text-align: right;"> <u><font style="font-weight: bold;">Exhibit 23.1</font></u><br>
    </div>
    <div> <br>
    </div>
    <div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">We consent to the incorporation by reference in this Registration Statement on Form F-1, as amended, of our report dated March 6,
        2020, relating to the financial statements of Check-Cap Ltd. appearing in the annual report on Form 20-F of Check-Cap Ltd. for the year ended December 31, 2019. We also consent to the reference to our firm under the heading &#8220;Experts&#8221; in such
        Prospectus.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">/s/ Brightman Almagor Zohar &amp; Co.</div>
      <div style="line-height: 1.25; font-weight: bold;">Brightman Almagor Zohar &amp; Co.</div>
      <div style="line-height: 1.25; font-weight: bold;">Certified Public Accountants</div>
      <div style="line-height: 1.25; font-weight: bold;">A Firm in the Deloitte Global Network</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">Tel Aviv, Israel</div>
      <div style="line-height: 1.25;">August 20, 2020</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25;">
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
      <div style="line-height: 1.25">&#160;</div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image0.jpg
<TEXT>
begin 644 image0.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0P!W@# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **3(HW"@!:*;O7UIOFC-.P$E%1B04GFT68$M%-# BDW\T
M6 ?13-_/M2[P.]%@'44PN!TI/,]*+ 244W>,9S3?,_*BP$E%1B0$]:?N&:+
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M 6BDR/6EH **,T9% !129'K2T %%%&: "BC(HH **** "BBB@ HHHH ****
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MQ_.E(I([X:T5'WZ)-<+ 8?I[UYX=0E^[O./K2K>R'JY]N:YY%6.]_MTYSO\
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MP^8B50::8QGVJ? [#I3N,9Q240YBML'?I0% X[U9.W'2DP!QCFFHBYBOL'_
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4A.*:\@3DU3FOD3.3Q5*+8KHEN)P@S6%>ZL$9N
MM0ZCJ^%/^-<7JNM'YL=?K6\:9E*1?U'Q$%9ADUR6HZ\&8@,:Y[5-;;S&Q_.N
M6O-8D+''\ZU42+G0W^M98C<:P[G4_,!ZUB37\CG)_G59KF1CTJTF.Y=FN"Y)
MJC)DG-/W,1DTN,BM8Q)N52&-.7(ZBI".PZ5(D>X#-:**#FL-4$]J4].E6-A
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M34M4(7+]^E6U.3UI@244T?>ZTZ@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H)Y0B'FB:=8QR
M:Q=2U&(1-\PXZ\U<(W9$I%+4-26,M^\Q^-<1J>O+O8&7]:BU_6(@),.,<]Z\
MRU+5T:5OG_6NR$#*3-S6-7WN<2?K7(ZE=[P?FYJG/?"1LAOUJC+*'/7FNA1)
MN5YW9SC.:A\L@^U6"!GBI%0$>U4HC<B.*,D5<@C..:='&,583 .#UJTC)RN
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M8;>]&!ZTNX=*3CJ*+ !7BC:"*5"">>E(Q - KB;<&EXHR*3C-,!._'>GJM&
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M5R>E4!)"ZKWJ8S#<.:SOXN*DY[_>H U$E'K3PX!X/6LQ"5&3UI\<I9QS0!K
MYHJ.-@1@5)0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&0,]J _- F/QSBFE2#3ER*1LDTA6$YHYS2]*0$D^U @&<TYF)YH*X&:9D]*
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MG1CFE8FU@VC;35'<]*?_ "I#C&>U5L(B) ;%+3<9;)_"GY&W'>BXA*<$#"D
MW<5(N.U("$H4Z=*EPNT9J0!>AZ5'*RIQCZ4 -+J#QUIHD^8^M1M@MQUII./K
M32 ER">*=M.,U70G=5C)QBG8 7!ZTX*.AJ,MM(JP -N3UI,"/:,XI"%SQ4F
M.:B?KQ4I@(Z@\=J50 ,&DH3J=U:= $+ -BG8&*0A>IZTX ,M3<!0JD4PXSQ4
MHQM.*8 .O:EU 08QS21Y)P:9DA_8]*G0 'GJ:H!' '3K3!UYJ1@"?>FMCH*
M'[%QFHG3)S3PPVX-.8C;0!&?]7QUI 05_P!JBF/\I#"@"0=>:"5!Y/%!&0&'
M0=:9P[Y_AH D&T\U&R!C4H4#^E*% .#WH @$(/2FM'SQ5P*!0(@>:0%<# Q0
MR9P34^U:&QC%.X$-,/WN.O>IB HYZU'M&<TTP&+]X!?QK2CPJ<FJ  4Y%2AV
MV\]*38&FI&T8I:AA;*"IJ28!1113 **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MN<UZ%X?TE%ECRG<5BZ!8^9(N5KU31=, :,E!U]*PG(JQVGAZV2.TC&S'%=$
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M*8J$D9Z4F_*X%,8X^M*P#R<F@$#K34RPIV#5 -8$CBGQ#&032!OD]J0=,T6
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MC[NWM3CR.*8WR@'U-  3L(S0VYNG6E8< FC)!I@(,CK4C O@BF ;N:<A(;%
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M7R>,9Z48&.M6IX=M5&4BM!,9CG-,)Q4ORXQWJ-D]*!#003UI< MC-1[>,4Y
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/%"JM >=WVDQL?NFL&\T1,$[37JTNF1L3\O6LZYT5#&?EJU5N*QX=J^CJ,D
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MP**8YP,4 1NRL<&J,NT$@58F.%.!SZU0)+F@"-\9XJ2-N,4@7<<XIXCP^10
M-C(S4BX(QWINW)&:E4;3B@"+&#14SID5$.#0 P':V6Z4I 8Y_*B1AUQ0.@H
M7>OW<<T_ 88%1X'4U)'US0 AC&/EIRX$0%.4Y'2AL =* (F7\C3"N!\M.;+
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M5ZCH.G&*)3MK$T?3<I&>.@KT+3;+;"IQ43G8EHNV%N57)JZR8Z4Z&/8HITF
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M4\'S<#\Z +L72I:BBXXJ6F 4444 %%%% !1110 4444 %%%% !1110 4444
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MUY=K/^J?Z5UQEH)'G>HD[VQTS1IHRH/:F:B_[QP.F:?IC84>E)CZ'>^'O?\
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M]JE5AC!J,G S2;N :0%A<U(, 9[U K$#FG*W8T@ Y!R*8Y!&!2LW/%-<CJ*
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M0^+94\]SGUKT+5;O#-S7E'B>Y62X<9]:]"DC%L\]U)MUTV?7BH1C''6G7_\
MQ\'ZU#&<G%=449O:Y94$CWI2N10KC&!UIQY&16L3)W!  ,'I3L@8J-6YIY(R
M*U,VP;';K2*,_6G'KFF@\U2(;)!A0:,#9GM2=:-W\-.Y1&,=Z7[O7K2$<TN>
M.:EE6 GC/>H]P8&G$Y&*;@ 5G)E(B/'(Z5?TL9ERWK6?]XX[5>T[Y),>]82+
M/5_## (H'7%>AZ802,]:\S\+DA%R>U>C:6=Q&#7-) F=;:,3TK0S@9K*L<UH
MD]ZY)K4T3,C6,&)L^E>+>*6Q.X;KN->RZTVV(GVKQ7Q4P:X?UR:Z:2T$V>?Z
ME]XUAR#+<5M7Y^<BLEEYSBNN )B(-O/:I$R3_*G0C>0,5:,.P#BNN!#8D>5^
M]1(RGIUIK':<&H68;R*TZ$[C<\U,N,<=*@SEL^E68\$]*3$U8=VYINW!SWJ<
MI2,G%(E/4J3#Y<CK57I5R4$#%4SUJ9;&JU1+$<'VK3M@#R:R4/S5H6[X'6L)
M,LZ33#\XS7I'A?&]<=<UYAIK].>:]$\,RX9>>]<U0=SUW3'S'\OI5QASDUEZ
M._R=>U;&W(K@EN4F5MNYN:L*H J-D*TA<JN":D>Q93&?>G526<#@FG_:!US2
ML*Y9VBEP*I_:U/>F->JO>GRL.8O\ TN 36;]N7'6@7@8\&GR,=S1(%,?"KDU
M1-Z"0,TK3[QC-"@PN3L%VDU3W $YZT_S 1C--,18YIB'1JS-FHKP'RR/SJU&
M#MP.M07D3>430(X?7EVQ-CI7FNL,QC<'IBO2O$38MV'>O,=7?$;_ $K6*).
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M% !1110 5FZD?W#?2M*LC57(@?Z5<-R9;'G>L7'S2#/>O*_$+_OFP:] URY
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M:8:,U&9,<4@'-TJ!B/QH+Y[TTD4T2PR2:>H.[)I@.#FI=XVYH(L28XS2[#3
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MTIK*57I4<I5R];Z@8\#=C%=WX?U;$"Y:O,,-G/2NCTF]\J)1FERE'M^AZLK
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M/K1<!X3K4,B>G6K!/!Q4&::8#H 58&M1#E15"'YB >*T%& *8"T444 %%%%
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MHY$-MGJNEZX'(^8YSZUUMEK6<#/ZUXUIMX\;C!KJ+34I,KAA2Y$+F/6H-17
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M,()(Q4F.,TPL3Q8XS5X=!5&(#C-7AT%4@%HHHH$%%%% !1110 4444 %%%%
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M2&D&.*3!SG/'I2T&@HLQ=JNCH*HQ<8J\.@JD2Q:***8@HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** *UVN8SZ5YOXESY4N>F#7I-T#Y9KSKQ,A\B
M4^U=-%F4CP77V_TF3ZFN>1L<BNF\0 ?:)..YKFXP,X(KNBS%DGRC!/>GY':F
M$;B,=JD"\5M%D,</?I3R!G-,"FG [>#6\3)BG)IISC^=.;IQ3<Y_"M$0)_*E
M^O2D]^U(0:=@'#KS2MC/O0.<4T\/S4C3$I#G.!TIY(-&1FDS0: .]*!BE[YI
MN>:C<!>=WO2CKQ^-'MWI!WHZB'-@G- ./I3>U*H]: $)SUH!!//6EQCCUHVX
M'O4L!-IS[4UPO0=*G)&T"HWP&HLQIE9F .#TIF!G-22IDYJ,\#%2T7$&D)XS
M2(O.:,=L<T[D#%)(;6@\G=P.E.P-N#THA0GGM4K1YY%%B+ZE5L9XI^!MS4@0
M9QBE*XXIL:9$@*\FESEN.E/Q0!@]*0F/49'/2E( I V#[4[>"*M$B$X^M-P.
MHZT[(V^]'!%4QC.*BE ZFK&0#4,HR<]J"HLK$8IZJ".:?@>E.'!Z55BB/:!2
M@C%2X#=!3&P.0*+"N.1<]>E/"C-)"<GI4V-OXT,3;(6/.!UIA('3KWJ1T.<U
M 0<T+<70D7/;I4F.*C4[>*E#>M-B&LO<TPKZ=:L8R*3;M&2*FPKE,CGFF.03
MQ5ITW=!59D.:5BTQH)/%.*],4](CC-2K'QBIL5S#$/SBK"8S[U&L6WK2J/FI
M6(D[EH*I'%,=1G':I8R,"F28W;NU38E%>0!5JLW3BK3D,<5$4R>*=BTRMG%+
MU/RU)LR<8J6.+':DT4VDA%!"XIZ#)J39Q1T%18BXUO;K46.:4OAL4TMN.!3L
M"(W SQ2@87VJ94'<5*(\G..*=B[V*=(>OO5IXN>!UJ-X]@YZU:071",?C0?F
M/'2EH'':FPOJ/0[>.U*2P/\ *A$SS4A7BIL*ZN,^OWJ<*80>G>CD\4 ]28_=
MP.E,V<>U.7I3PN>>U"1-R QX.<4_^'WJ<8VD$5"1@T["O<C=L#BH22>M3.,B
MF*IS18=QE.0<T]H^<BEC0@\T[ Q: H!XI^WG%(%.ZE85QCPG' XJ/RSMQ5P-
MFD9<'-&H^8J)".XJ=47'O4N!BA5P*5@YB'&#0_4;?QJ4C=P.M,Q32 <N",&I
M!4-2AQC%6D(<0#Q5>1>U3LP%0L>,U0TBL5^;BF.<G%2,#U%18)/0TF:"K4Z9
MIL*8ZBK*K@5G(SD(HQR>M-)R>*>W/2FY%9-$#PV1QTIJYW<TJ],T]"!UHL,D
M.2O%02+A?>IF; Q44K93I0M!HH.O<4(#^%/DYZ4^-01GM5<UC;H."C;4;+@^
M]3@@4H3/--/4A/4IX;.:<OWN*FD&!TJ)6&[I6BD.US1MR#C/2K#AL>W:JD+K
MQ5EI1C%5<S<2O)D=:KX&<]ZFD;UJ G)P*=Q)#\<<4F_ YI03BDQFBX6(RYS1
MOX]Z1E(:D*$'%5<HD1^:G"Y&14"KBK"<CB@S8Y<@>U#YQS2 \^U-+8SFH8):
ME2;AN::,$<4LJDMBA!VK.1LM@#=NU,DQ^%3%0.:3R_,.0.*PD4GU-+0US=Q^
MF:]LT&V#11<=A7D6@V^+N/(_BKW;PU;9ABX["N>1<4=?IEL%A7BMM!A *BMX
M@D0&*GKAG*[.A+0****@84444 %%%% !5:=L CO5GM5&X.": *V?FYZTDG;;
M^-!;CWIH.:M$W&G)X[5+$H+"H\'-21?>IJY++@7H:"!G-2(/DYJM-*%&*:$]
MC+U>7RT)4_6N$UO4E6%B6_6NGUZ[ B;FO*_$5Z/*8YXYK:"(:U,'5=5#;P7X
M^M<9>W(9VP>IJQ?7H);)K'+ YSWK6P6&]: .:3D\"KEO"7QQ5) 0I&2<8J4V
MWJ*TH;%F886M2'1Y''W#S5C1S(@^;I5E8.< 5U-OX=EQDQG\JT(M 8C_ %9_
M*IYAG%-:Y0X%49;?8AXKT270'"']V?RK&O="E*'Y#57N-'#./RI4^\*W)M*=
M 05K/:T*2X(K)H9V/AG:(5]:]0\.2+N%>8^'HOD KTWPZ!&02*EZ(+'I&ELI
M6J6N'9!(?:K&F,"N15#7Y,6LF?0UEU"QXYX@N5^T29/.:\]U.YS*1FNJ\2R_
MZ9)]:XJZP[GUII"*3'>3BFHISSTJ1%W/@=NM:=G9&5P<<5LHB:*"0[NW%6$M
MQW%=%!H[/T2KT6@2D_ZLUHD2VSEXX .W-,E@'4BNX30'Z>6?RJ&[T"0CB,\>
MU4I6)1Y_+PV/X:KD_-QTKIM0TAT.=AXK%FMFC.2I_*JO<LJCCK5F"3:PJ-HB
M.2*0MM&!6;3&CI=*N3O&#WKU/PU<GRE&>U>-:1.%D&?6O4_#<XVKCTK)DNYZ
MKITF47)K=MR&QG\*Y72YP5%=+9DGFLYH29HA<56O6^3CTJTK9XJO=XVFL5N-
MG$ZS]YL5YOXE \ML^E>E:W]XX%>;>)2/*;Z5UQ$CRO5?FD_&J<" L >M7M4!
M$OXU4CX>M([E="XL*XX%-9% YJU#@J.*LK8M/RJG%;,AWW,<J<?+TJ/RV)^8
M5T\.CR$?<-2_V'(3_JS^59,5SD_+(/ I0I)XKJGT*7&/+.?I4"Z)+G[A%9M(
M+F"J87VJ&9<#VKIVTE]F=AJC/IK@'*FH>@TSG.!G-,K3EL'7)VU3:(@8Q0FV
M:)CHGQC!K=TZ\"@?-7/1C;G-3PR$/QTK9>8'J_AS45W*"W&?6O3-'OP< MVX
MYKPC0[L(RY;O7HVB:F"ZC=4SB.Z/6[:?+#GFM+JM<GIEV'93G-=3$VY!7+-6
M)ZC77N.E0D'//2K$F<9'2H&.!7/+<L9UX/X4Y0 >>M,P0PJ4 9]Z2 ><8XJ&
M4@U-BF.F::+1#\NSVI<@8I=O;%(P^7Z4,H:^!\W>DWY'%-+90BG!1MI 2+@T
MK%1]*$(QTIV5[BD5LR/</\*=QF@@9Z4H'.*0%B+MBKHZ52CZC%71T%4B6+11
M13$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!',,H:X'Q+&/(E^
MAKOY?N'%<'XE4F"7'H:WHF<SP/7X\7,O^\:Y8?ZPUU_B 'SY0/4UR+85O>NV
M*,6ARMAJE!#'-09R14ZX R36\3*2T)1@"H2/FZU+E2O!J/OQ71%F3%Z\9H(
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MBD/6-0,TNP=>]/0 C-/P/QID-E<Q@FDV <U*0"?YTV3;CVI-C1&""<4XXJ,
M9YIXZ\U(T.'2E)X^E%*^-G%,0T8;KTI-PSCM4>>/:CCOTJ6-,?\ +G.:=G-0
MC&.>M21_=% #R!BHBN#4^!Q^M))MQ[4Q7(1@]:7J>::,9IXPW6J!A1UXH+!>
M*5-N<BE<E(:1@X[4[&13R%/':DX%(I#",U$8]QJQ@'K2<9]ZHHBV# Q05 -2
MX IF,].E!+$QGBG]!2?=%&<TF2"C/-.X-,+>G6G*!UI,:$V MSTICH%/'2K:
MJA%0S #Z5F_,NY &V\5)&H)J XS4T9 .1UIH1:"@"J[.0U6_E,>>_>LV=@&P
M.E7% M24R!N,TQD%1)@GFK*A2,G\*JQ:217*U-#*(SP:23'6JCC!S1*Q2.HT
MW4VB<'>:]%\-ZTTC*-_>O%(YF4X!KL_"]\8Y5W-QGUKFJ*Z-8L^C=&O]ZC+=
MJZ..0,*\MT+5%W("_P"M>@6-Y&^T;AFO,K0UN;1V-:BD!R,TM<A84444 %%%
M% !2,,BEHH R-3ME>!C@5Y-XGTX,9#MYYKVN:,/&17"^(+!3YGR\\]JZ:4^A
M$CY\U.R"2'Y:P)HQ&QQTKTW6],7>QV_I7 ZM"L+$ 8&:[H2,FC+W ]ZDC&>I
MJL.O%6(AGK73%D-$^ 1[TC  4W=AL=Z<W(H;,K:E=U&>*E@C!-1C&[GI5NV
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M@9/'%=[;@>1^%<'X:&$ /3BN]M<>6M85!Q*EQ"&&<<U7$ '05KRH,<=:A2(
MY(KG9JB**   XJ1B%/%6,#;QTJG<$ <=*QDRT!F(/7K1@.,]ZJ*VX_RJ>+=F
MLV6AP0 TW@-Q4[+\OO5=D[BA&J9('!;%/&*KH!U/2I%92<'\*VB&@KKGZTY
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M8<G=VJP@&_:!Q4*,,G'?K5F,@<BD!*N0<8I],4DGVI] !1110 4444 %%%%
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M=*0'%,+B@9X/6GC IN:"3BE<+BDX&:-W>F[CC.*-U)#N.+8-&1NHII]/UIW
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MR>&(CF,?2O+]!MR95XKUOP[&5:,_2N.JV.!V"#"TZD'2EKB.@**** "BBB@
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MJW3+,^3WK@M9NV><@&M$B69=Y+YDE1*I' J)BS29S5^UB\QQZ5:0%O3;-II
M".,UV.F>'R[J2/IQ570+)&E4$=Z]1T/24;:6':E*))!HVBLFSCGZ5W-IIWE1
M@@<]ZDLM/CC*\<ULHBJN,5BW84KF6\6V(@BN/\3<6S#'&#7=7( !]*X;Q5Q
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M!_"K:)CFH[=.,U8J1!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&2Q_>%7D4DY[U! HP,BKRK@4(!1TI:**8!1110 4444 %%%% !1110 4444
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M:#R>*"V11GK2<]:$ =.:>,>E(>E)GGBBP#J<Q^7I3>.M&XGBE8/,:#QTIV[
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M5$X;%1<]*8",S'K35))IY1O0T^.)CQ@UBT#-W2-V!ZUZ+X69@^!^-<!I,3!
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MI3C%(5@(_P#U4!>]"D,>:<2.E(+"%NU'&,9IF0#0",X[4(8F.O-.0X%,/6G
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M#[4\8[BG81&^/QIIP1P*<Y]J 1CI189!LY]J4)\WM5@ -SBAL#M0T.XF !3
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MCSGZTH(_&F!+\N>*:X'X5&"=U2'!J; 1[0.<THZ\TH'/-#8S[T6"XI8#@TS
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M-&.OYT<,*0]>*,@"JN2P^M+QFC@T'&:$P$/7CK2BCC/O2<<T7 >K!A@]*:P
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ML3R*;0R  #GUI,'..]/8%>V:<@VK@T["8Z$<X/6K*=:K8(YJ19>.E78EE[<
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M+&HR/EJS0 #@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 UU#*17+:QIP9G(KJZJW-J)@?4U<)69+1XQKFC?.Q45YQKVE88Y]:^AM5
MT+=DC^5>:>)M"/F';T^E=D*AFT>-26AC;VIV[:O-='J6F-%G_"N<N(70G)KH
MC(ADD+GAJL'!&168LK#Y<U.)R!BME(S:)7;G%-P1488LV>U2G.T5HI$6%[<_
MA2X.,]Z-IQS2C/0T^;4FP@I=_.*1@>U1$D'/:J3N"1(S4F<FH]W?M2KG-4-H
MFW'&.]* 2*9[=Z>"0*"&+R%]J;BG<E:;VIH@&.*3)Q28)ZTO.*+#N)WXI<FD
MP1TI<'K3L ')IN<=:?VINT]Z0!SBE R*,'%*,BG80F<?2E4DGVI""?I2@$?2
MDT4A><4G.WIS1S2KG&.])Z#(QG/%+T.*?MP:8?O5(-BG.*9G)YI_:F;3WK-H
M2'<[<TN3@8I.2,4<XH0Q')Q31R*?][Z4W[M4)BC-&#G/>D!.:?G(XZT A@Z\
M=:DII7 R.M)R:3*'$9I.@I>U(<TK"OH,[^]/YQQ3<<9[TX9IB$.:1?TIQ!-)
MC!]J8#\[N*:P(I,E32EBQQWI6$)GTZTM&W%-SD\50["\YHR>_P"%&#1M-2 ]
M"1R:1B>HHYQCO28-!0FZE7/X4FTTX<"A"!J:"<>]+SS2 '%,74"3BEY'TH I
M2">G2@$(3SGM3<__ %J4C'THVY'\J86 $XH.<4<].]!S0 I)% ))]J0@FD^[
M]*!#STIO.*.2* #B@!,^E2!L#%,VXI<$T!83G-*>E !S[48/- 6!20<FAB>H
MI.1Q31DG% 6%SZ4O)/M1M/:C[OTH'8<>E("<4<FEQQ[TKZA83DT$D4HX%-8[
MAQ3N%A"QZCI2@\<TU1GZ4K BF@L.YQ1DGIUH&=M !Z]ZH2%YQ2=.G2G')I",
M?2@JV@N>*;SCWHVD_P!*7!Q[U#0"9_.G@X%0C.ZGDG\JS:*&OG\*57XYIK$D
M9[4A4\4("92>]#9QQ3<G;CO2\XZU8AH!I<'H.E.(/:FY(^E6A-CQTQ3AE346
M2.:4.6&.]6A#G8GIUJ)<T_:1S2?3\:3* 9SQTJ;C;S40Z\=*>P.T5BT!"V=V
M<5$[U-_LGK4$J[:QD:1'6LA$PQ7H7AV_,9C].*\XA.&R*Z?2;PQ[3FN:HC4]
MWT35-Z*#7=:?*9(037BV@:D2%Y[UZSH%P9;=<GM7'-&D#>HHHK$V"BBB@ HH
MHH **** "BBB@ HHHH *9)TI],E^[0!0F#;\U"7#-CO4LS,3BH FT\]:+@.0
M;2?>I.W'2HU^?..U/7ISTH E+#9BH"-K9IS9Q3-K]">: %+,3E1S0&('/4T(
MK+QGFD*LQR#TZTKZ@-8D-D]*D#!A@TQL;>:<%PH(I@2H"HI&DXY'- 8@8-1M
MG/-( 63.<4W<V<8XI53J113 4ME<4U">IIY4@9IK?*P7UH ?NXSWINX\^]+L
M.<4FT\^U "4[<2,4PG:,TH.1F@!S$@\TH)+9 J-GYP:>F<\4 *,\\4W!QFC)
M!-&3C%%@%\P@=*9O8\D<T\J0,TC*>E #&9B,XYIZ$[?YTBJ>A/-*,C(I-@(Q
MRA6I$^5>:BIY!VT;@2J3G)I'?/3K35?(QWIC!L\'FE8!J_Q_K35!ZKTIP1N<
M'ZTY5(3BJ3 1OE7)[TBA@<G\*<RDJ,^M.(/% #MI^]WI3NXXI-QQCO2MG'!H
M BD#;@1TIR?.-M'S%:;@JNX4@)%/EYS2^9N'3FJAE9L@]>U.7>J<GYJ8$AZ\
MT5%B0]Z#O7DFF@)-S?=QQ2*6W<TU"3S2@D/@U8F3\X]ZI7(;'%7P..>M))!N
M7B@EHY'4(&D!KCM6TTD-D=J].EL"V<]*QK[1O,)]*9*/&+_16?)Q^E9)T%B>
MG/TKV2;PX&R#_*JZ^% 6]_I57*/,[#0RCCCOZ5Z'X>L"@7TQ6G#X5P>.WM6Q
M9:7]E'TIW)9=LDV$#M6W$Q(%9]O#W[5H1#:.:+B18#9'O49X-1-)MZ=:@,S,
M>#4%$SMZ4BG(YIBG<.:,'/M4LI(1V(8 #K2L#VZTX!3UZ]JD"_G6;*(UW*.1
M2@D<4]P2*A)(.>U(I$N[C%!SD$U&I);/:G.QVF@H9(Y)XZU 0<\TN6Z]Z%^<
MXIHEH9LR<#I5^TA('/2HXX><]JOP(1]*8$J CK3Z**"0HHHH **** "BBB@
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M-+L4&FLHZ9IH Q\W6@D],T@ 4XSQ2@*<\TP$.0F<U%O.,^O:IL#:>:CPH-"
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M 4#L QVHPN,]J;]*=UY[5+06&@#=[5*"H&#^%1Y&: ?6DT58<P4CC[U1AAG
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MUZ]J:H8'D<U=R;$A.!TIFXD<"G9)X%*!@TD[A8C)..13ADC..E*P)-)EAQ0
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M8$.XDXV\4XD!AVIY5]N<"HB&)R1R*5@%,A$A^4TNX\\=:<N<9(^:E ;/3K3
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MYN*[5&W**YV6/HHHJ0"BBB@ HHHH **** "HG7@FI:C=^,4 9\GW^:B(57W
MU).5).*A^78/2@!^T/R3TI!@.#G\*4,BKS^%)\A4MWHL N%SG-&U>@/'UI!Y
M9Y'6CY,<=.]%@' *O?BFR?,,@]*/W?\ P'M2\=NE(!B'YLGKZ4XJN<@\TA !
MW&D7:3Q18!IR#@'BG@A1UI<!5--^78/2G8!Q&X@YI^T!:CWA #2^8'- "F,
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MSFA8]IW8ZT 5MF>QI-O&,5=V@=NM-\OYL8IW KM%E/EJ)5);H<"KP3YL5)M
M'"T 9\F!VI(U.>>AJV8LG?CK2F/@ #K2 K/&6&T=Z9Y)QQQBKJP$4NW/&* ,
M_#,>AXIS# ^[5P1C'2D48/(H JA=V.*'BP.!5W;CMUI?+&V@"G_!C'-(A).<
M'\JG ._&*F,8Z@4P*<G W8_"A3\O(ZU8:,D[L=:1TQ@ =:- *IW,VU0>:<(>
MQ'2KL<00=.:0C<<8I 5 ,G!%##!P!Q4^/:GB+(SWI 4@K<\=:3:VTCO5_9MX
MQUIOE_-C%,"H%*C.*!ENU7=H/&*14 YQ35@*9^0=#2$],@U;9=QSMH:, #BD
MP*F3G&#^5.V?[-78D4CD4KH#VH6@%)5P>E,<8;H<?2KAZ_=IZH"<D4P*#'(
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M=M'I2T5=A" 8I:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "FE%/4"G44 1F%".5'Y5!):1MGY!^56
MZ*:DT%C+_L^-LYC7\JI3:5'DXC'Y5T--9<BK51DN)Q]QHZ$<1#\JQ;O1UW<1
M#\J]"DA)' K/N+-B<JM;1JD<IYU+I"@_ZL?E5:7205/[H?E7?RZ>YY*_I4)T
MR3NGZ57.A\IYLVDX;/EC\J@FTINT0_*O2)-+;^YS]*B.EMC[GZ5+F.QYLNE8
M/,8_*H9]*R>(^/I7I#:0[=$X^E,;1'V_ZO\ 2FI"L>;?V3_TS'Y5*FE'J8_T
MKT :*YZQ_3BG_P!C.%^YS]*?.%CS^32^!B,?E0NDY&/+'Y5WYT=^,)^E/&CO
MV3CZ4^?036AY\NDD-CR^/I4_]D@CF,?E7?)I#=T_2G'1I.Z?3BI50BS/.6TG
MCB,?E33I9XQ'^E>D-HS!<;/F^E0#19 <^7^E/G#E.$CTG(QY?Z4KZ1@8\L?E
M7H"Z1(%R$X^E!TISU3]*%4#E9YU_97'^K'Y4L>D\Y,8_*O0/[&?.=GTXIPT>
M0C&SGZ4>T'RG!/I(*\1C\JJ_V25/^K_2O25TAQQLY^E,?1W)X3]*.<.4\]72
M23_J_P!*>VD\?ZL?E7?IH\@X*<?2I'T=\#Y/IQ1S@XGG/]DG.?+'Y4G]D=Q'
MS]*]#.D2;#A#GZ4T:0W9/F^E/V@['"1Z3@?ZL?E39-,^;'EC'TKT$:2Q_@_2
MD.C.3RG'THYPY3SS^RL _)^E+%I63DQC\J[]M&<\;./I2C2' QLY^E'.+E."
MDTD 9$8_*H_[*Y_U8_*O11H[8Y3]*C.CMT5./I1SCY3S_P#LGG_5C'TI_P#9
M7R_ZL?E7?)H[C@H?RI?[(DYRGTXHY]1<IYV=+.?]6/RI?[+](Q^5>A#1F/)3
MGZ4HT4J<[/THYQV.!72 !CRQ^5-;2 O_ "S'Y5Z%_9#?W/TI&T@XY3]*/:"Y
M3SE]*/:,?E2QZ4<Y,8SZ8KT'^QWX^3Z<4X:2X/W/F[<52F.QP+Z3\N1&,_2J
M_P#99#8\L8^E>D'2I#_!SWXIC:.QZ)^E'.%NYY^-)Y_U8Q]*E72<J<QCCIQ7
M=+I#]TX[<5)_94F,%/IQ1SA8\\;2MW6,9^E,_LLYP(Q^5>B?V0W=/F[<4U=(
M?=]SGZ4G,7*<&FD\?ZL?E3)=+*MQ'Q]*]%&DOC[GZ5&VD-GE./I2YPY3ST:4
M2.8_TIR:20>8_P!*[XZ/(>B<=N*?_8\FW[G/THYPY3@CI0QQ&/RJ'^R2#CR_
MTKT/^QWQPG/TI#I#@_<X^E'M!\K.!_L@[?\ 5C\J/[+X_P!6./:O0UTHD8*<
M?2FMH[=D_2E[07*><OI;$Y\O]*4:7QQ&/RKT(Z.Y7&S]*/[&91Q'S]*?..QP
M2:4!_P LQ^5)+IF!Q'^E=]_9+YX3CZ4IT9R>4X^E'.+E//?[,R.8Q^5/72\\
MF,?E7?'17/\ RS_2E_L>0+]SGZ4<X^4X&32ODXC'Y5!_99/_ "S'Y5Z+_9$F
MW[GZ4AT9AT3Z\4>T"QYTNEDG'EC\JM_V0 H_=C\J[C^Q6#?ZO]*D_LASU3]*
M7.2XGGYT@EL^4/RI/[).[_5C\J]#_LI]F G/TIJZ2X.2G/TJ><.4X'^Q]H_U
M8_*HSI9Z>7Q]*]#DTI\?*GZ5&-)=?O)Q]*.<I(\_72?^F8_*G)I)/6,?E7?_
M -E,#RGTXIZ:2Y/W.?I1SCL>>OI.!Q&/RJ(:7G@QC\J]&?2),_<Y^E-.B-VC
M^O%4J@6//ETGG CX^E6?[(79_JQ^5=S_ &0R\;./I0=)E/\  <=N*?.%CS\:
M2 W^K'Y4CZ4.T8S]*[XZ1)UV<_2G)H[YR4Y^E+G#E."32MO_ "S'Y5')I9SQ
M&/RKT,Z0^>$_2E_LAO[GZ4<XK'GBZ83_ ,LQ^52?V1D;O+Y^E=\-%D!Y3Z<5
M)_9#@8V<_2E[03BSSTZ5\O\ JQGZ4U=*Y_U?Z5Z#_8\@;[G/TI/[)<?P?I2<
MQ6. ;2B3CR^/I2C2L#_5C\J[X:0_=/E^E*VCO_<X[<4N8.74\\&EL6R8_P!*
M<=+('$8_*O0O['<_P?-]*3^QY WW.?I1SA8\^_L@#_EF#Z\4U]-P,",8^E>B
MG1V(^5/KQ4)T9A_!\OTHYBDCSPZ5GK&/RJ2/2?\ IF/RKOO[(;NGTXIPTEP,
M[.?I4N91PHTS;_RS'Y5;M+(K*H"=?:NQ&DN>=GZ5)#I#[LA/TJ+W&D.TB)H]
MB@<>M=M;Y\I<UDZ?9%0N5XK80%1BI98^BBBI **** "BBB@ HHHH **** (3
MDGI28.<XJ>B@!BJ!SBD?.>!4E% $&T^E2#.WD4^B@"/G;TIJYSTJ:B@!G.[&
M*=@>@I:* (2#G.*7;WQ4M% $9Y XI""!@5+10!$H]A^5.YQTI]%.X$?.WI0B
M\Y(J2BD WG=C'%#*".E.HH @VD'I3L$<XJ6B@!N 5Y%1LN. *FHH A"Y[4X+
MGJ*DHH 8P ' %, .>1UJ:B@"+;V HP3QBI:* ("#GI3L$<XJ6B@!N 5Y%1LN
M. *FHH C0<X(IY  X%+10!'_  _='Y4P YZ5/10 U5 %+^%+10 U>>HHVC/2
MG44 -VCTJ-DP>!4U%.X$*KSTIP7)Y%2447 3 ]*,#TI:*0!@4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
***** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image00002.jpg
<TEXT>
begin 644 image00002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" !. R(# 2(  A$! Q$!_\0
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M]?5U_P"CY*V: $+J&52P#-T!/)I:Y_6?^1M\._2Y_P#0!704 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%>5_M#:[K
M'A?PC:ZMH&ISV=RU]!:LJJC(4<G)PRGGWH ]4K!\*_\ 'UX@_P"PD_\ Z*CK
M'\3:5K5O';2Z#XCU$WD$T4TEI*L4BW, D42+]P$?*3@@]:FMTD;3_%A@N9K:
M2.^ED62$@,"(8SW!&* .PK#\3?Z_0_\ L(I_Z ]>:?#'5/$GB;X+P^)IO$=S
M'K;17$@=X8F@)C=P R;!QA0#@@]\UM>"?%L_CCP)X.U^\M1:W-U?@21KG;N4
M2J2N><';D?6@#TVBO/8?$]QXH^(^K^&-)NWL[#0X(VO[F$ RRS29VQ(2"%50
M"6.,D\#&"3LK8^(+#Q/I:VVHO>: ZR_:EN54S1OM_=X< 94G/&,YQSB@#0\(
M_P#(';_KZNO_ $?)6S7.:+?V^E^%+W4+Z3R[2UEO)YGQG:BS2%C^0-5-$\<V
M>IW^C6TEE=V@UJV>[TZ278RSQJJL<[6.UMKJ<'^8Q0!>UG_D;/#OTN?_ $ 5
MT%<_K/\ R-GAWZ7/_H KF?"'B*X^(>J:_-8WTUEH&EWC:? ;; DNI$ +R,Q!
MPF2 H&,]2>P /1J*YG1[;Q!9^*;F&]O?MN@?9%:VD>-5E6;>=RN1C=\N,' [
MYR>:Z:@ HHHH **^-?BU\;_'GA[XD>(=)TK5HHK&TNFBAC-K$VU0!QDKDUB^
M&?CA\3M?URUTR#Q#:0/<,1YDME%M0!2Q)PA/0'H* /N2BOB.\^.'CJ.:&.R\
M<:??;UD9C%I9'E[5)&0T0)SC'&<=\"L\?'7XL'3_ +<+V3[%G'VC^S8_+ZX^
M]LQUH ^[**^(='^,WQ9U&_TN!M3-M!J-Q';PW4NFQB(ES@$'9@_AZ52U#XZ_
M%;3I42^U![<R<Q^;IL:;QZC*<T ?==%?"=S\=OBQ:W"P75])#.R[UCDTV-6*
M^H!3..#^52:=\<_BG>ZY9Z5_;$4%U=3QP*)K&)=I<@*3\F<<@_2@#[HHKXPU
MCXM_$BSTV^O;#QGI6I1V$RPW:0V 1XBQ(5L/$NY<@C(SV]:R+;XW_%:6YT^.
M;4_LT5](L<,TNG1JC;B!D'9R.>U 'W-17P]K_P :?BSHFIRV=YJ++MG>&*1M
M,C59BK;<IE.?_KU5N_CI\6;.>*&\O);>:7_5QRZ9&C/] 4YH ^ZZ*^#I/C]\
M48YHXI-4"22 %%:PB!8'H0-O.:Z/6OB[\0=)N6L9?'.DS:M',L$UG#IX;RW)
MPR[_ "MA*GK@]CC- 'V=17P_XE^-'Q8\/:E=6M]J95(;B2!)VTV-$FV,5)4E
M.1QFJ<_QU^+%NUNMQ?21&X&80^FQKYH_V<ISU'2@#[LHKX1OOCQ\5K#R_MVH
M-;>8NY/.TZ--X]1E.16]HWQ4^+6KW_ARUM/$%ANUW?Y#O:Q!8]CLK;SLXQMS
MQG@B@#[0HKX@N/C1\5;?2;B^FUNV58;[^SS%]BB+M+M).!LZ# S_ +PIVF_&
M7XKW6K-IUUJRV-PMM-<[;G3HT.V.)I.A3/(0@4 ?;M%?#6M?'/XFZ4NG-)X@
MMI/MMHEVNVRB&T,6&#\O7Y:Z&V^)?Q/F:VLCXRTB/7KFW6YATMK)?,8,F]$+
M^7L#LN"%)[@<$XH ^Q**^$8?CW\494$HU4"#(S+_ &=&54$[<DA/7CZU/_PO
M'XK2W=Y#8:DUZ+5F#O!IB$  D;B-F5''<"@#[GHKX4L_CI\6+V)Y+*]DN(T!
M+/%IL;A<=<D)4-C\?_B=?7UO:6^LP-//(L48-G",LQP.=OJ: /O&BOBKQ5\7
M_B=X?AAF'BK3K^"2>:T:2WLD&R:+;YB$/&"<;UP1P<U%X>^-'Q)U6RO;^[\5
MV&FZ;9E$EN+BQ1LN^=J*J1DLQVL?0!22: /MJBOAI_CC\3YM2GM=&UM-76,;
MA+::8I#+QSM,88=<<BLUOVA_B4K$-K40(."#90\?^.T ?>]%?$6F_&#XOZG-
MID%AJ4$UQJ2N]K%]FMU:15)4GY@!U5@/7!INJ_&3XNZ7:QW-WJ=L;:23REFA
MAMIDWXSM+(" <=C0!]OT5\.M\9OC LQB:\Q(+S^SROV*'_CX_P">?W>M)#\:
M?B],\2Q7P8RW9L8\64'S3C&4'R]?F'YT ?<=%?!]C\?/BC?7T-G::M'+=32"
M*.-;*'+,3@#[OK5JU^-GQ;NEM#;WZR"[,BP8LH?WAC&7Q\O8$4 ?<U%?$5G\
M8/B_>V/VNTU.TFC\MI0D<5J92BYR?+^_Q@GI4-G\:?B]>_9/LE\)?M:226X6
MRAS*(\[]HV\D8/'7TH ^XZ*^$?\ A?/Q3_LPZA_:L?V(3?9_.^Q0X\S;NV_=
MZXYK:L?B[\4=2T.SOM,\2:?//++)'-;21VD+0[=NT_/@G=N/;M0!]J45\/3?
M&7XP0W3V\EZ!,EY_9[*+. XN/^>?"]:I1_'GXIR:FNGIJB->M-]G$(LH=QDW
M;=OW>N>* /NZBOB/3_C!\8+ZWDGAU.U2&.8V[23Q6L*^8,$H"^,D9'3U%9FH
M_'KXIZ;?36=_JB074+;)(WL805/_ 'S0!]WT5\17GQ@^+]IITE])J=H]K%M,
MKPQVLQBW' +A,E03@9(ZG%+/\7_C!#I<FH'4[22UC19)##%:RM&IP S*N64<
MCDCO0!]N45\1'XP_%_\ LMM074[22V6(3/Y45J[HAQ\S(,L!R.2..]9^F?'G
MXHZE="WM-:M/,P6_>V]O$H Z_,P _6@#[MHKX@NOC'\8+6\2UDOHVE>![I/+
MM;>19(E!+.K*"& "MG![&H8_C9\6Y!$4OU(DM7O4Q90\P)NW/]WH-C?E0!]R
MT5\06GQC^+]W<"&+4(0QM5O<R6UO&HA8@!RS   D@<GO5?6?CA\5]&EB34-4
M@C\Y/-B=;:WD21<D95E!!&01P>HH ^YZ*^!_^&B?B3_T&X?_  "A_P#B:^H/
M'OB_6M)TWPY+872QO>68EF)B5MS84YY''4UI1I.K-0CN<V+Q4,)2=:ILNQZQ
M17SO_P +)\4]?MZ8]?(3_"C_ (61XJ.<7RG'7_1TX_2NS^S:O='C_P"LN$[2
M^Y?YGT117SO_ ,+)\5'&+].>G^CIS^E!^)/BH9S?H,=?]'3_  H_LVKW0?ZR
MX3M+[E_F?1%%?/\ 8_$#Q7=W'E+J"C"L[$6JL0H&3P!S2W7CWQ; J.+[?$Z[
M]_V51@;B.>.#Q2_LZI>UT5_K%AFN;EE;T7^9[_17S]:^/_%MQ+$HO0JR-L#F
MV7;GZXJ+_A8OBWRA(;O$9X#?9EP?QQ3_ +-J]T+_ %DPMK\LON7^9]#45\[_
M /"R?%/.;]./^G=/\*/^%D>*P<&^7/I]G3_"C^S:O="_UEPO:7W+_,^B**^>
M#\1O%@17-X C'"M]F7!^AQ3E^(?B]_N71;C/%JIX]>E']FU>Z#_63"_RR^[_
M ()]"T5\\)\1_%<C[4O0S?W5MT)_E2_\+%\6[7;[7\J'#'[,N%^O'%']FU>Z
M#_67"_RR^Y?YGT-17STOQ$\7,H9;HE2< BU7!_2FR?$?Q7&Q62]56'4-;H"/
MTH_LVKW0?ZRX7?EE]W_!/H>BO"?"_P 0/$=]XCTRTNKU'@GN$CD40H,J3SSB
MO=JYJ^'E0:4CT\!F%+'1<Z2>G<****P.X**** "BBB@ HHHH **** "BBB@
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MD]]''J^FFYBL8"2'=;I8T++_ +NV0G_>KW7_ (9,TG_H:;[_ ,!4_P#BJ/\
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MNV\E91'=$2-MB7R&W2\9RHQDC SFB'7+&>:*.&1W$F L@C;9N(R%+8P&QVH
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M6'S99=R!A))YA)*OSC )R/H.G.1M*EO-(U6T?,#S73R1LPR.&#*<>F17044
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<8,8 SQFMZBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
